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Abstract 
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that catalyse the synthesis of 
different lipid second messengers, regulating a plethora of intracellular functions. 
Deregulation of their signalling pathway has different functional consequences, and it has 
been associated with a variety of human diseases. The existence of eight distinct isoforms, 
divided into three classes, has raised in the past many questions on whether and to which 
extent their role was redundant or overlapping. The study of their intracellular signalling 
pathways and cellular functions is crucial, because some of these isoforms have been 
identified as important therapeutic targets. 
The most investigated PI3Ks belong to the class I subfamily, and they have a well established 
role in the regulation of cell growth, survival and proliferation. In the past years, attention 
and research efforts focussed on class I isoforms and alteration of their signalling pathways, 
one of the most common causes of cancer. More recently, evidence indicated that the least 
investigated class II PI3Ks have different intracellular roles. 
This work focussed on the class II isoform PI3K-C2α, the study of its intracellular function(s) 
in pancreatic β cells and the implications of its inhibition through downregulation in 
pancreatic β cells homeostasis. It was reported that PI3K-C2α has a crucial role insulin 
granules exocytosis. This study has demonstrated that this enzyme synthesises the lipid 
product PtdIns3P specifically at the plasma membrane of pancreatic β cells upon 
depolarisation of the plasma membrane and stimulation of insulin secretion. Moreover, the 
data herein presented indicated for the first time that glucose-induced activation of PI3K-
C2α is able to protect β cells from cell death induced by nutrients deprivation. Analysis of 
the intracellular pathways stimulated by glucose indicated that PI3K-C2α is able to modulate 
the activity of mTOR and its downstream effectors, key regulators of cell proliferation and 
growth. Importantly, the activation of mTOR pathway upon glucose does not seem to 
involve the activation of the upstream regulator Akt or class I PI3K, suggesting a novel 
intracellular pathway  stimulated by glucose.   
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Chapter 1 
Introduction 
1.1 Phosphoinositide 3-kinases 
Phosphoinositide 3-kinases (PI3Ks) are enzymes that regulate several biological 
functions, including cell growth, differentiation, survival, proliferation, migration, 
intracellular vesicular transport and metabolism (Vanhaesebroeck et al. 2010). PI3Ks 
were first discovered in 1984 and subsequently found in all eukaryotic cell types 
examined (Foster et al. 2003). It has subsequently emerged that PI3Ks are a family of 
structurally related enzymes, that can use different lipid substrates and can be 
differently regulated, which explains the plethora of biological functions that the 
enzymes control (Foster et al. 2003). Because of their multiple intracellular 
functions, dysregulation of their signalling pathway is associated to the onset and/or 
progression of several human diseases. For instance, impaired signalling 
downstream of PI3Ks is one of the major contributors towards the progression of 
Type 2 diabetes (T2D), while hyperactivation of PI3K-dependent signalling has been 
reported in human cancers (Engelman et al. 2006). PI3Ks share high sequence 
homology within their kinase domain and they have been divided into three main 
classes, based on their substrate specificity and structure (Vanhaesebroeck et al. 
2010). All PI3K isoforms catalyse the phosphorylation of the 3-OH position within 
25 
 
the inositol head groups of their lipid substrates phosphoinositides (PIs), generating 
3-phosphorylated lipids (Vanhaesebroeck et al. 2001).  
 
1.1.1 PI3Ks products: 3-phosphorylated phosphoinositides 
PIs consist of a glycerol backbone attached to two fatty acids and an inositol 1-
phosphate group. The unphosphorylated form of phosphoinositide is 
phosphatidylinositol (PtdIns). The hydroxyl groups of the inositol ring can be 
phosphorylated in position 3, 4, and 5 in different combinations, generating seven 
distinct PIs, all naturally occurring in cell membranes of higher eukaryotes (Maffucci 
2012). PIs have several intracellular functions, from being part of the cellular 
membranes to acting as intracellular second messengers. Because of their lipid tail, 
they bind intracellular membranes and therefore mark cellular compartments. As 
amphipathic molecules, they also possess a polar inositol head, which can interact 
with cytosolic proteins and regulate the activation of signalling molecules both 
temporally and spatially (Maffucci 2012). 
As mentioned before, PI3Ks are able to catalyse the phosphorylation of the position 
3 of the inositol ring of PtdIns, phosphatidylinositol 4-phosphate (PtdIns4P) and 
phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2], generating 
phosphatidylinositol 3-phosphate (PtdIns3P), phosphatidylinositol 3,4-bisphosphate 
[PtdIns(3,4)P2] and phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] 
respectively (Fig 1.1). The 3-phosphorylated PI phosphatidylinositol 3,5-
26 
 
bisphosphate [PtdIns(3,5)P2] is not a direct enzymatic product of PI3Ks and it is 
generated by further phosphorylation of PtdIns3P in position 5 (Maffucci 2012).  
 
 
Figure 1.1: Structure of PI3Ks lipid products. Phosphorylation sites on hydroxyl groups of the 
inositol head of the molecules are indicated.  Adapted from Maffucci 2012 
 
Another characteristic of some phosphorylated PIs, crucial for their role as second 
messengers, is their rapid rate of synthesis and turnover, which allows the activation 
of intracellular signalling pathways only when they are needed. Also, PIs are 
associated to cellular membranes, and this limits their intracellular localisation. At 
the same time, the fact that they are compartmentalised, and that they are able to 
recruit different proteins in distinct subcellular compartments is a clear indication of 
the specificity of their action (Vanhaesebroeck et al. 2001). 
The number and the position of the phosphate groups on the inositol head of PIs 
define the type of protein(s) that can interact and be activated by them. Therefore, 
distinct intracellular pathways can be regulated by PI3Ks, depending on their lipid 
product. Intracellular levels of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are undetectable in 
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normal resting cells, but they rapidly increase upon cellular stimulation, consistent 
with their well established role as second messengers (Sotsios and Ward 2000, 
Hinchliffe 2001, Falasca and Maffucci 2009). PtdIns(3,4)P2 and PtdIns(3,4,5)P3 can 
bind the pleckstrin homology (PH) domain of several proteins, including protein 
kinase B/Akt. Binding of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 to Akt PH domain allows 
translocation of the enzyme to the plasma membrane and subsequent activation 
(Maffucci 2012). Another well characterised protein domain that is able to bind 3-
phosphorylated PIs is the phox homology (PX) domain, which can interact with 
PtdIns(3,4)P2 but preferentially binds the monophosphorylated lipid PtdIns3P (Table 
1.1). 
Phosphoinositide Binding domain 
PtdIns3P FYVE, PX, PH 
PtdIns(3,4)P2 PX, PH 
PtdIns(3,4,5)P3 PH 
Table 1.1: PI3Ks lipid products and interaction with protein domains 
 
The fact that different types of phosphorylated PIs are able to interact with different 
protein domains, therefore binding distinct proteins, suggests that they have specific 
intracellular roles.  
The lipid PtdIns3P is constitutively present in eukaryotic cells and it is the most 
abundant 3-phosphorylated PI in resting conditions, representing 0.1-0.5% of all PIs 
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(Falasca and Maffucci 2006). Several lines of evidence indicated that at least two 
distinct pools of PtdIns3P are present within the cells: a constitutive pool, which 
regulates endosomal trafficking and membrane dynamics and is detectable in 
unstimulated cells, and a regulated pool, synthesised upon cellular stimulation 
(Falasca and Maffucci 2009, Maffucci 2012). PtdIns3P can selectively bind the zinc 
finger domain conserved in Fab1p-YOPB-Vac1-EEA1 (FYVE).  
Another key regulator of PtdIns3P homeostasis is the family of phosphatases 
myotubularins (MTMs). They catalyse the dephosphorylation of the position 3 of the 
inositol ring of PtdIns3P and PtdIns(3,5)P2. In humans, this family comprises 14 
members, 6 of which are mutated in their catalytic domain, and are predicted to be 
inactive (Falasca and Maffucci 2009, Maffucci 2012). Interestingly, it appears that 
the inactive MTMs have a regulatory role on the active isoforms, although the 
precise mechanisms of MTMs activation are not completely understood. Also, an 
isoform-specific intracellular localisation of some MTMs has been reported, which 
may represent a mechanism of regulation of their activity (Maffucci 2012). 
 
1.1.2 Classification of PI3Ks 
 
Class I 
Class I PI3Ks are the best characterised and they are further divided into class IA and 
IB. Class IA PI3Ks consist of a catalytic subunit of 110 kDa which interacts with a 
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regulatory subunit through a specific binding domain (p85 binding domain, Fig 1.2). 
The regulatory subunit is able to bind phosphotyrosine residues of other proteins 
through its Src Homology (SH2) domain and it can be of 85 or 55 kDa (Sotsios and 
Ward 2000, Engelman et al. 2006). Class IA catalytic subunits are p110α, p110β and 
p110δ, which are encoded by separate genes. p110α and p110β isoforms are 
ubiquitous, while p110δ is primarily expressed in thymus, lung, spleen and cells of 
the haematopoietic lineage, such as B and T cells (Domin and Waterfield 1997, 
Vanhaesebroeck et al. 2001, Herman and Johnson 2012). They have multiple 
intracellular roles, including regulation of cell size, motility, metabolism, survival and 
proliferation (Foster et al. 2003). The catalytic subunits of class I PI3Ks comprise the 
PI3K core shared by all PI3K isoforms, which includes the catalytic domain, a p85 
domain that ensures the interaction with the regulatory subunit, and a Ras binding 
domain which enables activation via Ras signalling.  
 
 
Figure 1.2: Schematic structure of class I PI3Ks. Catalytic and regulatory subunits are shown, and 
the domains comprised in class I PI3Ks are indicated (Vanhaesebroeck et al. 2010). 
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Class IB catalytic subunit p110 can bind the regulatory subunits p87 or p101. Tissue 
distribution for p110indicated that this isoform is mainly found in leukocytes and 
its function is to modulate inflammation and allergy (Foster et al. 2003).  
Originally, class IA PI3Ks were thought to be specifically activated upon stimulation 
of receptor tyrosine kinases (RTKs) by several growth factors and hormones such as 
insulin (Vanhaesebroeck et al. 2001), while class IB was believed to be solely 
activated upon stimulation of G-protein coupled receptors (GPCRs) (Sotsios and 
Ward 2000, Vanhaesebroeck et al. 2001). More recently it has been shown that 
p110β can also be activated downstream of GPCRs, and p110 can be activated 
downstream of RTKs (Vanhaesebroeck et al. 2010). Also, Ras can be activated 
downstream of both RTKs and GPCRs, and it can in turn activate class I PI3K 
signalling by direct interaction and regardless of the type of receptor activated 
(Vanhaesebroeck et al. 2010). 
In vitro, class I PI3Ks are able to phosphorylate the substrates PtdIns, PtdIns4P and 
PtdIns(4,5)P2. However, in vivo, the preferred substrate is PtdIns(4,5)P2 and 
therefore the main lipid product is the trisphosphate PtdIns(3,4,5)P3 
(Vanhaesebroeck et al. 2001). The action of class I PI3Ks can be counteracted by 
intracellular phosphatases, which are able to remove specific phosphate groups 
from the inositol head of PIs. These enzymes act in direct antagonism to PI3Ks, 
degrading their lipid products. For example, PtdIns(3,4,5)P3 can be converted into 
PtdIns(4,5)P2 by the phosphatase and tensin homolog (PTEN) which removes the 
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phosphate group in position 3, or into PtdIns(3,4)P2 by 5-phosphatases (such as 
SHIP2, SKIP, INPP5E) which remove the phosphate group in position 5 (Maffucci 
2012). 
PtdIns(3,4,5)P3 can activate several downstream targets and therefore it is 
responsible for regulation of many intracellular functions (Hinchliffe 2001, Maffucci 
2012). The most studied downstream effector of class I PI3Ks is the Ser/Thr kinase 
Akt, which exists in three isoforms: Akt1/PKBα, Akt2/PKBβ and Akt3/PKB (Schultze 
et al. 2011). The PH domain of Akt can directly bind PtdIns(3,4,5)P3 and 
PtdIns(3,4)P2. This leads to Akt translocation to the plasma membrane, where it can 
be phosphorylated at two key regulatory residues, Thr 308 and Ser 473 (Alessi et al. 
1996).  
 
 
Figure 1.3: PI-dependent activation of a target protein. PH domain of Akt can bind PtdIns(3,4,5)P3 
synthesised by class I PI3Ks, leading to its translocation to the plasma membrane and activation 
(Maffucci 2012). 
 
The residue Thr 308 is phosphorylated by the enzyme 3’phosphoinositide dependent 
protein kinase 1 (PDK1), which can also be activated by PtdIns(3,4,5)P3. The residue 
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Ser 473 of Akt can be phosphorylated by the mechanistic target of rapamycin 
(mTOR) complex 2, mTORC2 (Sarbassov et al. 2006). The concomitant 
phosphorylation of these two amino acid residues allows full activation of Akt, which 
in turn activates intracellular signalling pathways that regulate multiple cellular 
functions, such as cell metabolism, growth, survival, motility, proliferation and 
protein synthesis (Manning and Cantley 2007). Deregulation of this signalling 
pathway is associated with metabolic conditions such as diabetes (discussed later in 
this chapter) and also with the onset and the progression of cancer. Indeed, 
deregulation of PI3K signalling has been detected in many types of human cancers 
(Engelman et al. 2006). For instance, several mutations of the gene encoding for 
p110α have been found in tumours, suggesting that mutant p110α could function as 
an oncogene (Samuels et al. 2004). More recently, it has been suggested that 
amplification of other class I PI3K isoforms can also be associated with cancer. For 
example, immunohistochemical screening and Western blot analysis revealed that 
the isoform p110 was overexpressed in human pancreatic cancer tissues and in 
several cancer cell lines (Edling et al. 2010). Similarly, it has been reported that 
p110 was expressed at high level in leukemic blasts from patients with acute 
myeloid leukemia (Sujobert et al. 2005). Furthermore, PTEN is a well established 
tumour suppressor and its inhibition, either through mutations or epigenetic 
modifications, is associated with hyperactivation of PI3K signalling pathway and it is 
detected in many cancer types (Leslie and Downes 2002). Consistent with this, it was 
reported that heterozygous inactivation of PTEN in mice models was sufficient to 
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increase the incidence of tumours (Suzuki et al. 1998). Other lines of evidence also 
indicate that alteration of the signalling pathway downstream of class I PI3Ks is 
relevant in cancer. For instance, amplification of Akt has also been found in many 
human cancers (Cheng et al. 1996, Fresno Vara et al. 2004). 
 
Class II 
Class II PI3Ks are high molecular weight monomers, that lack the regulatory subunit 
present in class I isoforms (Fig 1.4). They were discovered on the basis of their 
sequence homology with the members of other classes and their physiological roles 
are still poorly understood (Vanhaesebroeck et al. 2010, Falasca and Maffucci 2012). 
In humans, three class II isoforms were discovered: PI3K-C2α and PI3K-C2β, which 
have a broad tissue distribution and PI3K-C2,whose expression is limited to liver, 
prostate and testis (Kok et al. 2009). The three isoforms PI3K-C2α, PI3K-C2β and 
PI3K-C2are encoded by three separate genes and differ from each other at their N-
terminus region (Vanhaesebroeck and Waterfield 1999). 
In vitro, class II PI3Ks are able to phosphorylate the substrates PtdIns and PtdIns4P, 
with a stronger preference for PtdIns over the other PIs (Maffucci 2012). As for their 
in vivo product, contrasting results were originally reported, but strong evidence 
now suggest that the lipid product of class II PI3Ks is the monophosphorylated 
PtdIns3P (Falasca et al. 2007, Falasca and Maffucci 2009, Mazza and Maffucci 2011, 
Yoshioka et al. 2012). Class II PI3Ks differ from other isoforms for their large N-
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terminal region and their C-terminus region, which contains a C2 domain that binds 
phospholipids in vitro in a Ca2+-independent manner. Also, it has been also observed 
that in vitro PI3K-C2α and PI3K-C2β can use Ca2+/ATP for their kinase activity 
(Vanhaesebroeck and Waterfield 1999). PI3K-C2α will be discussed more extensively 
later in this chapter. In terms of cellular functions, it was reported that PI3K-C2β is 
involved mainly in the regulation of cell migration (Domin et al. 2005, Maffucci et al. 
2005, Tibolla et al. 2013), cell cycle (Visnjic et al. 2003) and activation of Ca2+ 
activated K+ channel (Srivastava et al. 2009), through the synthesis of  PtdIns3P. Less 
information are available on the functional role of PI3K-C2. It has been reported 
that has a role in liver regeneration (Ono et al. 1998). 
 
 
Figure 1.4: Schematic structure of class II PI3Ks (Vanhaesebroeck et al. 2010) 
 
Class III 
Vacuolar protein sorting 34 (Vps34) was first discovered in yeast. It is the only 
member of class III PI3K and its sequence is conserved from unicellular organisms to 
plants and vertebrates (Backer 2008). Mammals ubiquitously express its homologue, 
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the protein hVps34. The enzyme associates with a subunit of 150 kDa (in yeast 
Vps15, in humans hVps15, Figure 1.5) that possesses kinase activity required for 
Vps34 function (Foster et al. 2003), although its precise role is not fully understood 
(Backer 2008). Class III PI3K hVps34 is implicated in endosomal trafficking, 
phagocytosis and autophagy (Vanhaesebroeck et al. 2010). It can only phosphorylate 
PtdIns both in vitro and in vivo, and it is generally accepted that this isoform is 
responsible for the majority of the intracellular pool of PtdIns3P (Vanhaesebroeck 
and Waterfield 1999, Falasca and Maffucci 2007). 
 
 
Figure 1.5: Schematic structure of class III PI3Ks (Vanhaesebroeck et al. 2010) 
 
1.1.3 Physiological roles of PI3K in insulin target cells 
Following food consumption, glucose blood concentration rises, and this stimulates 
the secretion of insulin by pancreatic β cells. Insulin in turn stimulates glucose 
uptake in insulin target tissues, mainly skeletal muscle and adipocytes, and reduces 
hepatic gluconeogenesis (Muoio and Newgard 2008, Foukas and Withers 2010). The 
binding of insulin to its membrane receptor activates intracellular signalling 
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pathways that are regulated, among others, by PI3Ks, mainly by class I PI3Ks. The 
binding of insulin to insulin receptor (IR) results in receptor activation through 
autophosphorylation on tyrosine residues on its cytosolic domain. This allows 
recruitment and binding to the receptor of insulin receptor substrate (IRS) proteins 
(Figure 1.6), mainly insulin receptor substrate 1 (IRS 1) in skeletal muscle and 
adipocytes, and insulin receptor substrate 2 (IRS 2) in liver (Taniguchi et al. 2006). 
Upon tyrosine phosphorylation by the activated IR, IRS can bind SH2 domain-
containing proteins, including the regulatory subunits of class IA PI3K. Recruitment 
of the regulatory subunit leads to the activation of PI3K and synthesis of the lipid 
second messenger PtdIns(3,4,5)P3. Enzymes like Akt and PDK1, which possess a PH 
domain, are then able to bind PtdIns(3,4,5)P3 and become activated (Saltiel and 
Kahn 2001) . 
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Figure 1.6: Activation of class I PI3Ks signalling pathway upon insulin stimulation. Main molecules 
involved in the intracellular signalling of insulin (Cohen and Frame, 2001). 
 
Activated Akt is able to modulate several processes through its many downstream 
targets. For instance, Akt can regulate glucose uptake and storage in insulin sensitive 
tissues by increasing the number of glucose transporters (GLUT) at the plasma 
membrane. GLUT family comprises 14 proteins, which are involved in the transport 
of glucose against its concentration gradient. They are membrane-associated 
proteins, which possess 12 transmembrane domains. GLUT isoforms differ between 
them for their affinity to glucose and their tissue distribution (Bogan 2012). The 
isoform GLUT4 has a very high affinity for glucose and it is the predominant isoform 
in adipose and muscle tissues. It is stored on the membrane of intracellular vesicles 
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in unstimulated conditions. Insulin stimulates the translocation and fusion to the 
plasma membrane of GLUT4-containing vesicles, allowing the internalisation of 
glucose and its removal from the bloodstream.  
In the final steps of GLUT4 translocation, fusion of GLUT4-containing vesicles to the 
plasma membrane occurs. This process involves soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) proteins, which facilitate GLUT4 
integration into the plasma membrane. Specifically, the vesicle-associated SNARE 
vesicle-associated membrane protein 2 (VAMP2) and the membrane-associated 
SNAREs syntaxin 4 and synaptosomal-associated protein of 23 kDa (SNAP23) are 
required for GLUT4 fusion to the plasma membrane, which leads to glucose 
internalisation in skeletal muscle cells (Jewell et al. 2011). The steps of the complex 
process of GLUT4 translocation are schematically represented in Figure 1.7. 
 
 
Figure 1.7: Glucose uptake via insulin-stimulated GLUT4 translocation and fusion in muscle and 
adipose tissues. Numbers indicate sequential steps of the process (Jewell et al. 2010). 
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GLUT4 translocation is a very complex process that requires several proteins. Among 
these, the PI3K/Akt pathway plays a central role. Specifically, Akt phosphorylates 
and activates Akt substrate of 160 kDa (AS160), and it was shown that insulin-
induced phosphorylation of AS160 was associated with GLUT4 translocation in 3T3-
L1 adipocytes (Sano et al. 2003). AS160 can indeed regulate the activation of Rab 
proteins, which facilitate intracellular trafficking of GLUT4 vesicles and their docking 
to the plasma membrane (Jewell et al. 2011). However, it is worth mentioning that 
while activation of class I PI3K/Akt signalling is necessary for GLUT4 translocation, it 
is not sufficient and evidence suggested that other signalling pathways are also 
required for glucose uptake (Czech and Corvera 1999). For instance, it has been 
demonstrated that GLUT4 translocation also requires the activation of the small 
GTP-binding protein TC10 (Chiang et al. 2001) and the synthesis of the lipid second 
messenger PtdIns3P (Maffucci et al. 2003). Specifically, a key role for class II PI3K-
C2α has been demonstrated and this will be discussed later in this chapter.  
Once glucose is internalised by the cells, it is converted into glycogen, ensuring long-
term storage of energy supplies within the cells. This process requires the 
phosphorylation of glycogen synthase kinase 3 (GSK3), the first physiological 
substrate identified for Akt (Figure 1.6). Phosphorylation of GSK3 by Akt has an 
inhibitory effect, preventing GSK-mediated phosphorylation of its substrate glycogen 
synthase, a crucial process for the conversion of glucose into glycogen in muscle 
cells and liver (Cross et al. 1995). 
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Figure 1.8: Schematic representation of the intracellular pathways triggered in insulin target cells.  
Arrows indicate activation, whereas blunt-end lines indicate inhibition. The resulting positive or 
negative regulation is indicated by black and red colours, respectively (Dann et al. 2007). 
 
In addition, PI3K/Akt signalling modulates lipogenic and adipogenic processes, and 
the release of leptin in adipocytes in response to insulin stimulation (Mannaa et al. 
2013). Specifically, it was reported that pharmacological inhibition of PI3K-
dependent pathway inhibited adipocytes diﬀerentiation (Tomiyama et al. 1995, Cho 
et al. 2004) and prevented the accumulation of lipid droplets in 3T3-L1 adipocytes 
(Cho et al. 2004).  
Akt can further control cell metabolism by regulating the winged helix or forkhead 
(FOXO) class of transcription factors (Figure 1.8), some of which have a role in insulin 
signalling. For instance, activation of PI3K/Akt signalling in liver cells can inhibit the 
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transcription of gluconeogenic enzymes, such as phosphoenolpyruvate 
carboxykinase and glucose-6-phosphatase, which results in the inhibition of hepatic 
glucose production (Engelman et al. 2006). 
 
1.1.4 Physiological roles of PI3K in insulin producing cells 
The endocrine region of pancreas is organised in clusters of cells called islets of 
Langherhans, named after the German pathologist who discovered them around 
150 years ago. There are ~1 million pancreatic islets in a human pancreas, 
representing 1-2% of its total mass, and they comprise different types of cells. The 
most important pancreatic endocrine cells are the glucagon-releasing pancreatic α 
cells (35–40% of pancreatic human islets), the insulin-secreting pancreatic β cells 
(50%) and the somatostatin-releasing  cells (10–15%) (Rorsman and Braun 2013). 
The function of endocrine pancreas is essential for glucose metabolism and 
regulation of glycaemia. In physiologic conditions, pancreatic β cells respond to 
increased glucose levels in the bloodstream by releasing insulin. Specifically, glucose 
enters pancreatic β cells via the specific transporters of the GLUT family 
constitutively present on the plasma membrane. In particular, the subtype GLUT2 
allows glucose uptake in rodent pancreatic β cells, while GLUT1 and GLUT3 have this 
function in humans (McCulloch et al. 2011, Rorsman and Braun 2013, Bernal-
Mizrachi et al. 2014). This process is schematically represented in Figure 1.9 (step 1). 
Glucose is then metabolised, through glycolysis and Krebs cycle, resulting in 
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adenosine trisphosphate (ATP) production (Figure 1.9, step 2). The first step of this 
process is the phosphorylation of glucose to glucose-6-phosphate catalysed by the 
enzyme glucokinase (GK), and this conversion is the rate limiting step of the 
biochemical reaction. The subsequent increase of ATP/ADP ratio closes the ATP-
sensitive K+ channels, causing the depolarisation of the plasma membrane and 
opening of the voltage-gated Ca2+ channel (Figure 1.9, steps 3, 4, 5). Intracellular 
concentration of Ca2+ subsequently increases and this event triggers the exocytosis 
of insulin granules, in a mechanism still not fully understood (Figure 1.9, steps 6, 7) 
(Jewell et al. 2011). The proteins involved in insulin granules exocytosis belong to 
the SNARE family, and specifically the isoforms syntaxin 1 and synaptosomal-
associated protein of 25 kDa (SNAP25) on the plasma membrane and VAMP2 on the 
insulin granule form a complex that allows insulin exocytosis (Rorsman and Braun 
2013). 
 
Figure 1.9: Mechanism of insulin granules exocytosis upon glucose stimulation in pancreatic β cells. 
Numbers indicate sequential steps of the process (Jewell et al. 2010). 
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Insulin exocytosis follows a biphasic time course, comprising a rapid first-phase 
secretion (15 insulin granules secreted/min in humans) which is induced ∼5 min 
after glucose increase in the bloodstream, followed by a slower second-phase 
secretion (5 granules/min) (Rorsman and Braun 2013).  Insulin granules in pancreatic 
β cells form distinct functional pools, based on their competence and their proximity 
to the plasma membrane. It was thought that insulin granules in close proximity to 
the plasma membrane formed a ‘ready releasable pool’ that was involved in the first 
phase of insulin secretion. According to this model, when this pool was depleted 
new granules were recruited and docked to the plasma membrane, accounting for 
the slower second phase of insulin release (Rorsman and Braun 2013). More 
recently, this model has been challenged by evidence suggesting that both first and 
second phase of insulin release rely on the recruitment, docking and immediate 
fusion of granules to the plasma membrane. This hypothesis is based on data 
obtained with total internal reflection fluorescence (TIRF) microscopy, that allows 
observation of events within the first 100–200 nm to the plasma membrane, and on 
intracellular signalling similarities between first and second phase of insulin release, 
which suggested that the late phase is probably a reiteration of the first. However, 
more studies are required to fully elucidate these mechanisms (Prentki et al. 2013, 
Rorsman and Braun 2013). 
PI3Ks have a well established role in pancreatic β cells, as they are involved in the 
regulation of both pancreatic β cell mass and function. It was shown that mRNA of 
all members of class I and II PI3Ks was expressed in human islets of Langerhans, 
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along with members of class I PI3K signalling cascade, such as IR-A, IR-B, IRS1, IRS2, 
PDK1 and Akt. Even more important is the finding that the mRNA coding for the 
aforementioned proteins was expressed specifically in human pancreatic β cells 
(Muller et al. 2006), which suggests a relevant role of PI3K-dependent signalling in 
this specific cell type. 
 
Pancreatic β cell mass 
The class I PI3K/Akt pathway has a crucial role in cell proliferation (increase in cell 
number), cell survival (protection from death) and cell growth (increase in cell size).  
For instance, Akt is able to control cell proliferation by modulating cell cycle 
progression. Specifically, Akt is able to stabilise the proteins c-Myc and cyclin D1 
through inhibition of GSK3, and to promote the transition from G1 to S phase, by 
blocking the transcription of cell cycle inhibitors regulated by FOXO (Engelman et al. 
2006, Marchetti et al. 2008).  
In addition, Akt can regulate cell survival through inhibition of apoptotic processes. 
Apoptosis is a type of programmed cell death, used by multicellular organisms to 
eliminate unwanted or damaged cells in a diversity of settings. During apoptosis, 
cells are dismantled in a controlled way, minimising the damage to the neighbouring 
cells (Taylor et al. 2008). This cellular process is finely regulated by a number of 
antiapoptotic (BCL2, BCL-XL) and proapoptotic (BAD, BAK, PUMA) proteins. 
Activated Akt can inactivate the proapoptotic protein BAD by direct 
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phosphorylation, and therefore inhibiting the initiation of apoptotic processes 
(Figure 1.10). 
Furthermore, apoptosis involves activation of the caspase family of proteases, which 
normally exist as inactive precursor enzymes (zymogens) in healthy cells. Once they 
are activated, they can initiate the apoptotic process (isoforms 8 and 9) and 
modulate the proteasome proteolysis once the apoptotic process is triggered (Taylor 
et al. 2008). In addition, it was reported that Akt can directly phosphorylate and 
inhibit caspase 9, therefore preventing apoptosis (Figure 1.10). 
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Figure 1.10: Schematic representation of Akt signalling downstream of class I PI3K in pancreatic β 
cells. Akt is a signalling hub, able to regulate both pancreatic β cell mass and function (Elghazi 
2007). 
 
Furthermore, Akt regulates the activation of mTOR, a key enzyme that is conserved 
through evolution and has a critical role in cell growth and proliferation (Huang and 
Manning 2008, Blandino-Rosano et al. 2012). The kinase core of mTOR can associate 
with several other proteins, forming two large complexes (1 MDa)  named mTORC1 
and mTORC2. Both mTOR complexes comprise mammalian lethal with Sec13 protein 
8 (mLST8) and DEP domain-containing mTOR-interacting protein (DEPTOR). The 
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presence of other adaptor proteins distinguishes the two mTOR complexes: mTORC1 
associates with the regulatory-associated protein of mTOR (raptor) and proline-rich 
Akt substrate of 40 kDa (PRAS40), while rapamycin insensitive companion of mTOR 
(rictor), mammalian stress-activated map kinase-interacting protein1 (mSin1) and 
protein observed with rictor (protor)1/protor2 are found in mTORC2 (Mavrommati 
and Maffucci 2011, Lamming and Sabatini 2013). 
A very simplified representation of PI3K/Akt/mTOR signalling pathway is presented 
in Figure 1.11. Activated Akt can inhibit the tuberous sclerosis complex (TSC1/TSC2). 
The function of TSC1 is to stabilise the other subunit TSC2, preventing its 
degradation. Direct phosphorylation of TSC2 by different proteins results in 
enhanced or reduced activity of the TSC1/TSC2 complex, depending on the specific 
site of phosphorylation. For instance, Akt phosphorylates TSC2 on multiple residues, 
and studies using phosphorylation-site mutants of TSC indicated that Akt activity 
results in inhibition of the TSC1/TSC2 complex (Huang and Manning 2008). 
Specifically, Akt-dependent phosphorylation of TSC2 prevents the GTPase activity of 
the complex towards the protein Ras homolog enriched in brain (Rheb), allowing the 
accumulation of GTP-bound Rheb which in turn activates mTORC1 (Engelman et al. 
2006). On the other hand, activated AMP-Activated Protein Kinase (AMPK) can 
directly phosphorylate TSC2 on Ser1345 and Thr1227, resulting in the activation of 
TSC2 and inhibition of mTORC1 (Inoki et al. 2003, Huang and Manning 2008).  
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Figure 1.11:   Schematic representation of PI3K/Akt/mTORC1 signalling pathway. PI3K-dependent 
stimulation of mTOR contributes to the regulation of cell growth and metabolism (Geissler and 
Schlitt 2010). 
 
Once activated, mTOR can regulate several cellular functions that are crucial for 
pancreatic β cells. For instance, mTORC1 can induce phosphorylation of eIF4E 
binding proteins (4EBPs), releasing the eukaryotic translation initiation factor 4E 
which can then associate to the multisubunit complex that recruits 40S ribosomal 
subunits to the 5' end of mRNAs. This allows protein translation initiation, the rate 
limiting step process of protein synthesis (Figure 1.11), which is under strict control 
in eukaryotic cells (Modrak-Wojcik et al. 2013). The mTOR-dependent activation of 
protein translation results in the expression, among others, of proteins promoting 
cell cycle progression (Xie and Herbert 2012). Another downstream target of 
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mTORC1 is the protein S6K, which in turn phosphorylates several substrates. The 
most studied is ribosomal protein S6 (S6), which positively regulates β cell growth. 
However, it cannot be excluded that S6K-dependent functions in β cells are 
mediated by other targets of S6K, such as the eukaryotic elongation factor 2 (eEF2), 
eukaryotic initiation factor 4B (eIF4B) and programmed cell death protein 4 
(PDCD4). Other mTORC1 targets include transcription factor 3C (TFIIIC), which 
regulates ribosome and tRNA biogenesis (Xie and Herbert 2012).  
In addition, mTORC1 can negatively regulate autophagy, by modulating the initial 
steps of this intracellular process. Autophagy is a cellular process through which the 
recycling of cellular proteins and organelles is ensured, allowing de novo protein 
synthesis (Mazza and Maffucci 2014). Basal autophagy (often referred to as 
‘constitutive’ autophagy) occurs in many cell types and it is crucial to maintain 
cellular homeostasis, ensuring the removal of protein aggregates, ubiquinated 
proteins, damaged organelles (i.e. mitochondria and ribosomes) (Fujitani et al. 2010, 
Mazza and Maffucci 2014). Also, autophagy is important during starvation, allowing 
the cells to recycle existing macromolecules to sustain energy requirements and to 
maintain neosynthesis of essential proteins and glucose. This process is often 
termed as ‘adaptive’ or ‘protective’ autophagy (Mazza and Maffucci 2014). 
Autophagy is emerging as a key process in maintaining pancreatic β cell 
homeostasis. Impairment of autophagy in pancreatic β cells resulted in 
mitochondrial  dysfunction, oxidative stress (Wu et al. 2009), degeneration of 
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pancreatic islets (Ebato et al. 2008) and decreased β cell mass, due to both reduced 
proliferation and increased apoptosis (Jung et al. 2008) in mice models. 
The complex formed by Unc-51-like kinase 1 (ULK1), autophagy-related gene 13 
(ATG13) and focal adhesion kinase family-interacting protein of 200 kDa (FIP200) is 
essential in the initial stages of autophagy and it is regulated by mTOR. Evidence 
indicate that overexpression of an inactive form of mTOR, rapamycin treatment or 
nutrient starvation inhibited phosphorylation of ULK1 and ATG13, activating ULK1-
ATG13-FIP200 complex and promoting autophagy (Ganley et al. 2009, Hosokawa et 
al. 2009). Specifically, mTORC1 was associated with the complex ULK1-ATG13-FIP200 
when HEK cells were cultured in complete medium, and mTORC1 component Raptor 
directly interacted with ULK1. Nutrient starvation caused the dissociation of the two 
complexes, inhibited ULK1 and ATG13 phosphorylation and promoted autophagy 
(Hosokawa et al. 2009). 
Class I PI3K/Akt/mTORC1 axis integrates signals from nutrients and growth factors 
and is one of the most important intracellular signalling pathways in the regulation 
of β cell proliferation/survival, because of its crucial effect on pancreatic β cell mass 
and protein translation. Its key role in pancreatic β cell homeostasis has been 
confirmed by mouse models. For instance, knockout mice model for S6K isoforms 
have indicated its crucial role in the regulation of pancreatic β cell mass. Deletion of 
both S6K 1 and S6K 2 caused perinatal lethality in mice, while the knockout of S6K 1 
alone produced a more severe phenotype compared to the knockout of S6K 2. 
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Specifically, S6K 1 deficient mice were smaller at birth compared to both S6K 2 
deficient mice and wild type controls, and had reduced levels of circulating insulin. 
The observation of their phenotype suggested a preponderant role for S6K 1 over 
S6K 2 in the regulation of pancreatic β cell mass and function, as it appeared that 
S6K 1 is able to compensate for the lack of S6K 2 isoform but not vice versa (Pende 
et al. 2004). Interestingly, mice deficient for S6K 1 showed a selective decrease in 
pancreatic β cell mass and an impaired glucose-induced insulin secretion. This was 
not caused by defects in glucose sensing or insulin production, and it was due to a 
reduction in pancreatic endocrine mass, and specifically due to a selective decrease 
in β cell size (Pende et al. 2000). These observations supported the conclusion that 
mTOR has a key role in regulation of pancreatic β cell mass. Whether class I PI3Ks 
are the only PI3K isoforms able to activate mTOR remains to be established.  
In this respect, a role for class III PI3K in regulating mTORC1 has been reported. 
Indeed, overexpression of hVps34 or the presence of inhibitory anti-hVps34 
antibodies were able to positively or negatively regulate S6K activation, respectively. 
In the same study, the authors proposed that amino acid or glucose starvation and 
activation of AMPK were able to regulate mTORC1 activation through class III PI3K, 
while the involvement of hVps34 in insulin stimulated pathway was ruled out 
(Byfield et al. 2005). Interestingly, the presence of a FYVE domain sequestering 
PtdIns3P inhibited insulin-stimulated activation of S6K (Byfield et al. 2005), clearly 
suggesting the involvement of a PtdIns3P-producing enzyme upstream of 
mTORC1/S6K. More recently, it was suggested that class II PI3K-C2α had a role in 
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mTORC1 and S6K activation, by producing PtdIns3P upon stimulation with insulin. 
Interestingly, evidence indicated that Akt pathway upstream of mTOR was not 
involved (Bridges et al. 2012). 
 
Pancreatic β cell function 
More recent lines of evidence suggest that, besides its key role in the regulation of 
pancreatic β cell mass, class I PI3Ks can also be directly involved in control of 
pancreatic β cell function. For instance, it was shown that knockdown of Akt target 
AS160 in both MIN6 cells and primary mouse β cells increased insulin secretion in 
unstimulated conditions, while glucose-induced insulin release was abolished 
(Bouzakri et al. 2008). Also, using specific knockout mice models lacking the 
regulatory subunits of class I PI3Ks in β cells (βDKO mice), it has been shown that 
PI3K signalling is crucial for maintaining β cell function (Kaneko et al. 2010). The 
authors reported that inhibition of class I PI3K signalling pathway resulted in an 
impaired glucose-induced insulin secretion in this mice model. Consistent with this, 
isolated islets from either βDKO mice or mice lacking the regulatory subunit p85α 
alone, displayed impaired KCl-induced insulin secretion. In addition, the authors 
reported decreased protein expression of SNAREs involved in insulin secretion, 
which might account, at least in part, for the impaired exocytosis (Kaneko et al. 
2010).  
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Similarly, homozygous knockout for p110 showed impaired glucose-induced insulin 
secretion both in vivo and in ex vivo perfused pancreas (MacDonald et al. 2004). In 
this study, insulin exocytosis was impaired, despite greater pancreatic insulin 
content and compensatory hypertrophy of pancreatic β cells. This indicated that the 
isoform p110 has a role specifically in insulin secretion while it does not regulate 
pancreatic β cell mass. This suggest that the role and the intracellular signalling 
activated by p110 is different from other class I PI3K isoforms. Subsequently, the 
role of p110 in pancreatic β cells was investigated using specific inhibitors and 
downregulation of p110 with siRNA in INS1 cells (Pigeau et al. 2009). Results 
indicated that insulin secretion induced by depolarisation was modulated by p110, 
as this enzyme regulates the recruitment of the insulin granules pool associated to 
the plasma membrane in both INS1 cell lines and human pancreatic islets (Pigeau et 
al. 2009).  
 
1.1.5 Dysregulation of PI3K signalling pathway and type 2 diabetes 
As discussed so far PI3Ks, mainly class I isoforms, have a central role in regulation of 
insulin action and production. Several lines of evidence indicate that deregulation of 
PI3K pathway is associated with the onset and progression of metabolic diseases 
such as T2D. 
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Type 2 diabetes  
Diabetes is the most common metabolic disease, with 382 million people affected 
worldwide in the year 2013 and the prediction that the number of affected people 
will rise to 592 million by 2035 (Guariguata et al. 2014). It is characterised by 
impaired glucose handling in response to a physiological stimulus to produce insulin. 
The molecular mechanisms involved in T2D development and progression are at the 
level of both insulin target tissues and insulin producing tissues. Individuals affected 
by T2D show impaired insulin signalling in insulin target tissues (i.e. muscle cells, 
adipose tissue, liver), with a defective response in terms of blood glucose uptake 
and storage. In physiological conditions, insulin is produced by pancreatic β cells in 
response to a rise in blood glucose levels. When insulin signalling is impaired in 
target tissues, glucose is not adequately removed from the bloodstream and 
internalised in muscle and fat cells. This stage is termed ‘insulin resistance’ and it is 
temporarily compensated through increased insulin secretion, either by increased 
pancreatic β cell mass or increased β cell efficiency (Bonner-Weir 2000). It was 
originally thought that insulin resistance always preceded pancreatic β cell 
dysfunction and full blown diabetes, but more recent studies have shown that this 
paradigm is not always true (Bartolome and Guillen 2014). Indeed, in the UK 
Prospective Diabetes Study it was observed that pancreatic β cell function was 
already reduced by 50% in patients at the time of diagnosis and it progressively 
declined regardless of the therapy used (U.K. prospective diabetes study 16, 1995). 
Nevertheless, the state of insulin resistance often accompanies the diabetic 
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condition and it is considered a major risk factor for T2D (Taylor 2012). It is now 
generally accepted that T2D appears when pancreatic β cells are no longer able to 
compensate, either because insulin resistance exceeds insulin production capacity, 
or because of a decline in their function (β cell failure) (Bartolome and Guillen 2014). 
This causes the progression to overt diabetes, which is characterised by reduced 
pancreatic β cell function, and reduced pancreatic β cell mass and viability (Butler et 
al. 2003, Muoio and Newgard 2008).  
The loss of pancreatic β cell mass and viability can be ascribed, at least in part, to the 
elevated circulating levels of glucose and free fatty acids (FFA), typical of the diabetic 
condition (Barlow and Affourtit 2013). Indeed, the metabolic deregulation caused by 
T2D leads to impaired handling of glucose and fatty acids, which subsequently 
circulate at higher levels in the bloodstream. Several lines of evidence suggested 
that increased glucose and FFA levels are toxic and induce apoptosis, and they are 
one of the main factors contributing to the decrease of β cell mass (Lee et al. 1994, 
McGarry 2002, El-Assaad et al. 2003). These toxic effects on cell viability are defined 
as glucotoxicity, lipotoxicity and glucolipotoxicity. It was observed that pancreatic β 
cell mass mainly decreases because of increased apoptosis in diabetic subjects 
(Butler et al. 2003). Interestingly, recent lines of evidence indicated a crucial role for 
autophagy in the regulation of β cell mass and function. For instance, using mice 
models, it has been shown that genetic impairment of autophagic processes in 
pancreatic β cells results in glucose intolerance (Ebato et al. 2008, Jung et al. 2008). 
Also, these mice showed decreased β cell mass and pancreatic insulin content and 
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lower fasting serum insulin concentration, which suggested a crucial role for 
autophagy in pancreatic function (Jung et al. 2008). In addition, analysis of human 
islets of diabetic patients indicated that 50% of β cells showed signs of autophagy-
associated cell death (Masini et al. 2009). Due to the key role of PI3K in regulation of 
pancreatic β cell mass, survival and autophagy, it is not surprising that alterations of 
PI3K pathway have been detected in diabetes. 
 
Role of PI3K-dependent pathway in diabetes 
Analysis of mice models demonstrated that genetic manipulation of PI3K pathway 
could cause alteration of insulin signalling and induce T2D. It was reported that the 
lack of IRS1 in knockout mice retards growth and causes mild insulin resistance but 
overt diabetes does not develop. Specifically, IRS1 knockout mice were able to 
compensate the impaired insulin signalling by increasing pancreatic β cell mass and 
increasing the secretion of insulin. This indicated that other IRS isoforms are able to 
compensate in insulin signalling for IRS1 absence. On the other hand, the lack of 
IRS2 causes overt diabetes in knockout mice, because of their selective decrease in β 
cell mass (Withers et al. 1998). Importantly, this was already observed in newborn 
mice and therefore it was not the consequence of a metabolic phenotype (Withers 
et al. 1998).  
Homozygous knockout of p110α or p110β are lethal in embryo (Bi et al. 1999, Bi et 
al. 2002). Mice with heterozygous loss of p110α or p110β showed no impairment in 
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insulin signalling, while the double heterozygous p110α+/- p110β+/- had a mild defect 
in insulin response, namely a slight glucose intolerance and hyperinsulinemia in 
fasting state (Brachmann et al. 2005), suggesting a complementary role of the two 
isoforms. Nevertheless, several studies supported the conclusion of a predominant 
role for p110α in insulin response: chemical inhibitors of p110α (but not of p110β or 
p110) have been shown to prevent insulin-induced phosphorylation of Akt in 3T3 
adipocytes and L6 myotubes, and to decrease insulin sensitivity and glucose 
transport in mice (Knight et al. 2006). Mice with homozygous mutation inactivating 
p110α kinase activity died in embryo (E10-11), while heterozygous mice carrying this 
mutation were viable and showed impaired insulin signalling, with insulin resistance 
and glucose intolerance (Foukas et al. 2006). On the other hand, homozygous 
inactivation of p110β kinase activity in mice did not always result in embryonic 
lethality. Specifically, homozygosity for a catalytically inactive form of p110β caused 
embryonic lethality with incomplete penetrance, as the number of viable mice was 
lower than expected. In addition, heterozygous mice displayed only mild increase in 
blood glucose (Ciraolo et al. 2008). 
Selective knockout models for Akt isoforms have also been developed. Global 
knockout of Akt2 in mice models caused metabolic effects such as hyperglycemia 
and compensatory hyperinsulinemia, and impaired repression of gluconeogenesis in 
the liver (Cho et al. 2001). 
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Taken together, data from mice models indicated that deregulation of PI3K pathway 
can impair insulin signalling and pancreatic β cell function and lead to T2D. Deletion 
of mTORC1 downstream effector 4EBP1 increased ER-stress-induced susceptibility 
to apoptosis in MIN6 cells and decreased insulin secretion and pancreatic insulin 
content in mice models fed a high fat diet. In the same study, the authors reported 
that deletion of 4EBP1 in diabetic mice models accelerated β cell loss and decreased 
protein synthesis, suggesting  a deregulated translational control under ER stress 
conditions (Yamaguchi et al. 2008). 
Importantly, evidence of deregulation of PI3K pathway in T2D has also been 
reported. For instance, human islets carrying the Arg972 polymorphism of IRS1, 
which has been associated with T2D, showed reduced insulin secretion, reduced 
number of insulin granules and increased apoptosis following serum deprivation 
(Marchetti et al. 2002, Marchetti et al. 2008). Moreover, studies on the db/db 
mouse model (a well established mouse model of obesity-induced diabetes) showed 
that insulin secretion is impaired, probably through downregulation of class I 
PI3K/Akt pathway (Kaneko et al. 2010). Specifically, the authors showed that plasma 
insulin levels are transiently increased in this diabetic mice model, along with the 
expression of regulatory subunits of class I PI3K, p110α, insulin receptor and IRS2, 
only to subsequently decline in a later stage marked by insulin deficiency. In 
addition, it was demonstrated that the downstream effector of Akt AS160, is 
expressed in human islets, and it is phosphorylated in human islets and primary 
mouse β cells following glucose stimulation and activation of Akt (Bouzakri et al. 
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2008). Importantly, AS160 expression was decreased in type 2 diabetic subjects and 
this can be associated with reduced β cell function, since knockdown of AS160 
impairs glucose-induced insulin secretion, increases apoptosis and decreases 
proliferation in both MIN6 cells and primary mouse β cells (Bouzakri et al. 2008). 
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1.2 PI3K-C2α 
Human PI3K-C2α was first cloned from the cell line U937. Studies showed a wide 
tissue distribution of the mRNA encoding for PI3K-C2α, with the highest levels of 
expression found in the heart, placenta and ovary (Domin et al. 1997). As the other 
class II PI3K isoforms, PI3K-C2α lacks the regulatory subunit binding domain. Class II 
PI3Ks differ between them for the N-terminus extension; specifically, PI3K-C2α 
possesses a clathrin-binding region in its N terminus domain (Mazza and Maffucci 
2011). One of the specific features of PI3K-C2α is its low sensitivity to classical PI3K 
inhibitors wortmannin and LY294002 (Domin et al. 1997), which has been used as a 
tool to identify the involvement of this specific isoform in biological processes. 
 
1.2.1 Activation of PI3K-C2α 
One of the first studies on PI3K-C2α in vivo activation reported that the enzyme was 
activated by insulin in the insulin-responsive cell lines Chinese hamster ovary cells 
expressing insulin receptor (CHO-IR), L5L6 myotubes, and 3T3-L1 adipocytes but not 
in 3T3-L1 preadipocytes, undifferentiated L5L6 myoblasts, or HEK 293 cells (Brown 
et al. 1999). Consistent with this, insulin-induced activation of PI3K-C2α was also 
reported in intact rat skeletal muscle, suggesting the involvement of PI3K-C2α in 
insulin signalling in a central insulin-responsive tissue (Soos et al. 2001). 
Subsequently, work from our laboratory showed that insulin stimulation of L6 
muscle cells was able to activate PI3K-C2α through TC10 (Maffucci et al. 2003), a 
61 
 
small GTPase which has been implicated in insulin-dependent GLUT4 translocation 
to the plasma membrane (Chiang et al. 2001). Further investigation revealed that 
PI3K-C2α translocated to the plasma membrane of L6 cells upon insulin stimulation, 
promoting the synthesis of the lipid product PtdIns3P (Falasca et al. 2007). 
Consistent with this, PI3K-C2α-like activity was observed in immunocomplexes of IR-
B but not IR-A in insulin stimulated HIT-T15 β cells. This suggested that insulin 
activates PI3K-C2α through its association to IR-B at the plasma membrane, in a 
distinct mechanism compared to class I PI3Ks, which associate to IR-A (Leibiger et al. 
2001). The authors further reported a codistribution of PI3K-C2α and IR-B at the 
plasma membrane in MIN6 cells upon either insulin or glucose stimulation (Leibiger 
et al. 2010). In contrast with this, Brown and colleagues reported that PI3K-C2α did 
not form a complex with the insulin receptor, since PI3K-C2α and insulin receptor 
did not coimmunoprecipitate in insulin-stimulated CHO-IR cells (Brown et al. 1999).  
In this study, the authors suggested that PI3K-C2α associated with two tyrosine 
phosphorylated proteins, one of 207 kDa and the other of 160 kDa but their identity 
remains unknown (Brown et al. 1999). More recently, and in a different cellular and 
functional context, relocalisation of PI3K-C2α was also described. Specifically, it was 
observed that PI3K-C2α translocated from the cytoplasm to plasma membrane and 
vesicular compartments at the periphery of the cells in HeLa cells following 
dynamin-independent endocytotic processes (Krag et al. 2010). Taken together, 
these data suggest that one of the mechanisms of PI3K-C2α activation may involve 
its translocation to the plasma membrane, at least in certain conditions.  
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Since PI3K-C2α lacks a regulatory subunit, different mechanisms of activation for 
PI3K-C2α were proposed. In the original report showing an insulin-dependent 
activation of PI3K-C2α, it was proposed that the enzyme may undergo 
phosphorylation, but this hypothesis was not further investigated. Specifically, 
Western Blot analysis showed that the enzyme PI3K-C2α was detected as a single 
band in unstimulated cells, and as a doublet upon insulin stimulation, suggesting a 
post-translational modification dependent on insulin treatment (Brown et al. 1999). 
The fact that PI3K-C2α possesses several binding domains led to the hypothesis that 
they could be involved in its activation. It was reported that PI3K-C2α could directly 
bind clathrin through its N-terminal domain, and that its activity was enhanced in 
vitro in the presence of clathrin (Gaidarov et al. 2001). Also, PI3K-C2α has been 
shown to be enriched on clathrin-coated vesicles in fibroblasts (Domin et al. 2000), 
whereas no detectable PI3K-C2α association with clathrin-coated vesicles was found 
in chromaffin cells (Meunier et al. 2005). More recently, it was reported that PI3K-
C2α regulates clathrin-mediated endocytosis in the COS7 fibroblast-like cell line, by 
regulating the maturation of clathrin coated vesicles (Posor et al. 2013). 
In addition, several lines of evidence reported that PI3K-C2α activity was regulated 
by Ca2+. Specifically, kinase assay was performed on recombinant PI3K-C2α 
immunoprecipitated from HEK cells and results showed that Ca2+ was able to directly 
activate PI3K-C2α (Wen et al. 2008). Consistent with this, the activity of PI3K-C2α 
immunoprecipitated from de-endotheliased rabbit aortic vascular smooth muscle 
increased upon stimulation with KCl, noradrenaline or ionomycin, and extracellular 
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Ca2+ depletion prevented the noradrenaline-induced activation of PI3K-C2α. This 
indicated that PI3K-C2α stimulation was Ca2+-dependent (Wang et al. 2006). 
Interestingly, it was recently shown that PI3K-C2α is implicated in KCl-induced 
insulin secretion in INS1 cells, a process dependent on intracellular Ca2+ increase 
(Dominguez et al. 2011). However, further studies are needed to determine whether 
Ca2+ alone is sufficient to induce the activation of PI3K-C2α in vivo. 
 
1.2.2 Lipid product of PI3K-C2α 
As reported for the other members of class II PI3K, PI3K-C2α is able to 
phosphorylate the substrates PtdIns and PtdIns4P in vitro, with a strong substrate 
preference for PtdIns (Mazza and Maffucci 2011, Falasca and Maffucci 2012). 
Evidence from in vivo studies indicated that cells have different pools of PtdIns3P: a 
constitutive pool, regulated by class III PI3K and associated with intracellular 
endosomes, and an inducible pool which is emerging as the product of class II PI3Ks, 
generated at the plasma membrane (Falasca and Maffucci 2009). 
Indeed, studies on L6 muscle cells and 3T3-L1 adipocytes indicated for the first time 
that an insulin dependent pool of PtdIns3P was synthesised at the plasma 
membrane of the cells, and that its synthesis was resistant to classical PI3Ks 
inhibitors (Maffucci et al. 2003, Falasca et al. 2007). The fact that class II PI3K-C2α is 
the most resistant isoform among PI3Ks to treatment with classical inhibitors 
wortmannin and LY294002 suggested its involvement in the insulin-induced 
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neosynthesis of PtdIns3P (Maffucci et al. 2003). Subsequent studies showed that 
PtdIns3P was the sole product of PI3K-C2α, through specific downregulation of  
PI3K-C2α expression in L6 cells and analysing the levels of intracellular PIs, and the 
intracellular localisation of PtdIns3P (Falasca et al. 2007). Specifically, HPLC analysis 
showed that insulin stimulation induced synthesis of PtdIns3P, which was 
significantly reduced upon downregulation of PI3K-C2α. No changes were detected 
in the insulin-stimulated levels of PtdIns(3,4)P2 and PtdIns(3,4,5)P3 in PI3K-C2α 
knock down cells. Consistent with these data, it was reported that the steady-state 
levels of PtdIns3P were reduced in pheochromocytoma (PC12) cells expressing a 
catalytically inactive mutant of PI3K-C2α (Meunier et al. 2005). In addition, these 
authors also showed that the synthesis of a pool of PtdIns3P on neurosecretory 
vesicles is dependent on PI3K-C2α activation (Wen et al. 2008). Specifically, in this 
study they demonstrated that PI3K-C2α knockdown or expression of a catalytically 
inactive mutant of PI3K-C2α in PC12 cells inhibited the nicotine-induced, Ca2+-
dependent production of PtdIns3P on neurosecretory vesicles, and that knockdown 
of PI3K-C2α abolished the wortmannin-insensitive pool of PtdIns3P in PC12 cells 
(Wen et al. 2008). Consistent with these data, it was recently shown that 
simultaneous knockdown of class II PI3K-C2α and PI3K-C2β reduced the levels of 
PtdIns3P, with no effect on PtdIns4P or PtdIns(4,5)P2 in mouse embryonic fibroblasts 
(MEF) cultured in complete medium (Devereaux et al. 2013). Importantly, it has 
been recently observed that the total cellular content of PtdIns3P, but not of 
PtdIns(3,4)P2, PtdIns(3,5)P2 or PtdIns(3,4,5)P3, was reduced in PI3K-C2α
-/- MEFs, and 
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that the endosomal localisation of a fluorescent PtdIns3P probe was decreased in 
humbilical vein endothelial cells (HUVEC) upon downregulation of PI3K-C2α, but not 
p110α or Vps34 (Yoshioka et al. 2012). Consistent with this, a very recent study 
using MEF with homozygous deletion for PI3K-C2α confirmed the conclusion that 
PtdIns3P is the lipid product of this enzyme (Franco et al. 2014). Specifically, the 
authors reported that staining wild type MEF with a PtdIns3P-selective GFP-2XFYVE 
fluorescent probe or with anti-PtdIns3P antibodies revealed an intracellular pool of 
PtdIns3P localised at the base of the cilium,  an organelle that has crucial roles in 
vertebrate development, regulating cell proliferation, polarity, differentiation and 
tissue organization. The levels of PtdIns3P at the base of the cilium was significantly 
reduced in PI3K-C2α knockout MEF. Interestingly, the localisation of PtdIns3P 
detected in the rest of the cell did not show significant changes. This indicates that 
PI3K-C2α is able to regulate a specific intracellular pool of PtdIns3P. These data were 
confirmed by HPLC analysis of intracellular PIs, and specifically the authors reported 
a significant reduction in PtdIns3P levels upon metabolic labelling of serum-starved 
PI3K-C2α-/- MEFs, confirming the conclusion that PI3K-C2α modulates the levels of a 
specific pool of PtdIns3P.  
In contrast with these data, HPLC analysis of intracellular PIs showed that PI3K-C2α 
specifically generated PtdIns(3,4)P2 in MIN6 cells upon insulin stimulation, while no 
changes in the levels of PtdIns3P and PtdIns(3,4,5)P3 were observed (Leibiger et al. 
2010). Recently, using specific PI-binding domain based sensors and an anti-
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PtdIns(3,4)P2 antibody, it was reported that PtdIns(3,4)P2 is synthesised by PI3K-C2α 
in COS7 cells (Posor et al. 2013). 
 
1.2.3 Functions of PI3K-C2α 
Studies on the intracellular functions regulated by PI3K-C2α revealed that this 
enzyme is involved in many intracellular processes. In the past few years, it has been 
reported that PI3K-C2α has a role in exocytotic and endocytotic processes, glucose 
transport and insulin secretion. Although these processes seem distinct, they share 
some similarities that might suggest a common mechanism of action for PI3K-C2α. In 
addition, it was shown that PI3K-C2α is able to regulate cell survival and apoptotic 
processes. 
 
Exocytosis/endocytosis 
Several lines of evidence indicate that PI3K-C2α is involved in exocytotic processes. 
PI3K-C2α is required for the ATP-dependent priming phase of neurosecretory 
granules exocytosis in chromaffin cells, in a process that requires synthesis of 
PtdIns3P (Meunier et al. 2005). In particular, the authors showed that 
neurosecretion in PC12 cells was increased by overexpression of PI3K-C2α, while its 
catalytically-inactive mutant or expression of a probe sequestering PtdIns3P had an 
inhibitory effect. In a subsequent study, the authors demonstrated that knockdown 
of PI3K-C2α inhibited the Ca2+-dependent synthesis of PtdIns3P on neurosecretory 
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vesicles of PC12 cells (Wen et al. 2008), confirming the role of PI3K-C2α in this 
context. 
More recent studies have also shown that PI3K-C2α is required for exocytotic 
processes in different cellular contexts. For example, it was reported that PI3K-C2α 
is involved in glucose-induced insulin secretion in MIN6 cells (Leibiger et al. 2010). In 
addition, previous work indicated that KCl-induced insulin granules exocytosis is 
impaired by downregulation of PI3K-C2α (Dominguez et al. 2011). Specifically, it was 
reported that stable knockdown of PI3K-C2α in the insulin secreting cell line INS1 
strongly reduced KCl-induced fusion of insulin granules to the plasma membrane, 
without affecting the total insulin content of the cells. Moreover, downregulation of 
PI3K-C2α also impaired proteolysis of the protein SNAP 25, an event associated with 
insulin secretion. As KCl stimulation specifically induces the fusion of insulin granules 
to the plasma membrane, these data suggested that PI3K-C2α was specifically 
involved in the late steps of insulin exocytosis, namely the fusion of insulin 
containing granules to the cellular plasma membrane. 
Consistent with this observation, several lines of evidence reported a role for PI3K-
C2α in exocytotic-like processes in different cellular contexts, supporting the 
hypothesis that PI3K-C2α is critical for fusion events in distinct cellular contexts. In 
particular, in the context of insulin signalling, it was shown that downregulation of 
PI3K-C2α in L6 muscle cells impaired GLUT4 translocation to the plasma membrane 
in response to insulin stimulation (Falasca et al. 2007). Also, it was shown that a 
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maximal GLUT4 translocation requires the synthesis of PtdIns3P at the plasma 
membrane. 
The fusion of GLUT4 vesicles to the plasma membrane required the same family of 
accessory proteins involved in insulin granules fusion, and that the SNAREs 
machinery required in both GLUT4 translocation and insulin secretion is also similar 
to that implicated in neurosecretion (Jewell et al. 2010). In addition, it has recently 
been reported that depletion of PI3K-C2α in MEF caused impaired activation of 
Rab11, a small GTPase member of the Rab family, which modulate delivery and 
docking of secretory vesicles at the base of the cilium in MEF (Franco et al. 2014). 
Also, results from this study showed that GFP-tagged PI3K-C2α in wild type MEF was 
localised in vesicular structures surrounding the ciliary basal body, which is involved 
in primary cilium biogenesis. These results were confirmed by analysing the 
intracellular localisation of endogenous PI3K-C2α in inner medullary collecting duct 
3 (IMCD3) cells, a cell line widely used in cilium studies. The authors proposed that 
the loss of PI3K-C2α in MEF caused Rab11 delocalisation/deactivation, which in turn 
impaired cilia formation, likely as a consequence of defective trafficking of ciliary 
components. 
A role for PI3K-C2α has also been reported in the context of endocytosis. 
Specifically, it was shown that silencing of PI3K-C2α in HeLa cells reduced fluid-phase 
endocytosis and internalisation of diphtheria toxin, in a dynamin-independent 
process that did not require other PI3K isoforms (Krag et al. 2010). Similarly, it was 
69 
 
reported that PI3K-C2α was able to modulate clathrin-mediated endocytosis. 
Specifically, overexpression of PI3K-C2α impaired endocytosis of transferrin and 
clathrin-mediated membrane trafficking to plasma membrane and trans-Golgi 
network, without affecting the overall Golgi structure (Gaidarov et al. 2001).  
 
 
Cell viability 
It was reported that downregulation of PI3K-C2α caused decreased proliferation and 
increased apoptosis in HeLa cells, without affecting class I PI3K/Akt survival pathway 
(Elis et al. 2008). The same study analysed the viability of several normal and cancer 
cell lines upon downregulation of PI3K-C2α and in normal growth conditions. Results 
indicated that the majority of the cell lines tested (21 of 23) showed decreased 
viability upon downregulation of  PI3K-C2α, and in more than a half of them (13 of 
23) viability was decreased by more than 50% (Elis et al. 2008). Consistent with this, 
it has been recently shown that downregulation of PI3K-C2α specifically induced 
apoptosis in HUVEC cells (Yoshioka et al. 2012, Tibolla et al. 2013). Also, 
downregulation of PI3K-C2α mRNA in DLD1 cells caused dosage-dependent 
inhibition of cell growth (Schepeler et al. 2012). In contrast with these results, 
downregulation of PI3K-C2α cells had no effect on cell proliferation in the muscle 
cell line L6 (Falasca et al. 2007), while only a slight increase of the percentage of cells 
in the sub-G1 phase of the cell cycle was observed in INS1 cells (Dominguez et al. 
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2011). In addition, other findings suggested that PI3K-C2α has a role as survival 
factor. For instance, downregulation of PI3K-C2α induced apoptosis in CHO-IR cell 
lines cultured in normal growth medium (Kang et al. 2005). Similarly, it was 
observed that downregulation of PI3K-C2α decreased proliferation and the ability to 
form colonies in 3D soft agar assays and increased apoptosis of hepatocarcinoma 
cell line Mahlavu (Ng et al. 2009). 
 
1.2.4 Mouse models 
The first PI3K-C2α null mouse model was reported in 2011 by Harris and colleagues 
(Harris et al. 2011). First, they generated heterozygous PI3K-C2α+/- mice, which had 
normal size, were fertile and were intercrossed to obtain progeny carrying 
homozygous deletion for PI3K-C2α. PI3K-C2α-/- mice were viable but smaller in size 
compared to control mice. At 4 to 6 weeks of age, PI3K-C2α-/- mice showed lower 
body weight and both lean and fat mass were reduced compared to control 
littermates. PI3K-C2α-/- mice became progressively sick as they aged, and 30% of 
them died within 6 months of age, compared to 5% of control animals. This 
indicated that PI3K-C2α was important for post-natal development of the animals. 
Analysis of blood and urine samples from animals at 6 weeks of age indicated kidney 
failure in PI3K-C2α-/- mice. Subsequent analysis revealed that kidney damage 
became apparent in mice of 4 weeks of age, with glomerular leakage, proteinuria 
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and severe lesions to podocytes, critical components of the glomerular filtration 
barrier. 
A second knockout model has been generated in 2012 (Yoshioka et al. 2012). The 
authors reported that PI3K-C2α-/- genotype was lethal, as mice embryos showed 
retarded growth at day E8.5, and they died at day E10.5-11.5. This indicated a crucial 
and specific role for PI3K-C2α in embryonic development. In particular, data showed 
that lack of PI3K-C2α affected vascular development, as the major blood vessels 
were disorganised or absent in PI3K-C2α-/- embryos. In order to further study the 
function of PI3K-C2α, tissue specific and inducible knockout models were created. 
Results showed that endothelial-cell-specific PI3K-C2α-/- also presented embryonic 
lethal phenotype, with impairment of vessels formation and development. The 
generation of a tamoxifen-inducible and endothelial-cell-specific PI3K-C2α knockout 
mice allowed studying postnatal physiological angiogenesis. Evidence indicated 
increased apoptosis in retinas upon PI3K-C2α depletion and an impairment in retinal 
angiogenesis, suggesting a crucial role for PI3K-C2α in vascular formation. These 
data are consistent with the observation that downregulation of PI3K-C2α impaired 
morphogenesis, inhibited cell survival and increased apoptosis in human endothelial 
cells (Tibolla et al. 2013). 
More recently, global knockout for PI3K-C2α was performed and the phenotype of 
MEF was analysed. In contrast with the mice model previously reported by Harris 
and colleagues, where a truncated form of PI3K-C2α was still detected, in this case 
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the authors reported a complete ablation of PI3K-C2α (Franco et al. 2014). Similarly 
to what observed by Yoshioka and colleagues, these authors reported that 
homozygous deletion of PI3K-C2α caused growth defects at embryonic day 8.5 and 
lethality between E10.5 and E11.5. However, while Yoshioka and colleagues 
indicated that loss of PI3K-C2α was lethal during vasculogenesis due to endothelial 
abnormalities, this study indicated that lethality in PI3K-C2α-/- embryos was caused 
by defective trafficking of ciliary components, in a developmental stage preceding 
vasculogenesis (Franco et al. 2014). 
 
1.2.5 PI3K-C2α and diabetes 
The link between class I PI3Ks and human diseases such as diabetes and cancer is 
well established. On the other hand, much less is known about class II PI3Ks and 
their physiologic and pathophysiologic roles. The precise role of class II PI3K-C2α 
remains to be understood. However, evidence suggest a potential link between 
PI3K-C2α and T2D. Indeed, it was shown that the mRNA encoding for class II 
enzymes PI3K-C2α and PI3K-C2 was expressed in the majority of human islets of 
Langerhans (more than 75%), with frequency even higher than class I PI3Ks (Muller 
et al. 2006). Also, human islets from T2D individuals showed reduced mRNA levels of 
PI3K-C2α, compared to islets from non diabetic subjects. No difference in the levels 
of the mRNA encoding PI3K-C2β or PI3K-C2 was reported (Dominguez et al. 2011). 
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Whether or not PI3K-C2α downregulation is linked to type 2 diabetes, or whether it 
could be a cause or an effect of the diabetic condition remains to be understood. 
As briefly mentioned before, a crucial role for PI3K-C2α in pancreatic β cell function 
has also recently emerged. For instance, it was shown that insulin-induced 
expression of β-glucokinase mRNA did not involve the activation of class I PI3Ks and 
was not impaired by the use of classical PI3K inhibitors wortmannin and LY294002, 
which suggested the involvement of PI3K-C2α (Leibiger et al. 2001). Indeed, it was 
later demonstrated by the same group that this process specifically involved the 
action of PI3K-C2α in MIN6 cells (Leibiger et al. 2010). In this study, the authors also 
showed that downregulation of PI3K-C2α impaired glucose-induced insulin secretion 
in MIN6 cells (Leibiger et al. 2010). Consistent with this, it was also shown that 
downregulation of PI3K-C2α in INS1 cells decreased KCl-induced insulin secretion 
(Dominguez et al. 2011). Taken together, these data indicate that PI3K-C2α has a 
crucial role in regulation of pancreatic β cell function.  
Interestingly, it has been recently suggested that PI3K-C2α might be involved in the 
activation of mTOR. Indeed, it was reported that PI3K-C2α was required for mTORC1 
activation and its translocation to the plasma membrane in 3T3-L1 adipocytes 
(Bridges et al. 2012). Specifically, the authors reported that downregulation of PI3K-
C2α impaired mTORC1 activity, as assessed by phosphorylation of its downstream 
effector S6K upon serum starvation and stimulation with insulin. Importantly, no 
effect on the phosphorylation of Akt was observed, indicating that PI3K-C2α is not 
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involved in the ‘classical’ Akt/mTOR axis. Furthermore, it was shown that 
downregulation of PI3K-C2α impaired endogenous mTORC1 translocation to the 
plasma membrane in response to insulin and amino acids stimulation in the same 
cell line (Bridges et al. 2012).  
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1.3 Aims of the project 
Evidence discussed in this chapter indicated that PI3Ks have a central role in both 
insulin producing and insulin target cells. Most of our knowledge comes from the 
study on class I PI3Ks but more recently it became evident that PI3K-C2α also has an 
important role in insulin producing and insulin target cells. However, many 
questions on the functional role of PI3K-C2α and its mechanisms of action and 
activation are still unanswered.  
The rationale of the present study was mainly based on the findings published by my 
research group (Dominguez et al. 2011). In this study, it was shown that 
downregulation of PI3K-C2α impaired insulin granule exocytosis in the rat 
insulinoma cell line INS1. Interestingly, it was also shown that the mRNA encoding 
for PI3K-C2α was significantly lower in pancreatic islets from T2D patients compared 
to non diabetic individuals. This suggested a crucial involvement of PI3K-C2α in the 
regulation of pancreatic β cell function. 
Therefore, the aims of this project were: 
 Investigation of the mechanisms of downregulation of PI3K-C2α 
 Investigation of the functions and the signalling pathways regulated by PI3K-
C2α in pancreatic β cells  
 Investigation of the mechanisms of activation of PI3K-C2α in pancreatic β 
cells   
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Chapter 2 
Materials and Methods 
2.1 Cell culture 
2.1.1 Cell culture and propagation 
Rat insulinoma cells INS1 were cultured in RPMI (powder medium, Sigma-Aldrich, 
UK), supplemented with 11mM D-glucose (Sigma-Aldrich, UK), 26 mM sodium 
bicarbonate (Sigma-Aldrich, UK), 10 mM HEPES (Sigma-Aldrich, UK), 50 μM β-
mercaptoethanol (Sigma-Aldrich, UK), pH 7.4. Dissolved medium was filtered using 
sterile bottles with a 0.22μm top bottle filter (Merck Millipore, UK) and it was 
supplemented with 10% v/v Foetal Bovine Serum (FBS) (Life Technologies), 1X L-
Glutamine/Penicillin/Streptomycin (PAA), 1% v/v Sodium Pyruvate (Life 
Technologies).  
Cells were seeded in T75 vented flasks, with gas-permeable caps, tissue culture 
treated or multi-well dishes (BD, UK) and grown in humidified incubator at 37°C in a 
5% CO2 atmosphere. 
Stable cell lines lacking the enzyme PI3K-C2α were previously generated in Dr. 
Maffucci’s laboratory by retroviral infection of a pSuper vector containing a specific 
short hairpin RNA sequence (sh RNA). Stable control cells were generated at the 
same time using a non-targeting,  ‘scrambled’ shRNA (Dominguez et al., 2011). 
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2.1.2 Cell amplification and passage 
INS1 were passaged every 2 days, when 80% confluent. Medium was removed and 
cells were washed with sterile, pre-warmed, calcium free phosphate buffered saline 
solution 1X (PBS) (PAA, Austria). Then, 4ml of trypsin-EDTA (PAA, Austria) were 
added, in order to detach the cells, and flasks were put back in the incubator for 2-3 
minutes. Trypsin was inactivated with 8ml of pre-warmed complete growth medium 
and cells were gently harvested, pipetting up and down to disperse the medium on 
the flask surface. Cells were collected in 15ml or 50ml centrifuge tubes (Falcon-BD, 
UK) and centrifuged at 250g for 5 minutes at room temperature. Medium was gently 
aspirated, cells were resuspended in complete growth medium and seeded as 
required in new T75 tissue culture flasks or multiwell plates. 
 
2.1.3 Cryo-preservation and recovery of cell lines 
Cells in a T75 tissue culture flask were detached when 80% confluent. Cells were 
washed, detached, harvested and pelleted as previously described 2.1.2. Cell pellets 
were resuspended in 1ml of 90% FBS:10% DMSO (Sigma Aldrich, UK) freezing 
solution and the total volume of 1 ml was transferred in cryovials (VWR). Cells were 
stored at -80°C in a polystyrene box for a maximum of 10 days. For long term 
storage, cells were placed in dry ice and transferred into liquid nitrogen. 
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2.2 Biochemistry 
2.2.1 Protein sample preparation from cell lysates 
Cells were detached from T75 flasks when 80% confluent as previously described for 
cell passage. The pellet was resuspended in 10 ml of growth medium and an aliquot 
was transferred into a Bürker chamber for manual counting. Cells were then seeded 
at the desired confluence in 6 or 12 wells plates. When required, the following day 
after being plated cells were washed using sterile PBS and cultured in serum free 
medium for further 24 hours before stimulation. Alternatively, cells were starved in 
Krebs-Ringer buffer (0.1% w/v BSA, 125mM NaCl, 25mM Hepes, 5mM KCl, 2mM 
MgSO4, 1.67mM D-glucose, 1.2mM KH2PO4) and stimulated as required. 
Cells were then washed twice in ice-cold, non sterile PBS and lysed in 200μl of cold 
Triton X-100 lysis buffer (50mM Tris-pH 8.0, 150mM NaCl and 1% v/v Triton-X100) 
containing 1X protease inhibitor cocktail (Sigma-Aldrich, UK) and 1X phosphatase 
inhibitor cocktail II (Sigma-Aldrich, UK). In order to detach the cells, disposable cell 
scrapers were used. Lysates were then transferred in 1.5 ml tubes (VWR, UK) and 
centrifuged at 10,000g for 3 minutes at 4°C to remove debris and cellular 
membranes. The supernatants were collected and transferred into new 1.5 ml tubes 
and kept on ice until protein quantification. Lysates were stored at -20°C or -80°C for 
long conservation. 
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2.2.2 Measurement of Protein Concentration using Bradford protein 
assay 
Protein concentration was determined using the Bio-Rad Protein Assay, based on 
the method of Bradford. This was necessary to ensure equal loading of lysates 
during Western Blot experiments. Bradford solution (Bio-Rad, UK) was diluted to 1X 
with ddH2O and Bovine Serum Albumin (BSA, Sigma-Aldrich, UK) was used to 
generate a calibration curve for protein quantification. In a 96 wells plate, six 
dilutions of BSA/Bradford solution were prepared in duplicates, with concentrations 
range from 0 to 2 μg/μl (Table 2.1).  
 
Biorad protein 
assay 
1X Bradford 
reagent  (μl) 
BSA 200 μg/ml 
(μl) 
BSA (μg) 
Standard 
Curve 
200 0 0 μg 
198 2 0.4 μg 
196 4 0.8 μg 
196 6 1.2 μg 
192 8 1.6 μg 
190 10 2 μg 
Table 2.1: BSA Standard curve protein concentration 
 
 
Aliquots of cellular lysates were diluted 1:200, using the same Bradford solution. 
Duplicates were prepared for each sample and the absorbance at 595 nm was 
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measured using a microplate reader. A linear calibration curve was set, using 
Microsoft Excel® and plotting BSA concentration (X axis) and absorbance value (Y 
axis). The unknown protein concentration of the samples was calculated using the 
following formula: 
 
Abs = mx+b 
Abs=Absorbance; m=slope of the line; x=protein concentration; b=Y intercept 
Protein samples were then diluted in 5X denaturing sample buffer (Table 2.2) and 
heated at 95°C for 5 minutes to allow denaturation. Samples were analysed by SDS-
Polyacrylamyde Gel Electrophoresis (SDS-PAGE) and Western blot. Denatured 
samples were stored at +4°C for short period or at -20°C for long-term storage. 
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5X denaturing sample buffer (per 16 ml) 
ddH2O  6.8 ml 
0.5M Tris-HCl pH 6.8 2 ml 
Glycerol 87% 4 ml 
SDS 20% 1.6 ml 
Bromophenol Blue solution (6mg/ml) 1.6 ml 
Table 2.2: 5X Denaturing Sample Buffer  
 
2.2.3 SDS-PAGE and Western blot 
A resolving polyacrilamide gel solution was prepared using Tris-HCl pH 8.8, H2O, 
Acrylamide, 10% APS  and Temed (Table 2.3). The volume of Tris-HCl, Acrylamide 
and H2O was adjusted according to the desired final concentration of Acrylamide, in 
order to obtain a 7%, 10% or 15% resolving gel solution. The solution was poured 
into an assembled electrophoresis apparatus (Bio-Rad Laboratories, UK), overlaid 
with 1ml of ddH2O and left at room temperature (RT) until polymerised. 
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10% separating gel solution (per 5 ml)5X  
ddH2O  1.9 ml 
1.5M Tris, pH 8.8  1.3 ml 
Acrylamide mix ProtoGel (30% (w/v) acrylamide, 
0.8% (w/v) bisacrylamide stock solution (37.5:1) 
1.7 ml 
SDS 20% 0.05 ml 
10% APS 0.05 ml 
TEMED 0.02 ml 
Table 2.3: 10% separating gel solution. The volume of Tris-HCl, Acrylamide and H2O was adjusted 
according to the desired final concentration of acrylamide for 7% and 15% separating gel solutions 
 
Then, H2O was removed and a 5% stacking gel solution (Table 2.4) was prepared and 
poured on top of the prepared gel. A 10 or 15 sample comb was used and 
polymerysation was allowed at RT.  
 
5% stacking gel solution (per 1 ml) 
ddH2O 0.67 ml 
1M Tris, pH 6.8 0.13 ml 
Acrylamide mix ProtoGel (30% (w/v) acrylamide, 
0.8% (w/v) bisacrylamide stock solution (37.5:1) 
0.17 ml 
SDS 20% 0.01 ml 
10% APS 0.01 ml 
TEMED 0.01 ml 
Table 2.4: 5% stacking gel solution.  
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After removing the comb, gel wells were washed with ddH2O to remove residues 
and the gels were mounted in a tank with 1X Running Buffer (Table 2.5). Gel 
electrophoresis was performed applying a constant voltage of 110V, allowing the 
separation of proteins according to their molecular weight.  
 
1X Running Buffer 
25 mM tris, pH 8.3  
192 mM Glycine  
0.2% SDS  
Table 2.5: Running Buffer  
 
Proteins were then transferred from the gel onto a Protran® nitrocellulose 
membrane filter (Whatman, UK) by electroblotting in a dedicated tank (Bio-Rad 
Laboratories), using ice cold 1X Blotting Buffer (Table 2.6) supplied with 20% v/v 
methanol.  
 
1X Transfer Buffer 
25 mM tris, pH 8.3  
192 mM Glycine  
20% v/v Methanol 
Table 2.6: Transfer buffer  
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Transfer was allowed for 90 minutes at a constant current of 400mA at RT. 
Overheating was prevented by the presence of an icepack in the tank.  
Then, the nitrocellulose membrane was incubated with Ponceau-S solution 
(Applichem GmbH, UK) for 1-2 minutes at room temperature to assess correct 
protein transfer. Excess of Ponceau-S solution was removed by rinsing the 
membrane with ddH2O. 
 
2.2.4 Immunoblotting and analysis 
Nitrocellulose membrane was incubated for 30 minutes with PBS-0.05%Tween-20 
(v/v), supplemented with 5% milk (w/v) (Invitrogen), in order to achieve blocking of 
non-specific binding. Then, the membrane was incubated overnight at 4°C under 
agitation with a solution of PBS-0.05%Tween-20 (v/v) containing the primary 
antibody (Table 2.7). The solution was removed the following day and the 
membrane was washed in PBS-0.05%Tween-20 (v/v) 3X for 7-8 minutes.  
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Primary 
Antibody 
Company Cat. No Secondary Antibody Dilution 
PI3K-C2α BD Transduction 
Laboratories 
611046 
 
Anti-Mouse IgG 1:500 
PI3K-C2β BD Transduction 
Laboratories 
611343 
 
Anti-Mouse IgG 1:500 
p110α Cell Signalling 
Technology 
4249 Anti-Rabbit IgG 1:1000 
p110β Cell Signalling 
Technology 
3011 Anti-Rabbit IgG 1:1000 
p110 Santa Cruz 
Biotechnology 
sc-7177 Anti-Rabbit IgG 1:1000 
hVps34 Zymed 
Laboratories 
38-2100 Anti-Rabbit IgG 1:1000 
pmTOR 
(Ser 2448) 
Cell Signalling 
Technology 
5536 Anti-Rabbit IgG 1:1000 
P4EBP1 
(Ser37/46) 
Cell Signalling 
Technology 
2855 Anti-Rabbit IgG 1:1000 
pAkt (Ser473) Cell Signalling 
Technology 
4060 Anti-Rabbit IgG 1:1000 
pAkt (Thr308) Cell Signalling 
Technology 
2965 Anti-Rabbit IgG 1:1000 
pS6K (Thr389) Cell Signalling 
Technology 
9234 Anti-Rabbit IgG 1:1000 
pS6 
(Ser235/236) 
 
Cell Signalling 
Technology 
4858 Anti-Rabbit IgG 1:1000 
pS6 
(Ser240/244) 
Cell Signalling 
Technology 
5364 Anti-Rabbit IgG 1:1000 
pAMPKα 
(Thr 172) 
Cell Signalling 
Technology 
2531 Anti-Rabbit IgG 1:1000 
Akt 1/2/3 Santa Cruz 
Biotechnology 
Sc-8312 Anti-Rabbit IgG 1:1000 
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S6K Cell Signalling 
Technology 
9202 Anti-Rabbit IgG 1:1000 
S6 Cell Signalling 
Technology 
2317 Anti-Mouse IgG 1:1000 
AMPK Cell Signalling 
Technology 
2603 Anti-Rabbit IgG 1:1000 
Caspase 3 Cell Signalling 
Technology 
9665 Anti-Rabbit IgG 1:1000 
LC-3 Cell Signalling 
Technology 
2775 Anti-Rabbit IgG 1:1000 
ERK1/2 Santa Cruz 
Biotechnology 
sc-
135900 
Anti-Rabbit IgG 1:1000 
Tubulin Sigma-Aldrich T9026 Anti-Mouse IgG 1:10000 
Calpain 1 Cell Signalling 
Technology 
2556 Anti-Rabbit IgG 1:1000 
Calpain 2 Cell Signalling 
Technology 
2539 Anti-Rabbit IgG 1:1000 
Calpain 10 Kindly provided by 
Dr. M. Turner 
N/A Anti-Mouse IgG 1:1000 
Syntaxin 1 Santa Cruz 
Biotechnology 
sc-
12736 
Anti-Mouse IgG 1:1000 
Vamp 2 Kindly provided by 
Dr. G. Schiavo 
N/A Anti-Mouse IgG 1:1000 
Table 2.7: List of primary antibodies used 
 
Membrane was then incubated with a solution of PBS-0.05%Tween-20 (v/v) 
containing a dilution 1:15000 of the appropriate peroxidase-conjugated secondary 
antibodies anti-rabbit IgG (Sigma Aldrich, UK) or anti-mouse IgG (GE Healthcare, UK) 
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for 1 hour at RT. In order to remove the excess of secondary antibody, the 
membrane was washed 3X in PBS-0.05%Tween-20 (v/v) for 7-8 minutes and dried 
with chromatography paper (Whatman). Then, the membrane was incubated for 5 
minutes with ECL Prime solution (Amersham Bioscience, UK), dried, sealed in a 
plastic sheet, placed in a dedicated autoradiography cassette and exposed to an X-
ray film (Kodak) in a dark room. Exposure time varied depending on the amount of 
protein and antibody potency and was usually between 15 second and 10 minutes. 
 
2.2.5 Co-Immunoprecipitation 
INS1 cells were cultured in 100mm tissue culture treated Petri dishes (BD, UK). 
When cells reached 70% confluence, they were starved with Krebs-ringer buffer for 
30 minutes and stimulated with Krebs-ringer buffer supplemented with 60mM KCl + 
1mM Ca2+ for the indicated time. Then, cells were washed 3x with ice cold PBS, lysed 
on ice using lysis buffer containing 50mM Tris-pH 8.0, 150mM NaCl and 1% Triton-
X100 as previously described for preparation of cell lysates. Protein concentration 
was measured using the Bradford method and an aliquot of cell lysate was kept and 
processed as described for Western blot sample preparation. Then, 1 mg of cellular 
lysate for each sample was transferred in 1.5 ml eppendorf tubes and incubated 
overnight with 4 μg of anti VAMP2 antibody at +4°C in agitation. The following day, 
samples were incubated for 1 hour with 30 μl of Protein G Sepharose Fast Flow 
beads (GE Healthcare) to pull down the complex antibody/protein of interest. 
88 
 
Samples were centrifuged at 3,000 g for 5 minutes and supernatant was carefully 
removed. An aliquot of supernatant was kept and processed for Western Blot 
analysis to assess the efficiency of immunoprecipitation, and it was indicated as 
‘unbound’. Pellets were then washed 3X with PBS and samples were processed for 
Western Blot analysis, by adding 2X denaturing sample buffer and by heating at 95°C 
for 5 minutes to allow denaturation of the proteins and dissociation from the beads. 
Samples were then loaded on a 15% gel for SDS-PAGE. 
 
2.3 Cell Biology 
2.3.1 Cell counting 
INS1 cells were seeded in 12 well plates (15x105 cells/plate) in complete growth 
medium. They were left in the incubator for at least 12 hours, in order to let them 
attach to the plate, before being washed 1X with sterile PBS and incubated with 
serum-free medium. Culture medium was changed every 24 hours with fresh 
medium supplemented with the amount of glucose indicated in each experiment. 
Where indicated, medium also contained inhibitors. Cells were then detached using 
trypsin solution, harvested using complete growth medium and centrifuged at 2,000 
rpm for 5 minutes. The supernatant was carefully removed, the pellet was 
resuspended in complete growth medium (400 to 800 μl, depending on the 
experiments) and 10 μl of cell resuspension were placed in a Bürker chamber. 
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Usually, 4 or 5 fields were counted and the number of cells/ml was calculated with 
the formula: 
 
average number of cells/field * 10,000 = number of cells/ml 
All the measurements were performed in duplicate. 
 
2.3.2 MTT assay 
INS1 cells were seeded and treated as previously described for the cell counting. 
MTT 10X stock solution was prepared dissolving Thiazolyl Blue Tetrazolium Bromide 
(#M2128, Sigma-Aldrich, UK) 5mg/ml in serum free RPMI, filtered with a 0.22 μm 
syringe filter (Merck Millipore, UK) and kept at 4°C for a maximum of 5 days for 
further use. 100 μl of MTT 10X stock were added to 900 μl of serum free medium in 
a 12 well plate. Cells were placed in humidified incubator at 37°C in a 5% CO2 
atmosphere for 2 hours and 30 minutes. Then, medium was carefully removed from 
the plate with a vacuum aspirator and adherent cells were lysed in 600 μl of DMSO. 
The plate was placed on a shaker for 2 minutes in order to dissolve the formazan 
crystals completely and 100 μl of the solution were transferred to a 96 well plate. 
Triplicates of each sample and triplicates of a dilution 1:2 of each sample were 
analysed, measuring the absorbance at 570nm using a microplate reader, 
subtracting a background absorbance at 650nm.  
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2.3.3 Sodium Palmitate treatment 
INS1 cells were detached from T75 flasks when 80% confluent as previously 
described for cell passage. The pellet was resuspended in growth medium and 
manually counted into a Bürker chamber. Then, 12x105 cells were seeded in 
complete growth medium in 6 wells plates for lysates or 12 wells plates for cell 
counting and MTT assays. Cells were then left to attach to the plate for a minimum 
of 12 hours, in humidified incubator at 37°C in a 5% CO2 atmosphere. 
Fresh aliquots of sodium palmitate (#P9767, Sigma-Aldrich, UK) 100mM were 
prepared for every experiment. Palmitate was administered to cells after 
conjugation with free fatty acid-free bovine serum albumin (FFA-free BSA, Sigma). 
Sodium palmitate was dissolved in 100% Ethanol or Methanol (Sigma-Aldrich, UK) by 
vigorous vortexing followed by sonication, until it appeared as a milky solution. 
Complete growth medium was supplemented with 1% w/v BSA (Sigma-Aldrich, UK-
Aldrich, UK), filter sterilised and warmed up to 55°C. Then, medium was 
supplemented with the required amount of palmitate solution, cooled down to 
room temperature and administrated to INS1 cells for 24 or 48 hours.  
 
 
 
91 
 
2.3.4 GFP-2XFYVEHrs transfection 
Round coverlips of 60mm diameter were kept in ethanol. Then, coverslips were 
transferred to 12-well plates and ethanol was allowed to evaporate in a sterile 
environment. Cells were seeded (100000 cells/coverslip) in 12-well plates and 
incubated at 37°C and 5% CO2 atmosphere for 24 hours. Transfection of GFP-
2XFYVEHrs contained in pEGFP-C2 plasmid was optimised using 0.5μg of plasmid DNA 
and 2μl Lipofectamine® reagent according to the manufacturer’s instructions in 
serum free OPTIMEM medium. Two separate mixes were prepared, a ‘mix A’ 
containing 2μl Lipofectamine® (LifeTechnologies) in 50μl OPTIMEM and ‘mix B’ 
containing 0.5μg GFP-2XFYVEHrs plasmid in 50μl OPTIMEM (LifeTechnologies). The 
two solutions were incubated for 10 minutes at room temperature before being 
gently mixed and left to incubate for further 20 minutes at room temperature. Cells 
were washed with 1X PBS and 400μl serum free OPTIMEM were added to each well. 
Then, 100μl of transfection mix was added and cells were incubated for 4 hours at 
37°C and 5% CO2 atmosphere in a humidified incubator. Medium was then carefully 
removed and replaced with pre-warmed complete growth medium. 
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2.4 Molecular Biology 
2.4.1 RNA extraction 
Total RNA was extracted from INS1 cells treated with sodium palmitate for 24 or 48 
hours. Attached cells were trypsinised, collected and pelleted by centrifugation. RNA 
was immediately extracted using RNeasy kit (Qiagen, UK) following the 
manufacturer’s instructions. Total RNA was then quantified using Nanodrop and 
used for cDNA synthesis or stored at -80°C for subsequent use. 
 
2.4.2 RNA Reverse transcription 
cDNA was synthesised following the manufacturer’s instructions (Cat.No. EP0742, 
Thermo Scientific) using total RNA extracted from INS1 cells. Preparation for the 
reverse transcription reaction was performed on ice. Total RNA was diluted to a final 
concentration of 1μg/μl using RNAse-free water. Then, 1μg of template RNA was 
used for retrotranscription reaction, adding random primers, dNTPs, RT buffer, 
Ribolock RNase Inhibitor and Maxima Reverse Transcriptase as indicated in Table 
2.8. 
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Component Amount 
Template RNA 1μg 
Random Primers (#S0131) 1μl 
dNTP Mix, 10mM (#R0191) 1μl 
Nuclease free H2O To 12.5μl 
5X RT Buffer 4μl 
Ribolock RNase Inhibitor (#E00381) 0.5μl 
Maxima Reserve Transcriptase 1μl 
Total Volume 20μl 
Table 2.8: Reagents used for cDNA synthesis. 
 
The PCR thermal-cycler was programmed as indicated in Table 2.9. 
 
Time (min) Temperature (°C) 
10 25 
30 50 
5 85 
∞ (until collection) 4 
Table 2.9: Program used for PCR thermal cycler. 
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2.4.3 Real Time quantitative Polymerase Chain Reaction (RT-qPCR) 
Mix for RT-qPCR was prepared using 12.5 μl of 2X Maxima® SYBR green qPCR master 
mix (Fermentas), a final concentration of 0.25μM of forward and reverse primers 
and nuclease free H2O to a final volume of 25 μl. Then, 200ng of cDNA was added. 
For each qPCR reaction a 18S ribosomal subunit cDNA was amplified as internal 
control. ABI 7500 Real-Time PCR system was programmed as indicated in Figure 
2.11. 
 
Primer Sequence 
PI3K-C2α Fw 5’ TGTGGACCTCTGCTGTCAAG 3’ 
PI3K-C2α Rv 5’ AACTTTGTGGCAATGCTTCC 3’ 
18S Fw 5’ TCTTCCACAGGAGGCCTACACG 3’ 
18S Rv 5’ GCCCCACACCCTTAATGGCAGT 3’ 
Table 2.10: Primers used for the amplification of Rat PI3K-C2α and 18S ribosomal subunit 
 
 
Figure 2.11: Program used for RT-qPCR reaction using the ABI 7500 Real-Time PCR system software. 
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Relative quantification of gene was calculated using the relative ddCT method and 
the ABI 7500 Real-Time PCR system software. 
 
2.5 Imaging methods 
2.5.1 Confocal Microscopy Analysis 
INS1 cells were seeded on coverslips and transfected with GFP-2XFYVEHrs as 
previously decribed. 48 hours post transfection, cells were starved for 30 minutes in 
Krebs-Ringer buffer and then stimulated with Krebs-Ringer Buffer + 60mM KCl and 
1mM Ca2+. After stimulation, cells were washed 3x in PBS and fixed in 4% 
paraformaldehyde for 30 minutes. Cells were then permeabilised with PBS-0.25% 
Triton-X-100 for 2.5 minutes, washed 3x in PBS and incubated with PBS/0.1% BSA, 
0.3M glycine for 30 minutes to increase antibody specificity and reduce 
autofluorescence. Syntaxin 1 antibody (Santa Cruz Biotechnology) was diluted 1:50 
in PBS/0.1% BSA, and incubated for 2 hours at room temperature in a humidified 
chamber, 50μl/coverslip. Coverslips were washed 3x in PBS and incubated with 
Alexa Fluor 555 Goat Anti-Mouse IgG (1:500) in PBS 0.1% BSA for 1h at room 
temperature. Coverslips were then washed 3x in PBS, 1x in dH2O, mounted with 
Vectashield mounting media and analysed with a Zeiss Confocal Microscope 710. 
63x objective was used to observe cells and take pictures. Alternatively, coverslips 
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were analysed with a Leica DM5000 automated epifluorescence microscope, using 
63x objective to observe cells. 
 
2.6 Lipid analysis 
2.6.1 HPLC analysis of intracellular phosphoinositides 
INS1 cells were plated in 6 wells plates (18x105 cells/well) and left for 24 hours. 
Then, cells were incubated for 24 hours in M199 media (inositol-free media) 
supplemented with 1% v/v penicillin/streptomycin/glutamine and 5μCi/well myo-
[3H]inositol.  Cells were then starved in Krebs-Ringer buffer for 30 minutes and 
stimulated with Krebs-Ringer buffer containing 60mM KCl and 1mM Ca2+ for the 
indicated time points. Where necessary, cells were appropriately starved and 
stimulated as indicated in the text. Cells were lysed in HCl 1M/1mM EDTA and 
scraped from the well surface. Lysates were collected in glass chromacol vials and 
phospholipids were extracted by phase separation using 500 μl  1M hydrochloric 
acid, 670 μl methanol and 1.3 ml chloroform. Samples were vigorously vortexed and 
subsequently centrifuged until the aqueous and the organic phase appeared 
completely separated. The organic phase containing PIs was manually retrieved and 
solvents were removed using a rotary evaporator. Then, PIs were deacylated by 
resuspending the pellet in a mix of monomethylamine, water, butanol and methanol 
(5:4:3:1) and by incubating for 30-45 minutes at 53°C in a waterbath. Samples were 
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allowed to cool down and a second phase separation was performed. Aqueous 
phase containing glycerophosphoinositides was separated by the organic phase 
containing acyl chains using a mix of butanol, petroleum ether and ethyl acetate 
(20:4:1). Evaporation of the solvents was allowed in a rotary evaporator before 
samples were resuspended in 600 μl of ddH2O or stored at -20°C for subsequent use. 
HPLC separation of the samples was performed using a PartiSphere 5-μm strong 
anion exchange column (Whatman) and a non-linear gradient of 1mM EDTA (buffer 
A) and 1.3M (NH4)2HPO4 + 1mM EDTA (buffer B) as described in Figure 6.3. Eluted 
samples were collected in fractions of 1ml/min and the radioactivity was evaluated 
with a beta counter, using a scintillation liquid specific for samples with high levels 
of phosphate salt (#6013599 Ultima Flo-AP, Perkin Elmer). 
 
2.7 Statistical Analysis 
Statistical analysis was carried out performing one-tailed paired t-test by Microsoft 
Excel software. Error bars in graphs indicate the standard error of the mean (S.E.M.). 
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Chapter 3 
Mechanisms of PI3K-C2α downregulation 
3.1 Introduction 
A condition of insulin resistance, where insulin signalling is impaired in target 
tissues, generally precedes overt T2D. Obese individuals present an increased risk to 
develop T2D, which is the result of both genetic and environmental factors (Prentki 
and Nolan 2006). Healthy β pancreatic cells respond to chronic nutrients overload 
with a compensatory increase in insulin production in order to restore 
normoglycaemia. T2D develops only when β cell compensatory response fails 
(Prentki and Nolan 2006, Muoio and Newgard 2008), resulting ultimately in a 
defective insulin secretion. Impaired insulin secretion and insulin signalling cause 
metabolic defects, and the increase of glucose and fatty acids levels in the 
bloodstream. In particular, high levels of fatty acids can further aggravate the failure 
of pancreatic β cells. 
In particular, high circulating free fatty acid levels are generally associated with cell 
death and secretory defects of pancreatic β cells. This pathological link is often 
called  ‘β cell lipotoxicity’, although to date, the molecular mechanisms underlying 
this process have not been fully understood (Barlow and Affourtit 2013). Studies on 
lipotoxicity have indicated that different types of fatty acids do not exert the same 
toxic effects; toxicity on β cells is greater when long chain (C16 or greater), saturated 
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fatty acids are involved (Morgan and Dhayal 2010). Palmitic acid is a 16-carbon 
saturated molecule commonly used in lipotoxicity studies, as it normally circulates at 
the highest concentration in the bloodstream in humans (Morgan and Dhayal 2010). 
Also, in vitro studies using palmitate indicated that it is responsible for cytotoxic 
effects on pancreatic β cell lines (Koshkin et al. 2008). 
Failure of pancreatic β cells in T2D is caused by a decrease in both β cell mass and β 
pancreatic function (Butler et al. 2003). Several lines of evidence in literature 
indicated a role of PI3K-dependent signalling pathways in the regulation of 
pancreatic β cell mass and survival (Franke et al. 1997, Ueki et al. 2002, Kulkarni 
2005) and, more recently, evidence also suggested their involvement in the 
regulation of insulin secretion (Pigeau et al. 2009, Kaneko et al. 2010).  
To date, class II PI3Ks remains the least investigated. Interestingly, it has been shown 
that the mRNA encoding for class II enzymes PI3K-C2α and PI3K-C2 is expressed in 
more than 75% of human islets of Langerhans, and its frequency is higher than other 
class I PI3K isoforms (Muller et al. 2006). Recently, it has also been reported that 
PI3K-C2α has a role in glucose-induced insulin secretion (Leibiger et al. 2010). 
Previous work in my laboratory further demonstrated that the mRNA encoding for 
PI3K-C2α was expressed at lower levels in human islets from T2D individuals 
compared to islets from non diabetic subjects and that downregulation of this 
enzyme impaired insulin secretion in rat insulinoma cells (Dominguez et al. 2011). 
These lines of evidence clearly indicated a specific role for PI3K-C2α in insulin 
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granules exocytosis in pancreatic β cells. Therefore, I investigated whether the 
downregulation of PI3K-C2α might play a role in the functional failure of pancreatic 
β cells, contributing to the progression of diabetes. Also, I focussed on whether 
metabolic dysregulation, typical of T2D and mimicked in vitro by using lipotoxic 
concentrations of sodium palmitate, could be responsible for the downregulation of  
PI3K-C2α, both at a protein and mRNA level. Protein levels of other members of the 
PI3Ks family were also assessed.  
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3.2 Results 
3.2.1 Optimisation 
In order to incubate INS1 cells in lipotoxic growth conditions, sodium palmitate was 
used. The manufacturer’s data sheet recommends to dissolve this product in 
methanol or ethanol, at a maximum concentration of 50 mg/ml. I chose to prepare a 
stock concentration of 100mM, corresponding to 27.8 mg/ml. At first, sodium 
palmitate powder was insoluble at this concentration, in either methanol or ethanol, 
at room temperature and after vigorous vortexing. Therefore, I tried different 
protocols: incubation in a waterbath, at temperatures from 37 to 50°C for up to 2 
hours, or overnight incubation on a rotating wheel at room temperature. However, 
these procedures did not improve palmitate solubility. Finally, I obtained a milky 
solution of 100mM sodium palmitate in either methanol or ethanol by sonicating 
repeatedly the solution for 10-sec bursts at 200 W on ice (Peng et al. 2011). 
Then, I tested the effect of 0.5 mM sodium palmitate on INS1 cells. INS1 were plated 
in a 6 well plate and treated the following day as described below. An aliquot of INS1 
complete medium (containing 10% FBS as described in Materials and Methods) was 
supplemented with 1% FFA-free BSA and sterile filtered. FFA-free BSA works as a 
carrier, ensuring the shuttling of fatty acids inside cells (Zhao and Wang 2012). 
Medium with or without FFA-free BSA was then warmed up to 60°C and the 
required amount of sodium palmitate solution was added (Peng et al. 2011). 
Medium was allowed to cool down slowly by incubation in a waterbath at 37°C for 
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at least 2 hours before being used, to ensure the binding of sodium palmitate to the 
BSA. An equivalent amount (v/v) of methanol or ethanol was added to complete 
medium, with or without FFA-free BSA, to evaluate the effect of the vehicle alone. 
Growth medium was removed carefully from the plate and replaced with fresh 
complete medium, with or without FFA-free BSA and sodium palmitate or methanol 
alone. After 24 hours incubation, medium was removed, cells were lysed and 
samples were prepared for Western Blot analysis as described in the Materials and 
Methods section. 
Then, protein levels of PI3K-C2α were analysed, and the result of this experiment is 
shown in Figure 3.1. 
 
 
Figure 3.1: Expression of PI3K-C2α in the presence or absence of BSA and sodium palmitate. INS1 
cells were left untreated (“control”) or treated for 24 hours with medium containing 0.5mM 
sodium palmitate or methanol, with or without 1% w/v FFA-free BSA. PI3K-C2α expression was 
determined by Western Blot. Tubulin was used as control of equal loading. 
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Results showed that sodium palmitate treatment had no effect on the protein level 
of PI3K-C2α in absence of FFA-free BSA. This confirms that sodium palmitate is 
unable to pass through the cellular membrane without forming a complex with an 
appropriate carrier. Also, this suggests that the BSA already contained in the 
complete growth medium has no effect as a carrier, in these experimental 
conditions. On the other hand, 24 hours treatment with 0.5 mM sodium palmitate, 
in the presence of FFA-free BSA, reduced the protein level of PI3K-C2α. 
Pancreatic islets of diabetic patients are chronically exposed to lipotoxic conditions. 
In order to study the time-dependence of the effects of palmitate on INS1 cells, I 
extended the treatment of INS1 cells with FFA-free BSA conjugated sodium 
palmitate for further 24 hours.  
 
 
Figure 3.2: Expression of PI3K-C2α upon 24 and 48 hours treatment with sodium palmitate 
dissolved in methanol. INS1 cells were left untreated (“control”) or treated for 24 or 48 hours with 
medium containing 0.5mM sodium palmitate or methanol and conjugated with FFA-free BSA. PI3K-
C2α expression was determined by Western Blot. Tubulin was used as control of equal loading.  
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The result of this experiment showed that 0.5 mM sodium palmitate was able to 
significantly reduce the level of PI3K-C2α after 24 hours of treatment. A further 
decrease was visible after 48 hours of treatment.  
In parallel experiments, cells were incubated with sodium palmitate dissolved in 
ethanol, following the same procedure previously described for methanol. Then, the 
expression levels of PI3K-C2α were analysed by Western Blot. 
 
 
Figure 3.3: Expression of PI3K-C2α upon 24 and 48 hours treatment with medium containing 
sodium palmitate or ethanol. INS1 cells were treated for 24 or 48 hours with medium containing 
0.5mM sodium palmitate or ethanol and conjugated with FFA-free BSA. Protein levels were 
determined by Western Blot analysis. Representative blot of 3 independent experiments is shown. 
 
Consistent with the results shown in Figures 3.1 and 3.2, incubation of INS1 cells 
with 0.5 mM palmitate decreased the protein levels of PI3K-C2α after 24 hours 
treatment, with a further decrease after 48 hours.  
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It is well established that treatment of pancreatic β cells with increasing 
concentrations of sodium palmitate reduces cell viability (Morgan and Dhayal 2010). 
Consistent with these data, microscope observation of INS1 cells treated with 0.5 
mM palmitate suggested a decrease in cell viability. Therefore, cell counting analysis 
was performed in order to estimate the toxic effects of sodium palmitate. 
 
 
Figure 3.4: Cell viability in lipotoxic conditions. INS1 cells were left untreated (“control”) or treated 
with 0.5 mM sodium palmitate dissolved in ethanol and conjugated with FFA-free BSA (or ethanol 
alone in complete medium supplemented with FFA-free BSA). Number of cells was determined 
after 24h or 48h by manual counting. Data are expressed as fold increase of the number of 
untreated cells (“control”) at 24 hours and are means ± s.e.m. from 3 independent experiments. 
 
Results shown in Figure 3.4 indicate the viability of INS1 cells treated with vehicle 
alone (0.5% ethanol in complete medium) or 0.5 mM sodium palmitate for 24 and 
48 hours. Ethanol alone did not affect cell viability compared to control, untreated 
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cells. On the other hand, viability of INS1 was decreased by 30% after 24 hours and 
50% after 48 hours treatment with sodium palmitate.  
These explorative data were necessary to set the experimental conditions for my 
subsequent analysis of the effect of lipotoxic conditions on PI3Ks levels. Taken 
together, these data indicate that preparation of sodium palmitate as described in 
the Materials and Methods section was able to affect INS1 cells viability and also 
reduce the protein levels of PI3K-C2α. Ethanol alone had no effect on the viability of 
INS1 cells, compared to complete growth medium and therefore it was chosen as 
vehicle to dissolve sodium palmitate. 
 
3.2.2 Lipotoxic growth conditions reduce the protein expression levels 
of PI3K-C2α 
In order to investigate the effects of lipotoxic growth conditions on the levels of 
PI3K-C2α, I tested different concentrations of sodium palmitate. 
Following the protocol optimised in my preliminary experiments, INS1 cells were 
incubated for 24 and 48 hours in medium containing FFA-free BSA-conjugated 
sodium palmitate, at concentrations ranging from 0.05 mM to 0.5 mM. Western Blot 
experiments were performed to assess the expression levels of PI3K-C2α.  
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Figure 3.5: Expression of PI3K-C2α upon treatment with increasing concentrations of sodium 
palmitate. INS1 cells in complete growth medium were left untreated (“control”) or treated for 48 
hours with increasing concentrations of sodium palmitate dissolved in ethanol and conjugated with 
FFA-free BSA. Control with ethanol had the equivalent (v/v) as the maximum concentration of 
sodium palmitate used. PI3K-C2α expression was determined by Western Blot analysis and tubulin 
was used as loading control. Blot is representative of 3 independent experiments. 
 
Results showed that treatment with sodium palmitate downregulated PI3K-C2α 
levels in a dose-dependent manner. The decrease in protein level of PI3K-C2α was 
maximal when a concentration of 0.25 mM palmitate was used, with comparable 
results at 0.5 mM. 
These data indicated that lipotoxic conditions are able to reduce the protein 
expression of class II PI3K-C2α in INS1 cells. 
 
3.2.3 Lipotoxic growth conditions do not affect mRNA levels of PI3K-
C2α 
To further investigate the mechanisms of PI3K-C2α downregulation, I performed 
quantitative analysis of the mRNA encoding for PI3K-C2α. INS1 cells were incubated 
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for 48 hours with a range of concentrations of FFA-free BSA-conjugated sodium 
palmitate, from 0.05 mM to 0.5 mM, as previously described. Then, cells were 
trypsinised, collected and pellet was stored at -80°C for subsequent RNA extraction. 
Specific primers for rat PI3K-C2α were designed (Table 2.10), total RNA was 
extracted from samples and retrotranscripted to cDNA. Then, qPCR was performed, 
using primers targeting rat PI3K-C2α and 18S ribosomal subunit as housekeeping 
control gene. 
 
 
Figure 3.6: Levels of PI3K-C2α mRNA were determined by qPCR, after 48 h incubation in the 
indicated experimental conditions. Data are expressed as fold change relative to untreated control 
and are means ± s.e.m. from 3 independent experiments. 
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Results from qPCR experiments are shown in Figure 3.6: mRNA levels of PI3K-C2α 
were not significantly modified by lipotoxic growth conditions after 48 hours 
treatment. This indicates that the decreased protein levels of PI3K-C2α observed 
after 48 hours treatment with sodium palmitate are likely due to a defective 
translation or to an increased degradation of the protein, rather than a reduced 
protein transcription. 
 
3.2.4 Protein levels of other members of the PI3K family upon lipotoxic 
growth conditions 
To determine whether treatment with sodium palmitate specifically affects PI3K-
C2α protein expression, I then analysed the effect on the protein levels of other 
members of the PI3K family. Since treatment with sodium palmitate decreased the 
protein levels of PI3K-C2α irrespective of the solvent used (Figures 3.2 and 3.3), I 
performed the following experiments using either ethanol or methanol. First, I 
analysed the expression levels of class I PI3K p110α by Western Blot, upon 
treatment with sodium palmitate for 24 and 48 hours. 
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Figure 3.7: Expression of p110α upon 24 and 48 hours treatment with sodium palmitate. INS1 cells 
in complete medium were left untreated or treated for 24 and 48 hours with vehicle alone or 
0.5mM sodium palmitate conjugated with FFA-free BSA. Protein levels of p110α were determined 
by Western Blot and tubulin was used as loading control. Representative blot of 3 independent 
experiments is shown. 
 
Results showed that incubation of INS1 cells with sodium palmitate for 24 hours 
decreased the protein levels of p110α, which were further reduced after 48 hours 
treatment (Figure 3.7). 
In contrast, treatment with sodium palmitate did not affect the protein levels of 
class I p110β, upon either 24 or 48 hours incubation (Fig 3.8). 
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Figure 3.8: Expression of p110β upon 24 and 48 hours treatment with sodium palmitate. INS1 cells 
in complete medium were left untreated or treated for 24 and 48 hours with vehicle alone or 
0.5mM sodium palmitate conjugated with FFA-free BSA. Protein levels of p110β were determined 
by Western Blot and tubulin was used as loading control. Representative blot of 3 independent 
experiments is shown. 
 
 
Evidence in literature suggests that class I PI3K p110 has a crucial role in pancreatic 
β cells. Indeed, it has been shown that p110has an important role in insulin 
secretion in insulinoma cell lines and human β cells (Pigeau et al. 2009). Therefore, I 
assessed the effect of palmitate on p110 levels. 
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Figure 3.9: Expression of p110 upon 24 and 48 hours treatment with sodium palmitate. INS1 cells 
in complete medium were left untreated (“control”) or treated for 24 and 48 hours with vehicle 
alone or 0.5mM sodium palmitate conjugated with FFA-free BSA. Protein levels of p110 were 
determined by Western Blot and tubulin was used as loading control. Representative blot of 2 
independent experiments is shown. 
 
Figure 3.9 shows a representative blot of the protein levels of p110 upon treatment 
with palmitate for 24 and 48 hours. Lipotoxic conditions did not affect p110 protein 
levels in these experimental conditions.  
 
In addition, I analysed protein levels of class III PI3K hVps34 upon treatment with 
sodium palmitate. 
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Figure 3.10: Expression of hVps34 upon 24 and 48 hours treatment with sodium palmitate. INS1 
cells in complete medium were left untreated (“control”) or treated for 24 and 48 hours with 
vehicle alone or 0.5mM sodium palmitate conjugated with FFA-free BSA. Protein levels of hVps34 
were determined by Western Blot and tubulin was used as loading control. Representative blot of 2 
independent experiments is shown. 
 
Results showed that incubations of INS1 cells with palmitate for 24 or 48 hours did 
not affect protein levels of hVps34 in these experimental conditions. 
 
Taken together, these data indicate that treatment with sodium palmitate 
specifically decreased the protein levels of PI3K-C2α and p110α, with no effect on 
the protein levels of the other PI3Ks examined. 
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3.3 Discussion 
In this chapter, I analysed the effects of lipotoxic growth conditions on the 
expression levels of PI3K-C2α and other members of the PI3K family in INS1 cells. 
The mRNA coding for PI3K-C2α is expressed in the majority of human pancreatic β 
cells isolated from non diabetic donors, with a higher frequency compared to class I 
catalytic subunits (Muller et al., 2006), which suggests a role for the enzyme 
specifically in β cells. Interestingly, PI3K-C2α mRNA levels are downregulated in 
islets from diabetic patients (Dominguez et al. 2011), and this observation suggests a 
link between diabetes and PI3K-C2α function. These findings, together with the fact 
that diabetic patients have elevated levels of fatty acids circulating in the 
bloodstream, led us to hypothesise that lipotoxicity might be one of the causes of 
PI3K-C2α mRNA downregulation, leading to a reduced amount of enzyme. 
Furthermore, since we (Dominguez et al. 2011) and others (Leibiger et al. 2010) 
observed that PI3K-C2α has a role in insulin secretion, this could be associated with 
an impairment of pancreatic β cell function. Because of the large amount of sample 
required for protein studies and the scarcity of human pancreatic islets available for 
medical research, it was necessary to use an in vitro model of pancreatic β cells. Cell 
lines are a very useful tool to study physiological and pathophysiological conditions 
and INS1 cells are a well established model of pancreatic β cells. However, 
limitations of their use must always be considered. In vitro studies have to take into 
account the disadvantages of working with artificial cell lines, which might 
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encounter changes in cell characteristics due to the continuous growth and to 
genetic manipulation. More importantly, in vitro models cannot accurately 
reproduce the complexity of interactions of an intact organ in the context of a whole 
organism, due to the disruption of cell-cell interactions (Skelin et al. 2010). Also, 
pancreatic islets constitute a unique micro environment, where islets hormones 
finely modulate the activity of different cell types through autocrine and paracrine 
mechanisms (Barker et al. 2013). 
To the best of my knowledge, modification of the protein levels of PI3K family in β 
cells subjected to lipotoxic conditions has not been investigated before. Western 
Blot analysis of the levels of different PI3Ks revealed that PI3K-C2α and p110α are 
specifically decreased upon treatment with sodium palmitate for 24 hours, with a 
further decrease observed after 48 hours treatment (Figures 3.3 and 3.7). No 
difference in the levels of other PI3Ks was detected. Quantitative analysis of PI3K-
C2α mRNA was performed and results indicated that the levels of PI3K-C2α mRNA 
do not undergo significant modifications upon treatment with palmitate for 48 
hours. This result appears to be in contrast with the observation that PI3K-C2α 
mRNA is downregulated in human pancreatic islets from diabetic patients 
(Dominguez et al. 2011). This discrepancy might be explained by the difference 
between human pancreatic islets and the cellular system used, and by the limited 
time of treatment with sodium palmitate in this study, which is not comparable to 
the chronic lipotoxic conditions that islets of diabetic patients are exposed to. The 
correct functioning of PI3K pathway is particularly important in pancreatic β cells. 
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Insights from studies on mice models revealed that the disruption of the pathway 
involving IR/IRS2/PI3K/Akt axis leads to defects in β cell development and function. 
For instance, IRS2 knockout mice models develop diabetes, show β cell deficiency at 
birth and lack β cell compensation in the stages preceding overt diabetes (Withers et 
al. 1998, Kubota et al. 2000). Also, mice models deficient for S6K1, a class I PI3K 
downstream effector, show a reduction in pancreatic mass and a selective decrease 
in β cell size, as a result of the disruption of PI3K signalling pathway (Pende et al. 
2000). More recently, a specific role for PI3K isoforms in insulin secretion has also 
been reported, irrespective of their role in regulating β cell mass. For instance, it has 
been found that insulin secretion is impaired in db/db mice probably through a 
downregulation of class I PI3K/Akt pathway (Kaneko et al. 2010). Using βDKO mice 
models, which, as mentioned before lack the regulatory subunits of class I PI3Ks 
specifically in β cells, it has been shown that PI3K signalling is crucial for maintaining 
β cell function (Kaneko et al. 2010). Indeed, the activity of class I PI3K is blunted in 
these mice models, and this impairs insulin secretion . More recently, a role for class 
II PI3K and specifically for PI3K-C2α has also been reported, as this PI3K isoform is 
involved in glucose-induced insulin release in MIN6 cells (Leibiger et al. 2010). Also, 
in the pancreatic β cell line INS1 the downregulation of PI3K-C2α has been found to 
cause a decreased insulin secretion (Dominguez et al. 2011). 
My data suggest that an excess of free fatty acids is able to downregulate the 
protein levels of two PI3K isoforms (class I p110α and class II PI3K-C2α) in the 
pancreatic β cell line INS1. Since it was previously reported that downregulation of 
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PI3K-C2α impairs insulin secretion (Dominguez et al. 2011), this data suggests that 
an excess of free fatty acids might be accountable for the malfunctioning of the 
aforementioned signalling pathways, contributing to the reduced pancreatic β cell 
function. 
In addition, results show that lipotoxic conditions do not affect the levels of class I 
p110β, p110 and class III hVps34 (Figures 3.8, 3.9 and 3.10, respectively). This 
suggests that the observed decrease in the protein levels of PI3K-C2α and p110α is a 
specific effect of the lipotoxic growth conditions and it is not due to a general 
cytotoxic action of free fatty acids supplemented in the growth medium. 
Taken together, these findings underline how PI3K activity is essential to maintain 
both β cells mass and secretory ability. The fact that lipotoxic conditions are able to 
affect the protein levels of two PI3K isoforms might shed new light into the 
mechanisms of lipotoxicity and diabetes progression.  
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Chapter 4 
Intracellular functions regulated by PI3K-C2α  
 
Cell viability  
 
4.1 Introduction 
As mentioned in the previous chapter, the transition to overt diabetes is 
characterised by a failure of pancreatic β cells, in terms of insulin secreting function, 
pancreatic β cell mass and viability (Muoio and Newgard 2008). Increased β cell 
mass and function resulting from the correct balance between pancreatic β cell 
neogenesis, proliferation and cell size allows the organism to respond to defects in 
insulin signalling (insulin resistance). The failure of β cell to compensate is 
responsible for the progression of diabetes (Bonner-Weir 2000). 
Class I PI3Ks have a well established role in regulating cell mass, as they are 
activated upon serum and growth factors stimulation and they induce activation of 
several downstream effectors, including Akt (Franke et al. 1997). This leads to 
stimulation of cell proliferation, survival, growth and inhibition of apoptotic 
mechanisms in multiple organs (Elghazi et al. 2007). 
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Interestingly, studies on class II PI3Ks also outlined a role for the enzyme PI3K-C2α in 
regulation of cell survival. Specifically, downregulation of PI3K-C2α is associated with 
increased apoptosis in cancer and endothelial cell lines (Elis et al. 2008, Yoshioka et 
al. 2012, Tibolla et al. 2013). In contrast with these data, downregulation of PI3K-
C2α in L6 cells did not affect cell proliferation (Falasca et al. 2007), and only slightly 
increased the percentage of INS1 cells in the sub-G1 phase of the cell cycle, at least 
in normal growing conditions (Dominguez et al. 2011). However, the effect of PI3K-
C2α downregulation on cell survival in lipotoxic growth conditions, mimicking the 
metabolic alterations typical of diabetic patients, was not assessed in the previous 
study. Therefore, the possibility that the lipotoxicity-induced downregulation of 
PI3K-C2α underlies the reduced cell proliferation/survival in INS1 cells was 
examined.  
Moreover, it has been reported that glucose deprivation can contribute to β cell 
death through induction of apoptotic process (Guillen et al. 2008). The correct 
functioning of pancreatic β cells ensures the essential function of glucose 
homeostasis. In most cell types, glucose metabolism depends on ATP and metabolic 
requirements, while in pancreatic β cells it is modulated by glucose catabolism and 
glycaemia. Glucose sensing and metabolism are critical for pancreatic β cell function, 
in order to ensure an appropriate insulin secretion rate.  
The central role of glucose in pancreatic β cells is also underlined by other findings: 
glucose alone can induce cell proliferation in INS1 cells, upon 24 hours of nutrients 
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deprivation (Hugl et al. 1998). Indeed, it was shown that glucose deprivation (0 - 0.5 
mM) inhibited proliferation in INS1 cells, inducing a quiescent state. Substimulatory 
concentrations of glucose alone (1 - 3 mM) induced a modest increase in INS1 
proliferation, up to 1.4 fold compared to glucose deprived cells, while stimulatory 
concentrations (6 - 18 mM) were able to increase proliferation of INS1 cells up to 20 
fold (Hugl et al. 1998). In addition, it was reported that glucose can potentiate the 
mitogenic signals induced by IGF1 and growth hormone (GH) (Hugl et al. 1998, 
Cousin et al. 1999), stimulate the activity of PI3Ks (Cousin et al. 2001) and that PI3Ks 
have a role in glucose-dependent mitogenesis (Hugl et al. 1998, Cousin et al. 1999). 
Interestingly, further studies on glucose and IGF1-dependent β cell proliferation 
demonstrated that a constitutive activation of class I PI3Ks (which on its own did not 
affect β cell proliferation) was able to enhance IGF1-dependent mitogenesis, with no 
further increase when the cells were stimulated with 15 mM glucose alone (Dickson 
et al. 2001). This result suggests that the proliferation signalling triggered by glucose 
is mediated by another enzyme/class of enzymes than class I PI3K.  
Therefore, the potential contribution of PI3K-C2α to the glucose-induced 
proliferation/survival was investigated.   
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4.2 Results  
4.2.1 Downregulation of PI3K-C2α does not sensitise INS1 cells 
towards death in lipotoxic conditions 
In order to determine the potential role of PI3K-C2α in regulation of cell survival, I 
used stable cell lines previously generated in my laboratory. INS1 ‘sh PI3K-C2α’ and 
‘sh scrambled’ were obtained by retroviral infection of rat insulinoma cells INS1. The 
constructs used contained shRNA oligomers designed based on the sequence of rat 
PI3K-C2α and a scrambled control (Dominguez et al. 2011). The shRNA construct 
targeting PI3K-C2α, once introduced in INS1 cells, is able to downregulate both PI3K-
C2α mRNA and protein expression levels, without affecting the expression of other 
PI3Ks (Dominguez et al. 2011).  
 
 
Figure 4.1: Expression levels of PI3K-C2α were analysed by Western blot analysis in stable INS1 sh 
scrambled and INS1 sh PI3K-C2α cells. A representative blot is shown. 
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Western blot analysis confirmed downregulation of PI3K-C2α in the corresponding 
stable cell line, compared to the control scrambled cells (Figure 4.1), as previously 
described (Dominguez et al. 2011). Importantly, it was reported that INS1 sh PI3K-
C2α cells do not present any defect in terms of proliferation, compared to the 
scrambled control (Dominguez et al. 2011). 
First, I investigated the effects of PI3K-C2α downregulation on cell viability in 
lipotoxic conditions. INS1 sh scrambled and INS1 sh PI3K-C2α cells were plated in 6-
wells plates and incubated in normal growth medium, supplemented with 1% FFA-
BSA and increasing concentrations of sodium palmitate, for 24 or 48 hours. Then, 
they were trypsinised, collected and manually counted in a Bürker chamber. 
 
 
Figure 4.2: Cell viability of INS1 sh scrambled and sh PI3K-C2α in the presence of palmitate. Stable 
INS1 cell lines expressing a shRNA specifically targeting PI3K-C2α or a scrambled shRNA were 
treated with the indicated concentrations of palmitate or vehicle alone. Number of cells was 
determined after 24h or 48h by manual counting. Data are expressed as percentage of untreated 
cells and are means ± s.e.m. from 4 independent experiments performed in duplicate. *p<0.05; 
**p<0.01 vs corresponding control treated with ethanol. 
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As shown in Figure 4.2, a significant reduction in the number of cells was detected 
upon 24 and 48 hours treatment with sodium palmitate. Consistent with data in 
literature, these results indicated that lipotoxic conditions reduce cell viability of 
INS1. No difference was observed between INS1 sh scrambled and sh PI3K-C2α cells, 
suggesting that downregulation of PI3K-C2α does not enhance cell death in lipotoxic 
growth conditions. 
To further validate these results, MTT assay was performed to assess cell viability. 
The MTT assay is based on the cleavage of the yellow MTT [3-(4,5-Dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide] to a purple formazan by mitochondrial 
succinate dehydrogenase of living cells (Loveland et al. 1992). The amount of 
formazan is proportional to the number of living cells present during the incubation 
with MTT. Cells were treated as described before and incubated with MTT solution 
during the final 3 hours of treatment. Then, cells were lysed in DMSO and 
absorbance was read with a spectrophotometer (using a wavelength of 570nm and 
subtracting a background measurement at 650nm). 
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Figure 4.3: Cell viability of INS1 sh scrambled and sh PI3K-C2α in the presence of palmitate. Stable 
INS1 cell lines expressing a shRNA specifically targeting PI3K-C2α or a scrambled shRNA were 
treated with the indicated concentrations of palmitate or vehicle alone. Cell viability was 
determined after 24h or 48h by MTT assay. Data are expressed as percentage of untreated cells 
and are means ± s.e.m. from 3 independent experiments performed in duplicates. *p<0.05; 
**p<0.01 vs corresponding control treated with ethanol. 
 
Consistent with results from cell counting, MTT assay showed a decrease in cell 
viability in response to increasing concentrations of sodium palmitate. Furthermore, 
downregulation of PI3K-C2α did not alter the effect of palmitate on cell viability. 
Taken together, these data indicate that downregulation of PI3K-C2α does not 
sensitise pancreatic β cells towards death when cultured in lipotoxic growth 
conditions. 
 
4.2.2 Glucose alone is able to sustain survival of INS1 cells upon 
nutrients deprivation 
One of the mechanisms that allows the progression of diabetes is a decrease in β cell 
mass, as a result of reduced proliferation and increased cell death. Several lines of 
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evidence highlight the role of glucose as a key regulator of proliferation in pancreatic 
β cells (Bonner-Weir et al. 1989). It was previously reported that glucose-dependent 
proliferation in β cells requires activation of mTOR, a key regulator of cell 
proliferation, and its downstream effector S6K, independently of Akt activation 
(Dickson et al. 2001). 
In order to determine whether glucose can also stimulate cell survival, INS1 cells 
were incubated with serum free RPMI, supplemented with 0.5 mM glucose and 1% 
fresh glutamine (hereinafter referred to as ‘nutrients deprivation’) for 24 hours. 
Then, stimulatory concentrations of glucose (15 mM) were re-introduced in the 
serum-free medium for further 24 or 48 hours. Control cells were left in the absence 
of serum and reduced glucose levels. 
 
 
Figure 4.4: Cell viability upon nutrients deprivation and glucose reintroduction. INS1 cells were 
deprived of nutrients for 24 hours and then incubated with the indicated concentrations of glucose. 
Cell viability was assessed by MTT assay. Data are expressed as fold increase relative to day 0 and 
are means ± s.e.m. from 3 independent experiments performed in duplicate.  
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Results from these experiments are presented in Figure 4.4. The viability of INS1 
cells dramatically decreased when cells were cultured for more than 24 hours in 
serum and glucose starvation. Interestingly, after 24 hours of nutrients deprivation, 
re-introduction of 15 mM glucose alone was able to induce survival in INS1 cells, 
protecting them from death for further 48 hours. 
 
4.2.3 Glucose rescue upon nutrient deprivation is not inhibited by 
classical PI3Ks inhibitors 
PI3Ks are activated following several extracellular stimuli and their action triggers a 
plethora of intracellular responses. Previous studies have shown that PI3Ks activity is 
important for glucose-dependent β-cell mitogenesis and that glucose is able to 
activate PI3Ks (Cousin et al. 2001). 
Therefore, in order to test whether glucose-induced survival signal is transmitted 
intracellularly through PI3K family, I tested the effect of classical PI3Ks inhibitors 
wortmannin and LY294002. 
As described in the previous experiment, INS1 cells were deprived from serum and 
glucose for 24 hours and then they were incubated in serum free RPMI 
supplemented with 15mM glucose for further 24 or 48 hours, in the presence or 
absence of 100nM wortmannin. At this concentration, wortmannin is able to 
irreversibly inhibit all the PI3K isoforms except PI3K-C2α, by binding covalently to 
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the enzymes. Control cells were left in nutrients deprivation, with or without 
wortmannin.  
 
 
Figure 4.5: Cell viability upon nutrients deprivation and glucose reintroduction, in the presence or 
absence of wortmannin. INS1 cells were deprived of nutrients for 24 hours and then incubated with 
the indicated concentrations of glucose. Classical PI3Ks inhibitor wortmannin (W) was used at a 
concentration (100nM) that is effective on all PI3Ks isoforms except PI3K-C2α. Cell viability was 
assessed by MTT assay. Data are expressed as fold increase relative to day 0 and are means ± s.e.m. 
from 3 independent experiments performed in duplicate.  
 
Results from these experiments are shown in Figure 4.5: as previously shown, re-
introduction of glucose alone was able to induce cell survival for further 48 hours. 
Also, in these experimental conditions, treatment with wortmannin did not affect 
glucose-induced cell survival. Similar results were obtained by cell counting 
(experiments performed by Dr. Maffucci). 
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I then tested the effect of another classical PI3Ks inhibitor, LY294002, which is an 
ATP-competitive inhibitor able to bind PI3Ks in a reversible manner and is 
structurally unrelated to wortmannin (Blommaart et al. 1997). 
 
 
Figure 4.6: Cell viability upon nutrients deprivation and glucose reintroduction, in the presence or 
absence of LY294002. INS1 cells were deprived of nutrients for 24 hours and then incubated with 
the indicated concentrations of glucose. Classical PI3Ks inhibitor LY294002 (LY) was used at a 
concentration (10µM) that is effective on all PI3Ks isoforms except PI3K-C2α and, to a lesser extent, 
PI3K-C2β. Cell viability was assessed by MTT assay. Data are expressed as fold increase relative to 
day 0 and are means ± s.e.m. from 3 independent experiments performed in duplicate.  
 
Consistent with data obtained with wortmannin, glucose alone was able to protect 
INS1 cells from death induced by nutrients deprivation. Data showed that LY294002 
did not affect the protective effect of glucose in INS1 cells after 24 or 48 hours of 
treatment. Similar results were obtained by cell counting (experiments performed 
by Dr. Maffucci). 
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These data indicate that glucose-induced cell survival is not inhibited by classical 
PI3K inhibitors. This suggests that the intracellular signalling activated by glucose in 
this context is either mediated by another enzyme/class of enzymes or it involves 
the activation of PI3K-C2α, which is insensitive to the concentration of inhibitors 
used in these experiments. 
 
 
4.2.4 Glucose-induced survival upon nutrient deprivation requires the 
activation of PI3K-C2α 
In order to determine whether PI3K-C2α is required for glucose-induced cell survival, 
INS1 sh scrambled and sh PI3K-C2α cells were used.  
Following the same protocol used for the previous experiments, both INS1 sh 
scrambled and sh PI3K-C2α cell lines were seeded in 6 wells plates and starved for 
24 hours from serum and glucose. Then, they were incubated with serum free RPMI 
medium supplemented with 15mM glucose. 
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Figure 4.7: Cell viability assessed by manual cell counting - Effect of downregulation of PI3K-C2α on 
cell viability upon nutrients deprivation and glucose reintroduction. Stable INS1 cell lines were 
deprived of nutrients for 24 hours and then incubated with 15 mM glucose or left in nutrients 
deprivation. Data are expressed as percentage relative to day 0 and are means ± s.e.m. from 5 
independent experiments performed in duplicates. *p<0.01 vs corresponding value in sh scrambled 
cells. 
 
Consistent with the data previously shown, cell viability was significantly 
ameliorated by reintroduction of stimulatory glucose concentration after 24 hours 
of nutrients deprivation in both cell lines (Figure 4.7). Glucose reintroduction was 
able to induce survival in INS1 sh scrambled and sh PI3K-C2α cells for further 48 
hours, compared to cells left in nutrients deprivation.  
Interestingly, INS1 sh PI3K-C2α cells showed a decreased viability compared to the 
scrambled control upon glucose reintroduction, at both 24 and 48 hours post 
treatment. These data indicate that downregulation of PI3K-C2α in INS1 cells impairs 
the protective effect of glucose reintroduction and, as a consequence, the viability 
of sh PI3K-C2α cells is significantly reduced compared to control cells.  
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In order to confirm these data, similar experiments were performed using MTT 
assay. Cells were plated in 12 wells plates and duplicates were analysed for each 
condition. 
 
 
Figure 4.8: Cell viability assessed by MTT assay - Effect of downregulation of PI3K-C2α on cell 
viability upon nutrients deprivation and glucose reintroduction. Stable INS1 cell lines were 
deprived of nutrients for 24 hours and then incubated with 15 mM glucose or left in nutrients 
deprivation. Data are expressed as percentage relative to day 0 and are means ± s.e.m. from 4 
independent experiments performed in duplicates. *p<0.01 vs corresponding value in sh scrambled 
cells. 
 
Consistent with results from cell counting experiments, INS1 sh PI3K-C2α cells 
showed a significantly decreased viability, compared to the scrambled control upon 
nutrients deprivation and glucose reintroduction (Figure 4.8). 
Taken together, these data indicate that PI3K-C2α is involved in glucose-induced 
survival of INS1 cells following nutrients deprivation. These data, together with data 
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obtained with classical inhibitors previously performed in my laboratory, indicate 
that reintroduction of stimulatory concentrations of glucose is able to protect INS1 
from cell death induced by nutrients and glucose deprivation, through a mechanism 
that specifically involves the action of PI3K-C2α and not other PI3Ks. 
In order to further investigate the mechanisms of glucose-induced survival in INS1 
cells, I assessed the effect of substimulatory glucose concentrations in these 
experimental conditions (Briaud et al. 2003).  
To this end, INS1 sh scrambled and sh PI3K-C2α cell lines were starved for 24 hours 
from serum and glucose. Then, they were incubated with serum free RPMI 
supplemented with 3 mM glucose (substimulatory concentrations) or left in 
starvation medium as a control.  
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Figure 4.9: Cell viability assessed by manual cell counting - Effect of downregulation of PI3K-C2α on 
cell viability upon nutrients deprivation and reintroduction of stimulatory or substimulatory 
glucose concentrations. Stable INS1 cell lines were deprived of nutrients for 24 hours and then 
incubated with 3 mM glucose or left in nutrients deprivation. Data are expressed as percentage 
relative to day 0 and are means ± s.e.m. from 2 independent experiments performed in duplicates. 
 
Data show that after 24 hours in starvation medium the proliferation of both cell 
lines arrested and cell viability was slightly decreased (Fifure 4.9). When cells were 
left in starving conditions for further 24 or 48 hours, cell viability dramatically and 
rapidly reduced, with no difference between the two cell lines. Reintroduction of a 
substimulatory concentration of glucose was able to protect INS1 from cell death for 
further 24 hours, but cell viability then decreased. The survival curves observed in 
these experimental conditions were comparable between INS1 sh scrambled and sh 
PI3K-C2α cells. This indicates that PI3K-C2α is not required for cell survival induced 
by reintroduction of substimulatory glucose concentrations. 
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In order to confirm the data obtained with cell counting, similar experiments were 
performed using MTT assay. Cells were plated in 12 wells plates, using duplicates for 
each condition. 
 
 
Figure 4.10: Cell viability was assessed by MTT assay - Effect of downregulation of PI3K-C2α on cell 
viability upon nutrients deprivation and reintroduction of stimulatory or substimulatory glucose 
concentrations. Stable INS1 cell lines were deprived of nutrients for 24 hours and then incubated 
with 3 mM glucose or left in nutrients deprivation. Data are expressed as percentage relative to 
day 0 and are means ± s.e.m. from 2 independent experiments performed in duplicates. 
 
As observed in cell counting experiments, cells growing in serum and glucose 
deprivation for more than 24 hours showed a rapid decrease in cell viability. 
Introduction of a substimulatory concentration of glucose induced cell survival for 
further 24 hours before significantly decreasing cell viability. As observed before, 
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downregulation of PI3K-C2α did not affect cell viability compared to control cells in 
these experimental conditions (Figure 4.10). 
These data indicate that substimulatory concentration (3 mM) of glucose is less 
effective in preventing cell death compared to reintroduction of stimulatory 
concentration (15 mM) glucose, upon 24 hours of nutrients deprivation. 
Interestingly, using substimulatory glucose concentrations, the survival of control 
cells was comparable to that observed in PI3K-C2α knock down cells, while a 
significant difference between the two cell lines was observed upon reintroduction 
of glucose at stimulatory concentrations. This suggests that PI3K-C2α is involved in 
cell survival triggered by stimulatory but not by substimulatory concentrations of 
glucose. Furthermore, after 24 hours of glucose reintroduction, the number of 
surviving cells is higher upon reintroduction of 15 mM glucose compared to 3 mM 
glucose. Based on this observation, it is possible to conclude that reintroduction of 
15 mM glucose induces both cell survival and proliferation. 
 
4.2.5 Nutrients deprivation and apoptosis 
MTT and cell counting assays can quantitatively evaluate the viability of cellular 
populations, with no indication on the ongoing cellular death processes. My data 
indicated that 24 hours of nutrients deprivation caused a slight decrease in INS1 
cells viability and that downregulation of PI3K-C2α was responsible for a reduced 
cellular response to stimulatory concentrations of glucose. Therefore, I decided to 
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investigate whether the observed decrease in cell viability was caused by increased 
apoptosis. Also, in order to analyse the specific role for PI3K-C2α in this context and 
in the aforementioned experimental conditions, I sought to assess whether the 
improvement in cell viability upon reintroduction of stimulatory concentration of 
glucose occurred through inhibition of apoptosis.  
The protein caspase 3 is a critical executioner of apoptosis and it is activated by 
cleavage of its aspartic acid residue (Asp 175). This converts the inactive zymogen 
into activated fragments of 17 and 12 kDa, which are detectable by Western Blot 
analysis and their formation is used to assess an ongoing apoptotic process. 
Therefore, I performed a Western Blot analysis on INS1 sh scrambled and INS1 sh 
PI3K-C2α cells upon nutrients deprivation and reintroduction of stimulatory 
concentrations of glucose, as previously described, using specific antibodies 
recognising the uncleaved form and the cleaved fragments of caspase 3.  
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Figure 4.11: Activation of caspase 3 upon nutrients deprivation and glucose reintroduction. Stable 
INS1 cell lines were deprived of nutrients for 24 hours and then incubated with the indicated 
concentrations of glucose. Lysates were analysed by Western Blot analysis and incubated with an 
antibody anti caspase 3, detecting both the full length protein and the cleaved fragments. 
Representative blot of 3 independent experiments is shown. 
 
Results showed that nutrients deprivation induced the accumulation of the cleaved 
fragment of caspase 3, indicating that apoptosis was activated in both INS1 sh 
scrambled and sh PI3K-C2α cell lines, following 24 hours of starvation (Day 1, Figure 
4.11). After further 24 hours of nutrients deprivation, the fragment corresponding to 
cleaved caspase 3 had an increased intensity (Day 2, 0.5mM glucose), indicating that 
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apoptosis was fully ongoing in these experimental conditions. Interestingly, 
reintroduction of stimulatory glucose concentrations in sh scrambled cells decreased 
the amount of cleaved caspase 3 (Day 2, sh scrambled 15mM glucose), compared to 
samples kept in starvation medium. This data indicates that stimulatory glucose 
concentrations are able to inhibit the apoptotic process, protecting cells from death. 
The protective effect of stimulatory concentrations of glucose was even more 
evident when analysing samples from sh scrambled cells upon 48 hours of glucose 
reintroduction (Day 3, sh scrambled 15mM glucose), where caspase 3 fragment is no 
longer detectable. This further suggests an effective inhibition of the apoptotic 
process in these experimental conditions. These data are consistent with the 
increase in cell viability observed in INS1 sh scrambled cells upon reintroduction of 
stimulatory glucose concentrations described in Chapter 4.2.4. 
Interestingly, a clear band corresponding to cleaved caspase 3 fragment was still 
detectable in INS1 sh PI3K-C2α cells upon glucose reintroduction (Day 2, sh PI3K-C2α 
15mM glucose). This indicates that INS1 sh PI3K-C2α cells have a reduced ability to 
stop the apoptotic process, compared to the scrambled control, and therefore are 
more prone to cell death in these experimental conditions. This observation is even 
clearer upon 48 hours treatment with stimulatory glucose concentrations in PI3K-
C2α knock down cells (Day 3, sh PI3K-C2α 15mM glucose), since cleaved caspase 3 
fragment is still intense and clearly detectable by Western blot analysis. This further 
suggests that reintroduction of glucose is not able to inhibit apoptosis in PI3K-C2α 
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knock down cells in these experimental conditions, and is consistent with the data 
on cell viability showed in Figures 4.7 and 4.8. 
 
4.2.6 Nutrients deprivation and autophagy 
Autophagy is a critical process for cellular homeostasis. It ensures the recycling of 
damaged cellular components and misfolded proteins, which are enclosed in 
intracellular vacuoles (autophagosomes), then fused to lysosomes and degraded to 
simpler molecules (mostly amino acids). This, at the same time, supplies the cells 
with amino acids, which can be used for the synthesis of new proteins, especially 
during periods of starvation. It is a finely regulated process, essential for survival in a 
low energy state, but it can lead to cell death when it is deregulated, or during 
prolonged starvation. Recent data in literature demonstrate that basal autophagy is 
particularly important for the homeostasis of pancreatic β cells, contributing to their 
survival (Ebato et al. 2008, Jung et al. 2008) 
Data in section 4.2.2 showed that nutrient deprivation induces apoptosis in INS1 
cells. I then decided to investigate whether autophagy is also involved in these 
experimental conditions. Therefore, INS1 cells were deprived from nutrients for 24h 
and then incubated with serum free medium containing 15mM glucose, as 
previously described. Cellular lysates were then analysed by Western Blot using 
antibodies anti Light chain 3 (LC3), which is a commonly used autophagy marker. LC3 
is detected as two bands, LC3-I (16-18 kDa) and LC3-II (14-16). LC3-I is the cytosolic 
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form of the protein, which is post transcriptionally modified with a 
phosphatidylethanolamine (PE) tag (and converted to LC3-II) when it is bound to the 
autophagosome membrane during autophagy. Although LC3-II molecular weight is 
increased by the PE tag, due to its hydrophobicity it migrates faster than LC3-I in a 
Western blot gel and it appears as a band of lower molecular weight. The ratio 
between LC3-I and LC3-II provides an indicator of autophagic activity. 
 
 
Figure 4.12: Activation of autophagy upon nutrients deprivation and glucose reintroduction. Stable 
INS1 cell lines were deprived of nutrients for 24 hours and then incubated with the indicated 
concentrations of glucose. Lysates were analysed by Western Blot analysis and incubated with an 
antibody anti LC3. Tubulin was used as equal loading control. Representative blot of 3 independent 
experiments is shown. 
 
Results showed that, in these experimental conditions, nutrients deprivation 
induced an increase in the Western Blot band corresponding to LC3-II, suggesting an 
increase in autophagosomes formation (Figure 4.12). This suggests that an 
autophagic process is activated in these experimental conditions. Reintroduction of 
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stimulatory concentrations of glucose did not significantly modify the intensity of 
LC3-I and LC3-II bands compared to the control left in nutrients deprivation. Also, no 
difference was observed between scrambled and PI3K-C2α knock down cells, 
indicating that reintroduction of glucose alone does not seem to inhibit 
autophagosome formation. Moreover, downregulation of PI3K-C2α does not seem 
to affect the autophagic process. 
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4.3 Discussion 
PI3Ks activity controls many intracellular functions, including cell proliferation, 
survival and growth. The fact that multiple isoforms of PI3Ks exist, and the 
unanswered questions on whether their roles are overlapping or redundant 
complicate the investigation of this class of enzymes. Recently, several lines of 
evidence suggest a role for the class II isoform PI3K-C2α as a cellular survival factor. 
Specifically, downregulation of PI3K-C2α in HUVEC cells increased apoptosis 
(Yoshioka et al. 2012, Tibolla et al. 2013) and decreased proliferation upon 
stimulation with serum (Yoshioka et al. 2012). Furthermore, knockdown of PI3K-C2α 
also decreased proliferation and increased apoptosis in HeLa cells, without affecting 
class I PI3K/Akt survival pathway (Elis et al. 2008). Also, the viability of several cancer 
cell lines is affected upon downregulation of PI3K-C2α and in normal growth 
conditions (Elis et al. 2008), although, in the pancreatic β cell line INS1, no significant 
modification of cell viability was observed upon downregulation of PI3K-C2α 
(Dominguez et al. 2011).  
The effect of PI3K-C2α downregulation in pancreatic β cells upon stressful growth 
conditions was not investigated before. Therefore, I sought to investigate whether 
under adverse growth conditions PI3K-C2α downregulation might sensitise INS1 cells 
towards death. First, I focused on lipotoxicity, since one of the common metabolic 
alterations caused by diabetes is an increased free fatty acids concentration in the 
bloodstream, which can negatively affect pancreatic β cell viability. Using INS1 sh 
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scrambled and sh PI3K-C2α cell lines, I measured cell viability by both cell counting 
and MTT assay upon treatment for 24 and 48 hours with sodium palmitate. As 
expected, lipotoxic growth conditions caused a decrease in cell viability. Also, my 
results indicated that PI3K-C2α downregulation did not render INS1 cells more prone 
to cell death, in these experimental conditions (Figures 4.2 and 4.3). Considering 
that treatment with sodium palmitate caused a significant decrease in the protein 
levels of PI3K-C2α (Figure 3.5), the comparable decrease in viability upon palmitate 
treatment in the two cell lines can be due to a reduction of PI3K-C2α levels in 
control cells. Sodium palmitate concentrations of 0.25 and 0.5 mM, which caused a 
decrease in cell viability (Figures 4.2 and 4.3), were also able to affect PI3K-C2α 
protein levels in control cells (Figure 3.5), rendering them phenotypically similar to 
INS1 sh PI3K-C2α cells. However, the fact that cell viability is only slightly affected by 
concentrations of palmitate (0.25 mM upon 24h treatment, Figures 4.2 and 4.3) that 
strongly affect the protein levels of PI3K-C2α (Figure 3.5), suggests that PI3K-C2α 
might not be involved in the regulation of cell viability, in these experimental 
conditions.  
Then, I investigated the effects of other stressful growth conditions, such as 
nutrients deprivation, upon downregulation of PI3K-C2α. Data in literature suggest 
the central role of glucose on β cell proliferation (Hugl et al. 1998, Cousin et al. 1999, 
Dickson et al. 2001, Briaud et al. 2003), although the molecular mechanisms 
underlying this intracellular signalling are not fully understood.  
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It was reported that stimulatory concentrations of glucose can induce cell 
proliferation, with a maximal effect observed using 15 mM glucose upon 24 hours of 
serum and glucose deprivation in INS1 cells (Hugl et al. 1998). The stimulatory effect 
of glucose is potentiated by treatment with IGF-1, while no significant proliferation 
effect is observed using glucose concentrations up to 3 mM, with or without IGF-1 
(Hugl et al. 1998). Similar results were then obtained by the same group, using GH to 
potentiate glucose proliferation signal (Cousin et al. 1999). Interestingly, class I PI3Ks 
seem not to be involved in the intracellular signalling upon glucose stimulation. 
Indeed, constitutive activation of class I PI3K resulted in an enhanced IGF-1-induced 
proliferation, with no effect on glucose-induced signalling (Dickson et al. 2001). 
This suggests that the intracellular signalling triggered by stimulatory glucose 
concentrations involves other enzymes rather than class I PI3Ks and therefore I 
decided to investigate the potential role of class II PI3K-C2α in this context. To this 
end, INS1 sh scrambled and sh PI3K-C2α cells were deprived from serum and 
nutrients for 24 hours and then incubated with serum free medium supplemented 
with 15 mM glucose. Consistent with data in literature, my data show that, upon 24 
hours nutrient deprivation, glucose alone is able to protect INS1 cells from death, 
ameliorating cell viability upon treatment with a concentration of 3 mM glucose and 
with a further improvement on cell viability using  15 mM glucose.  
My data show for the first time that the enzyme PI3K-C2α is involved in the 
intracellular signalling of stimulatory concentrations of glucose, as INS1 cells 
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downregulating PI3K-C2α show a decreased viability upon nutrients deprivation and 
glucose reintroduction, compared to the control (Figures 4.7 and 4.8). After the 24 
hours starvation period and treatment of INS1 cells with serum free medium 
supplemented with substimulatory concentrations of glucose, no difference in cell 
viability was observed between sh scrambled and sh PI3K-C2α cells. This suggests 
that the intracellular mechanisms activated by 3 or 15 mM glucose are distinct, and 
only 15 mM glucose stimulation is able to activate PI3K-C2α. Furthermore, the 
extent of glucose-induced increase in cell viability depends on glucose 
concentration, being more pronounced with high glucose than with lower 
concentrations. This is in line with previous reports suggesting that both survival and 
proliferation mechanisms are activated upon high glucose stimulation (Hugl et al. 
1998, Cousin et al. 1999, Dickson et al. 2001). Further studies are needed to 
investigate whether these intracellular mechanisms are activated upon these 
experimental conditions. 
In addition, my data show that glucose-induced cell survival is not inhibited by 
classical PI3Ks inhibitors wortmannin and LY294002. This observation is consistent 
with data in literature showing that class I PI3Ks are not necessary for glucose-
induced cell proliferation (Dickson et al. 2001) and further support the hypothesis 
that the intracellular signalling upon glucose stimulation is mediated by PI3K-C2α, 
which is the only PI3K isoform resistant to both inhibitors (Domin et al. 1997).  
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An appropriate pancreatic β cell mass is the result of a balance between cell signals 
protecting from death (i.e. cell survival, proliferation, growth) and promoting death 
(i.e. apoptosis, necrosis). In order to study which cellular processes were responsible 
for the increase in cell viability upon treatment with stimulatory concentrations of 
glucose, I examined the activation of apoptosis and autophagy by Western Blot 
using the markers Caspase 3 and LC3, respectively. Results showed that nutrients 
deprivation in INS1 cells triggers both autophagy and apoptosis (Figures 4.11 and 
4.12). Interestingly, autophagy was not reverted by the reintroduction of stimulatory 
concentrations of glucose (Figure 4.12) in the time frame examined. On the other 
hand, treatment with stimulatory glucose concentrations was able to gradually stop 
the apoptotic process (Figure 4.11), which is consistent with the observed increase 
in cell viability. 
Furthermore, no difference was observed in terms of conversion from LC3-I to LC3-II 
upon downregulation of PI3K-C2α, suggesting that PI3K-C2α does not regulate 
autophagy in these experimental conditions. This is in contrast with the findings 
recently reported by Deveraux and colleagues, who showed that simultaneous 
downregulation of PI3K-C2α and PI3K-C2β was able to affect autophagy (Devereaux 
et al. 2013). This discrepancy could be explained by the different cellular system and 
experimental conditions used, or with the potential compensatory role of PI3K-C2β 
in our experiments. 
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Interestingly, my data showed that downregulation of PI3K-C2α has a role in 
overturning the apoptotic process upon reintroduction of stimulatory glucose 
concentrations. In fact, while treatment with glucose cause the progressive decrease 
of the fragment corresponding to cleaved caspase 3 in INS1 sh scrambled cells, the 
intensity of the band corresponding to the fragment does not decrease in PI3K-C2α 
knock down cells, indicating the inability of this cell line to inhibit the apoptotic 
process upon treatment with stimulatory concentrations of glucose. This suggests 
that PI3K-C2α is involved in the anti-apoptotic role of stimulatory glucose 
concentrations.  
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Chapter 5 
Intracellular functions regulated by PI3K-C2α 
 
Signalling pathways 
 
5.1 Introduction 
In the previous chapter I described how class II PI3K-C2α regulates a signalling 
pathway which is able to prevent death of pancreatic β cells upon nutrients 
deprivation and reintroduction of stimulatory concentrations of glucose. 
In order to further investigate the intracellular mechanisms triggered by stimulatory 
concentrations of glucose, the activation of the mTOR pathway was examined. 
mTOR is a serine/threonine kinase which can interact with several other proteins, 
forming two different complexes named mTORC1 and mTORC2. The understanding 
of mTORC signalling is complex and, more than 20 years after mTOR discovery, is still 
evolving (Laplante and Sabatini 2012).  
Both mTOR complexes are large (1 MDa). They share the catalytic core mTOR, 
mammalian lethal with Sec13 protein 8 (mLST8) and DEP domain-containing mTOR-
interacting protein (DEPTOR). The other components of the complex are specific, 
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with mTORC1 being associated with the regulatory-associated protein of mTOR 
(raptor) and proline-rich Akt substrate of 40 kDa (PRAS40) while rapamycin 
insensitive companion of mTOR (rictor), mammalian stress-activated map kinase-
interacting protein1 (mSin1) and protein observed with rictor (protor)1/protor2 
interact with mTORC2 (Figure 5.1) (Mavrommati and Maffucci 2011). 
The name mTOR was originally chosen as acronym of ‘mammalian Target Of 
Rapamycin’, (or, more recently, ‘mechanistic TOR)’ because of the discovery that 
mTOR was the target of rapamycin, an antibiotic, immunosuppressive and 
anticancer drug discovered in 1975. Rapamycin forms a gain-of-function complex 
binding the regulatory protein FK506-binding protein (FKBP12), which can directly 
interact and inhibit mTOR when it is part of mTORC1 but not mTORC2 (Laplante and 
Sabatini 2012). As a result, the complex mTORC1 is rapidly and acutely inhibited by 
rapamycin, while mTORC2 is resistant to acute treatment and can be inhibited only 
by prolonged rapamycin treatment. The long-term inhibition of mTORC2 induced by 
rapamycin is probably due to the lack of free mTOR, as the complex cannot be 
incorporated into newly synthesised mTORC2 (Sarbassov et al. 2006, Xie and 
Herbert 2012). 
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Figure 5.1: Diagram of mTORC1 and mTORC2 components and intracellular functions.the two 
mTOR complexes have different downstream effectors (Gao et al. 2012). 
 
mTOR is an intracellular signalling hub which can integrate different cellular stimuli, 
such as nutrients availability, cellular stress, and growth factors stimulation, 
controlling anabolic or catabolic pathways based on the energy requirements. Its 
role is particularly important in pancreatic β cells, as it regulates β cell mass, 
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viability, function and metabolism, playing a crucial role especially during conditions 
of insulin resistance and β cell compensation (Xie and Herbert 2012). 
Of the two mTOR complexes, mTORC1 is the best characterised (Laplante and 
Sabatini 2012). Its function is mediated mainly by its direct downstream target 
effectors 4EBPs and S6K (Figure 5.2), which are recruited through the specific 
mTORC1 component Raptor and phosphorylated by mTOR (Xie and Herbert 2012).  
Importantly, lack of S6K can cause a reduction in pancreatic endocrine mass and 
specifically it decreased pancreatic β cell size in knockout mice models (Pende et al. 
2000). 4EBPs promote protein synthesis and cell cycle progression when 
hyperphosphorylated. Indeed, phosphorylation of 4EBPs leads to the release of 
eukaryotic translation initiation factor 4E and the expression, among others, of 
proteins promoting cell cycle progression (Wang and Proud 2009, Xie and Herbert 
2012). Also, it has been reported that 4EBPs mediate mTORC1 proliferative signal 
and regulate cell proliferation in low serum conditions in MEFs (Dowling et al. 2010). 
Both mTORC1 and mTORC2 can be activated by growth factors and hormones. 
However, nutrients such as amino acids and glucose can only activate mTORC1 
(Dann et al. 2007). Hormones and growth factors are able to activate mTORC1 
through the canonical class I PI3K/Akt pathway (Dann et al. 2007, Vanhaesebroeck 
et al. 2010). It has also been reported that class III Vps34 is involved in mTORC1-
dependent activation of S6K (Byfield et al. 2005). 
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Figure 5.2: Schematic diagram of mTORC1 signalling pathway. mTOR can be activated by a variety 
of stimuli, leading to protein translation and cell proliferation through its downstream effectors 
4EBP1 and S6K (Kwon et al. 2004). 
 
In addition, it has been reported that glucose can indirectly activate mTORC1 
signalling through the serine/threonine kinase AMPK. Specifically, AMPK acts as a 
cellular energy sensor, since it is allosterically activated by adenosine 
monophosphate (AMP) when the cell is in a low energy status (Hardie et al. 1999). 
Activation of AMPK causes its phosphorylation and subsequent inhibition of 
mTORC1, preventing the activation of intracellular anabolic pathways.  
The fact that mTOR, and particularly mTORC1 can be activated by glucose, and can 
regulate both cell proliferation and cell size underlines its role in the context of T2D 
progression. Indeed, failure of pancreatic β cells observed in diabetic patients is due 
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to decrease in both β cell mass and size. As mentioned before, these processes are 
regulated, among others, by mTORC1 downstream effectors, S6K and 4EBP1. 
Therefore, in this chapter I analysed the effects of glucose stimulation on the 
intracellular signalling involving mTOR pathway and the potential role of PI3K-C2α. 
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5.2 Results 
5.2.1 Effects of stimulatory glucose concentrations on the activation of 
mTOR and its direct downstream effectors in INS1 cells 
Data presented in the previous chapter demonstrate that stimulatory 
concentrations of glucose can protect INS1 cells from death induced by nutrients 
deprivation, through an intracellular mechanism involving the enzyme PI3K-C2α. 
Since mTOR is one of the key regulators of cell proliferation, I decided to investigate 
whether stimulatory glucose concentrations were able to induce the activation of 
mTOR pathway by Western blot.  
Previous studies have shown that phosphorylation of the residue Ser 2448 of mTOR 
depends on mTOR kinase activity and that this residue is not an 
autophosphorylation site (Sekulic et al. 2000). Subsequently it was reported that 
mTOR Ser 2448 phosphorylation is mediated by S6K (Chiang and Abraham 2005). 
These lines of evidence indicate that mTOR phosphorylation at its residue Ser 2448 
occurs upon mTOR activation. Therefore, this specific post translational modification 
of mTOR can be used to monitor mTOR activity (Chiang and Abraham 2005, Subbiah 
et al. 2013).  
INS1 cells were deprived from nutrients as previously described, and then left in 
nutrients deprivation or treated with stimulatory concentrations of glucose for 
further 24 hours. 
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Figure 5.3: Activation of mTOR upon nutrients deprivation and glucose reintroduction in INS1 
parental cells. INS1 cells were deprived from nutrients for 24 hours and then incubated in serum 
free medium supplemented with 15 mM glucose or left in nutrients deprivation. Lysates were 
analysed by Western Blot and incubated with a specific antibody recognising phosphorylated Ser 
2448 of mTOR. Tubulin was used as loading control.  
 
As shown in Figure 5.3, Ser 2448 of mTOR was phosphorylated in INS1 cells grown in 
complete medium. This indicated that mTOR was activated, contributing to the 
normal cell proliferation. Upon nutrients deprivation, phosphorylation of Ser 2448 of 
mTOR was progressively reduced. Reintroduction of stimulatory concentrations of 
glucose in the culture medium triggered the phosphorylation of this amino acid 
residue, indicating mTOR activation in these conditions. 
In order to further investigate mTOR signalling cascade, phosphorylation of 4EBP1 
was also examined. INS1 cells were deprived from nutrients for 24 hours as 
previously described, and then treated for further 24 hours with stimulatory 
concentrations of glucose or left in nutrients deprivation as a control. 
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Figure 5.4: Phosphorylation of 4EBP1 upon nutrients deprivation and glucose reintroduction. INS1 
cells were deprived from nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose or left in nutrients deprivation. Lysates were analysed by 
Western Blot and incubated with a specific antibody recognising phosphorylated Thr 37/46 of 
4EBP1. ERK2 was used as loading control.  
 
Results showed that residues Thr 37/46 of 4EBP1 were phosphorylated in cells 
grown in complete medium. Upon nutrients deprivation, phosphorylation of 4EBP1 
was gradually decreased, until it was undetectable upon 48 hours of nutrients 
deprivation. Reintroduction of stimulatory concentrations of glucose induced a 
strong phosphorylation of the residues Thr 37/46 of 4EBP1, indicating that glucose is 
able to induce activation of mTOR-dependent signals. 
I then analysed the phosphorylation and activation of the protein S6K at its residue 
Thr 389, which is directly phosphorylated by mTOR. 
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Figure 5.5: Activation of S6K upon nutrients deprivation and glucose reintroduction. INS1 cells were 
deprived from nutrients for 24 hours and then incubated in serum free medium supplemented with 
15 mM glucose or left in nutrients deprivation. Lysates were analysed by Western Blot and 
incubated with a specific antibody recognising S6K when phosphorylated at Thr 389, then stripped 
and incubated with an antibody recognising total S6K. ERK2 was also used as loading control. 
Representative blot of 3 independent experiments is shown. 
 
S6K was phosphorylated when INS1 cells were cultured in serum, consistent with 
the activation of mTOR and 4EBP1 in these experimental conditions shown in 
Figures 5.3 and 5.4. 
S6K phosphorylation at its residue Thr 389 was slightly decreased upon 24 hours of 
nutrients deprivation and further reduced after additional 24 hours. Reintroduction 
of stimulatory concentrations of glucose increased the phosphorylation of residue 
Thr 389.  
These data indicate that reintroduction of stimulatory concentrations of glucose in 
INS1 cells deprived from nutrients for 24 hours is able to induce the phosphorylation 
and activation of mTOR and its direct downstream effectors 4EBP1 and S6K. 
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5.2.2 Glucose-induced stimulation of mTOR is affected by rapamycin 
Once assessed that glucose is able to activate mTOR pathway, I decided to 
determine the role of glucose-induced mTOR activation. To this end, I first tested the 
effect of mTOR inhibition on glucose-induced cell survival. Therefore, I determined 
which concentrations of rapamycin would inhibit glucose-induced mTOR activation. 
First, I analysed mTOR phosphorylation at Ser 2448. INS1 cells were deprived from 
growth factors and glucose for 24 hours. Then, cells were treated for 24 hours with 
stimulatory glucose concentrations in the absence of growth factors, following the 
same experimental conditions described in Chapter 4. Different rapamycin 
concentrations were used, ranging from 20 nM to 1 μM. 
 
 
Figure 5.6: Activation of mTOR upon nutrients deprivation and glucose reintroduction is inhibited 
by rapamycin. INS1 cells were deprived of nutrients for 24 hours and then incubated with 15 mM 
glucose, with or without the indicated concentrations of rapamycin. Lysates were analysed by 
Western Blot and incubated with antibodies recognising phosphorylated Ser 2448 of mTOR. 
Tubulin was used as control of equal loading.  
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As described before, in normal growth conditions, Ser 2448 of mTOR was 
phosphorylated and after 24 hours of nutrients deprivation the phosphorylation of 
mTOR was decreased, indicating that mTOR was inhibited (Figure 5.6). 
Reintroduction of stimulatory glucose concentrations was able to induce the 
phosphorylation of Ser 2448. Treatment with rapamycin prevented the 
phosphorylation of Ser 2448, confirming the role of mTOR in this activation. 
In the same experimental conditions, the phosphorylation of ribosomal protein S6, 
an indirect downstream effector of mTOR, was also analysed. S6 is phosphorylated 
by the protein S6K upon growth factors and mitogens stimulation (Dufner and 
Thomas 1999). The activation of S6 is often used as readout for mTOR activation and 
it is assessed by analysing the phosphorylation of the residues Ser 235/6 and Ser 
240/4. 
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Figure 5.7: Activation of S6 upon nutrients deprivation and glucose reintroduction. INS1 cells were 
deprived of nutrients for 24 hours and then incubated with 15 mM glucose, with or without the 
indicated concentrations of rapamycin. Lysates were analysed by Western Blot and incubated with 
antibodies recognising phosphorylated S6, then stripped and incubated with a specific antibody for 
total S6. 
 
Results from this experiment showed that S6 was phosphorylated at both residues 
Ser 235/236 and 240/244 in normal growth conditions. The phosphorylation of 
these residues was decreased upon 24 hours of nutrients deprivation. 
Reintroduction of stimulatory concentrations of glucose was able to induce the 
phosphorylation S6 at both residues examined, and this process was inhibited by 
treatment with rapamycin. These data are consistent with the data shown in 
Chapter 5.2.1, and confirm that stimulatory concentrations of glucose are able to 
activate mTORC1 in INS1 cells. Furthermore, these data confirmed that 
161 
 
concentrations of rapamycin as low as 20 nM were sufficient to inhibit mTOR and S6 
phosphorylation. 
 
5.2.3 Effects of rapamycin treatment on glucose-induced cell survival 
Once assessed that glucose was able to activate mTORC1 in INS1 cells, and set the 
concentrations of rapamycin necessary to inhibit its activation, I then decided to 
determine whether mTORC1 had a role in the glucose-induced survival/proliferation 
effect observed in INS1 cells (Chapter 4). To this end, I assessed the effect of 
rapamycin on cell viability. INS1 control cells were deprived from nutrients and then 
stimulated with 15 mM glucose, in the presence or absence of 20 and 50 nM 
rapamycin or left in nutrients deprivation as previously described. Cell viability was 
assessed by MTT assay. 
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Figure 5.8: Cell viability upon nutrients deprivation and glucose reintroduction, in the presence or 
absence of rapamycin. INS1 sh scrambled cells were deprived from nutrients for 24 hours and then 
incubated in serum free medium supplemented with 15 mM glucose, with or without the indicated 
concentrations of rapamycin, or left in nutrients deprivation. Cell viability was assessed by MTT 
assay. Data are expressed as fold increase relative to day 0 and are means ± s.e.m. from 6 
independent experiments. * p value < 0.05; ** p value < 0.01 vs corresponding untreated control. 
 
Consistent with data presented in Chapter 4, results in Figure 5.8 showed that 
stimulatory concentrations of glucose were able to protect INS1 sh scrambled cells 
from death, upon 24 and 48 hours treatment. Also, the presence of rapamycin 
significantly reduced glucose-induced survival, at both 24 and 48 hours post-
treatment. The effect of 20 nM rapamycin was not further enhanced by higher 
concentration of the drug, suggesting that a concentration of 20 nM already 
maximally inhibited the effect of glucose on cell viability.  
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Taken together, these data indicate that the intracellular signalling triggered by 
reintroduction of stimulatory concentrations of glucose activates mTORC1, which in 
turn is involved in glucose-induced cell survival. 
My results showed that both rapamycin and downregulation of PI3K-C2α affected 
glucose-induced cell proliferation (Figures 5.8 and 4.7, respectively), and that 
glucose was also able to activate mTOR pathway. Therefore, in order to assess the 
potential contribution of PI3K-C2α in glucose-induced activation of mTOR pathway, 
in parallel with experiments presented in Figure 5.8, I also assessed the effect of 
rapamycin in sh PI3K-C2α cells. The viability of sh PI3K-C2α cells upon nutrients 
deprivation and glucose reintroduction and in the presence or absence of rapamycin 
was compared to that observed in sh scrambled cells (Fig 5.8) and is shown in Figure 
5.9. 
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Figure 5.9: Cell viability upon nutrients deprivation and glucose reintroduction, in the presence or 
absence of rapamycin. Stable INS1 cell lines were deprived of nutrients for 24 hours and then 
incubated in serum free medium supplemented with 15 mM glucose, with or without the indicated 
concentrations of rapamycin, or left in nutrients deprivation. Cell viability was assessed by MTT 
assay. Data are expressed as fold increase relative to day 0 and are means ± s.e.m. from 6 
independent experiments. * p value < 0.05; ** p value < 0.01. 
 
Reintroduction of glucose alone was able to improve cell viability in both cell lines. 
Consistent with data described in Chapter 4.2.4, cell viability was reduced in INS1 sh 
PI3K-C2α cells compared to the scrambled control.  
Notably, the viability of  scrambled control cells treated with glucose and rapamycin 
was comparable to that observed in INS1 sh PI3K-C2α cells treated with glucose 
only. More importantly, rapamycin treatment did not affect the viability of PI3K-C2α 
knock down cells. These data indicate that rapamycin treatment has no further 
effect in PI3K-C2α knock down cells in terms of viability. This suggests that mTOR 
and PI3K-C2α might be part of the same signalling cascade activated by stimulatory 
concentrations of glucose upon nutrients deprivation. 
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5.2.4 Role of PI3K-C2α in the activation of mTOR pathway induced by 
stimulatory concentrations of glucose 
To directly investigate whether PI3K-C2α is involved in glucose-induced activation of 
mTOR, I used stable cell lines INS1 sh scrambled and sh PI3K-C2α. Specifically, I 
determined whether downregulation of PI3K-C2α affects mTOR activation upon 
glucose reintroduction. 
 
 
Figure 5.10: Activation of mTOR upon nutrients deprivation and glucose reintroduction. Stable INS1 
cell lines were deprived of nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose or left in nutrients deprivation. Lysates were analysed by 
Western Blot and incubated with a specific antibody recognising phosphorylated Ser 2448 of 
mTOR. Tubulin was used as loading control. Representative blot of 2 independent experiments is 
shown. 
 
Ser 2448 of mTOR was phosphorylated in both INS1 sh scrambled and sh PI3K-C2α 
cells when cells were grown in complete medium supplemented with serum. Upon 
nutrients deprivation, the residue Ser 2448 progressively decreased its 
phosphorylation in sh scrambled cells. Consistent with data obtained in parental 
cells (Figure 5.3), reintroduction of stimulatory concentrations of glucose induced 
the phosphorylation of mTOR Ser 2448 in sh scrambled cells. Interestingly, upon 
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nutrients deprivation or glucose reintroduction, the phosphorylation of Ser 2448 
was not significantly modified in INS1 sh PI3K-C2α cells. This data suggests that PI3K-
C2α is required for glucose-induced phosphorylation of mTOR at Ser 2448. 
In order to further assess the effect of downregulation of PI3K-C2α in glucose-
induced activation of mTOR pathway, mTOR downstream signalling cascade was 
analysed by Western blot. 
  
 
Figure 5.11: Activation of 4EBP1 upon nutrients deprivation and glucose reintroduction. Stable INS1 
cell lines were deprived from nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose or left in nutrients deprivation. Lysates were analysed by 
Western Blot and incubated with a specific antibody recognising phosphorylated Thr 37/46 of 
4EBP1. ERK2 was used as loading control. Representative blot of 2 independent experiments is 
shown.  
 
Consistent with data shown in Figure 5.4, Thr 37/46 of 4EBP1 was phosphorylated in 
serum, and the level of its phosphorylation progressively decreased upon 24 and 48 
hours of nutrients deprivation in both cell lines (Figure 5.11). Upon reintroduction of 
stimulatory concentrations of glucose, strong phosphorylation of 4EBP1 on Thr 
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37/46 was detected in sh scrambled cells. Interestingly, in the same experimental 
conditions, sh PI3K-C2α cells showed a decreased phosphorylation of 4EBP1 
compared to control cells. This suggests that the activity of PI3K-C2α is required for 
glucose-induced phosphorylation of 4EBP1 at residues Thr 37/46. 
Densitometric analysis of Western Blots for p4EBP1 was then performed and results 
are shown in Figure 5.12. Western blot films from 2 different experiments were 
scanned and analysed with the software ImageJ.  
 
 
Figure 5.12: Densitometric analysis of Western Blots for p4EBP1 (Thr 37/46) Data are means ± 
s.e.m. from 2 independent experiments.  
 
Data showed that in both cell lines Thr 37/46 of 4EBP1 was phosphorylated in serum 
and the phosphorylation of Thr 37/46 was progressively decreased by nutrients 
deprivation for 24 and 48 hours. When glucose was reintroduced in the culture 
medium, the phosphorylation of Thr 37/46 of 4EBP1 was increased in INS1 sh 
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scrambled cells. Notably, INS1 sh PI3K-C2α cells showed a strongly impaired 
phosphorylation of Thr 37/46 of 4EBP1 upon glucose reintroduction, compared to 
the scrambled control. Specifically, downregulation of PI3K-C2α seemed to impair 
glucose-induced phosphorylation by 50%. 
In the same experimental conditions, the phosphorylation status of the protein S6K 
was also investigated (Figure 5.13). 
 
 
Figure 5.13: Activation of S6K upon prolonged nutrients deprivation and 24 hours glucose 
reintroduction. Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated 
in serum free medium supplemented with 15 mM glucose or left in nutrients deprivation. Lysates 
were analysed by Western Blot and incubated with a specific antibody recognising phosphorylated 
Thr 389 of S6K, then stripped and incubated with an antibody recognising total S6K. ERK2 was also 
used as loading control. Representative blot of 3 independent experiments is shown. 
 
Results showed that Thr 389 S6K was phosphorylated in serum, and its 
phosphorylation level gradually decreased upon nutrients deprivation. In sh 
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scrambled cells, reintroduction of stimulatory concentrations of glucose induced the 
phosphorylation of Thr 389, consistent with data obtained using parental cells 
(Figure 5.5). On the other hand, glucose-induced S6K phosphorylation at Thr 389 
was impaired in INS1 sh PI3K-C2α cells, indicating that downregulation of PI3K-C2α 
inhibits the activation of S6K in these experimental conditions. 
In order to further clarify glucose-induced activation of S6K, additional experimental 
conditions were investigated. Stable INS1 cell lines were deprived from nutrients for 
24 hours and then stimulatory concentrations of glucose were added to serum-free 
medium for further 24 or 48 hours. Results are shown in Figure 5.14. 
 
 
Figure 5.14: Activation of S6K upon nutrients deprivation and 24 or 48 hours of glucose 
reintroduction. Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated 
in serum free medium supplemented with 15 mM glucose for 24 and 48 hours. Lysates were 
analysed by Western Blot and incubated with a specific antibody recognising phosphorylated Thr 
389 of S6K, then stripped and incubated with an antibody recognising total S6K. ERK2 was also 
used as loading control. Representative blot of 3 independent experiments is shown. 
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Consistent with data previously shown, Thr 389 S6K was phosphorylated in serum 
and the phosphorylation was decreased upon nutrients starvation in both cell lines. 
After reintroduction of stimulatory concentrations of glucose, phosphorylation of 
S6K increased in sh scrambled cells at both 24 and 48 hours post treatment. 
Downregulation of PI3K-C2α inhibited glucose-induced phosphorylation of S6K, 
compared to control cells. 
These data provide further evidence of the involvement of PI3K-C2α in the 
activation of mTOR pathway upon glucose stimulation.  
Densitometric analysis of Western Blots for pS6K was also performed, analysing 
scanned blots from 3 different experiments with the software ImageJ.  
 
 
Figure 5.15: Densitometric analysis of Western Blots for pS6K (Thr 389). Stable INS1 cell lines were 
deprived from nutrients for 24 hours and then incubated in serum free medium supplemented with 
15 mM glucose for further 24 or 48 hours. Scanned blots were analysed using the software ImageJ. 
Data are means ± s.e.m. from 3 independent experiments. * indicates INS1 sh scrambled vs INS1 sh 
PI3K-C2α. p value < 0.05. 
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Upon nutrient starvation (day 1), phosphorylation of Thr 389 of S6K was reduced 
compared to cells in serum (day 0) in both cell lines. Following 24 or 48 hours 
reintroduction of stimulatory concentrations of glucose (days 2 and 3, respectively), 
phosphorylation of S6K was increased in sh scrambled cells, suggesting that glucose 
is able to activate S6K. Interestingly, glucose-induced phosphorylation of Thr 389 
S6K was impaired in INS1 sh PI3K-C2α cells, either upon 24 or 48 hours treatment. 
Specifically, INS1 sh PI3K-C2α cells showed a 50% decrease in the phosphorylation 
levels, compared to sh scrambled cells. 
Taken together, these data indicate that PI3K-C2α is required for the 
phosphorylation and activation of S6K upon reintroduction of stimulatory 
concentrations of glucose, at both 24 and 48 hours post treatment. 
 
5.2.5 Effects of stimulatory glucose concentrations on the activation of 
other components of mTOR pathway 
In order to further investigate the role of PI3K-C2α in glucose-induced activation of 
mTOR pathway, the activation of other members of the mTOR signalling cascade 
was investigated. 
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Figure 5.16: Representative blot (A) and densitometric analysis (B) of Western Blots for pS6 (Ser 
235/236). Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated in 
serum free medium supplemented with 15 mM glucose for further 24 or 48 hours. Scanned blots 
were analysed using the software ImageJ. Data are means ± s.e.m. from 3 independent 
experiments. *p<0.05 and **p<0.01,  indicating INS1 sh scrambled vs INS1 sh PI3K-C2α. 
 
Densitometric analysis of levels of S6 phosphorylation at its residue Ser 235/236 
revealed that both cell lines showed a low phosphorylation upon 24 hours nutrients 
deprivation. Reintroduction of stimulatory concentrations of glucose increased the 
phosphorylation of S6 in sh scrambled cells, upon either 24 or 48 hours post 
treatment. Glucose-induced phosphorylation of Ser 235/236 was significantly 
reduced in INS1 sh PI3K-C2α, at both 24 and 48 hours post treatment. 
In addition, phosphorylation of residue 240/244 of S6 was analysed in the same 
experimental conditions (Figure 5.17). 
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Figure 5.17: Representative blot (A) and densitometric analysis (B) of Western Blots for pS6 (Ser 
240/244). Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated in 
serum free medium supplemented with 15 mM glucose for further 24 or 48 hours. Scanned blots 
were analysed using the software ImageJ. Data are means ± s.e.m. from 3 independent 
experiments. * indicates INS1 sh scrambled vs INS1 sh PI3K-C2α. p value < 0.01. 
 
Results indicated that both cell lines displayed low level of Ser 240/244 
phosphorylation upon nutrients deprivation. Consistent with results showed in 
Figure 5.16, sh scrambled cells treated with stimulatory concentrations of glucose 
for 24 or 48 hours showed an increase in the phosphorylation levels of S6. The level 
of glucose-induced phosphorylation was slightly decreased in INS1 sh PI3K-C2α cells 
after 24 hours of treatment and significantly decreased after 48 hours. 
174 
 
In summary, my results showed that glucose was able to activate the downstream 
effector of S6K, S6 ribosomal protein, as assessed by phosphorylation of the 
residues Ser 235/236 and Ser 240/244. The activation of S6, upon nutrients 
deprivation and glucose reintroduction, was impaired in INS1 sh PI3K-C2α cells 
compared to the control.  
Taken together, these data indicate for the first time that PI3K-C2α is involved in 
glucose-induced activation of mTOR and its downstream targets.  
 
5.2.6 Akt activation upon nutrients starvation and glucose stimulation 
In order to determine the upstream signalling involved in the PI3K-C2α-dependent 
activation of mTOR pathway, additional Western blots experiments were 
performed. 
Serum stimulation can activate the PI3K/Akt pathway, which can ultimately lead to 
the stimulation of mTOR catalytic activity (Sekulic et al. 2000). The serine threonine 
protein kinase B/Akt, is a key regulator of cell growth, differentiation, and survival 
and a key activator of mTOR (Vadlakonda et al. 2013). Some studies suggested that 
PI3K-C2α can activate Akt in pancreatic β cells (Leibiger et al. 2010) and therefore, I 
decided to investigate whether Akt is involved in PI3K-C2α-dependent mTOR 
activation. First, I investigated whether glucose stimulation could lead to the 
activation of Akt. Therefore, control cells lines were deprived from nutrients and 
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then treated with stimulatory concentrations of glucose, as previously described. 
Phosphorylation of residue Ser 473 of Akt was examined by Western blot. 
 
 
Figure 5.18: Activation of Akt upon nutrients deprivation and glucose reintroduction. INS1 cells 
were deprived of nutrients for 24 hours and then incubated with the indicated concentrations of 
glucose. Lysates were analysed by Western Blot analysis, incubated with a specific antibody 
recognising phosphorylated Ser 473 of Akt, stripped and incubated for total Akt. Representative 
blot of 3 independent experiments is shown. 
 
Results showed that the phosphorylation of Ser 473 Akt was not clearly modified by 
nutrients deprivation and glucose reintroduction. This residue was phosphorylated 
in serum and, upon 24 hours of nutrients deprivation, a clear band corresponding to 
phosphorylated Ser 473 was still detectable and not modified by further treatment 
with glucose. These data suggested that phosphorylation of Ser 473 Akt is not 
involved in the glucose-induced proliferation object of my study. 
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5.2.7 PI3K-C2α has a role in AMPK signalling 
In order to further investigate the intracellular signalling triggered by nutrients 
deprivation and reintroduction of stimulatory concentrations of glucose in INS1 
cells, the phosphorylation status of the protein AMPK was studied, as this protein is 
an upstream regulator of mTOR. 
AMPK plays a key role as a master regulator of cellular energy homeostasis. When 
cells are in a low energy state, scarce supplies of ATP, the intracellular source of 
energy, and large supplies of AMP are available. The binding of AMP to AMPK 
promotes AMPK phosphorylation and subsequent activation, inhibiting ATP-
consuming pathways and restoring ATP supplies by promoting catabolic pathways 
(Canto and Auwerx 2010). Interestingly, AMPK can negatively regulate mTOR 
through the activation of the TSC pathway (Inoki et al. 2003) and therefore 
contribute to regulate cell proliferation. 
Therefore, I sought to investigate whether glucose-induced stimulation of mTOR was 
mediated by inhibition of AMPK, and whether this pathway was regulated by PI3K-
C2α. To this end, INS1 sh scrambled and sh PI3K-C2α cells were deprived from 
nutrients for 24 hours, 15 mM glucose was supplied to the culture medium, and the 
phosphorylation of AMPK was analysed. 
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Figure 5.19: Activation of AMPK upon nutrients deprivation and glucose reintroduction Stable INS1 
cell lines were deprived of nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose. Lysates were analysed by Western Blot and incubated with an 
antibody recognising phosphorylated Thr 172 of AMPK, then stripped and reincubated with an 
antibody anti AMPK. Representative blot of 5 independent experiments is shown. 
 
As shown in Figure 5.19, phosphorylation of AMPK was low when cells were grown 
in complete medium. Upon 24 hours of nutrients deprivation (Day 1), AMPK 
phosphorylation increased in both scrambled and PI3K-C2α knock down cells, as a 
result of the low energy status. After incubation with stimulatory concentrations of 
glucose for 24 hours, phosphorylation of AMPK was still clear in both sh scrambled 
and sh PI3K-C2α cells. However, sh PI3K-C2α cells showed higher phosphorylation of 
AMPK compared to sh scrambled cells, in these experimental conditions. 
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Densitometric analysis of Western blot for pAMPK was performed and the results 
are shown in Figure 5.20. 
 
 
Figure 5.20: Densitometric analysis of Western Blots for pAMPK. Data are means ± s.e.m. from 5 
independent experiments. * indicates INS1 sh scrambled vs INS1 sh PI3K-C2α. p value < 0.05.  
 
Following nutrients deprivation (Day 1), sh scrambled and PI3K-C2α knock down cell 
lines showed comparable phosphorylation of AMPK. After glucose reintroduction, 
the phosphorylation level of AMPK did not change in control cells. Interestingly, sh 
PI3K-C2α cells showed a further increase in the phosphorylation level of AMPK. 
Specifically, AMPK resulted 25% more phosphorylated in INS1 sh PI3K-C2α 
compared to sh scrambled cells upon glucose reintroduction. This indicates that 
downregulation of PI3K-C2α leads to hyperactivation of AMPK, which might explain 
the inhibition of mTOR and its downstream effectors observed in Figures 5.10-5.17. 
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This observation provides a potential explanation on how PI3K-C2α is involved in the 
activation of mTOR pathway upon glucose stimulation. 
 
5.2.8 Short term signalling following 24 hours of nutrients deprivation. 
Long term starvation can activate survival mechanisms within the cells, activating 
intracellular pathways which do not necessarily depend on glucose reintroduction, 
and are rather due to prolonged nutrient deprivation. In order to further investigate 
the activation of mTOR pathway upon glucose stimulation and the potential role for 
PI3K-C2α in modulating this signalling pathway, additional experimental conditions 
were investigated. 
Specifically, I decided to perform time-course experiments to study whether 
glucose-stimulated intracellular signalling activates mTOR pathway components at 
earlier time points than those previously investigated. Therefore, INS1 sh scrambled 
and sh PI3K-C2α cells were deprived from nutrients as described for the previous 
experiments, and then treated with stimulatory concentrations of glucose for 5, 10 
and 30 minutes. Cells were lysed and samples were prepared for Western blot 
analysis.  
 
180 
 
 
Figure 5.21: Activation of Akt and S6 upon nutrients deprivation and short time points of glucose 
stimulation. Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated in 
serum free medium supplemented with 15 mM glucose for the indicated time points. Lysates were 
analysed by Western Blot and incubated with the indicated primary antibodies specific for ERK2, 
the phosphorylated forms of Akt and S6. Membranes were stripped and reincubated with the 
appropriate antibodies recognising total Akt or S6. 
 
As shown in Figure 5.21, Ser 473 of Akt was phosphorylated when the cells were 
grown in complete medium. This is consistent with data in literature reporting the 
activation of Akt in serum following activation of class I PI3Ks. Upon 24 hours of 
nutrients deprivation the phosphorylation of Ser 473 was strongly reduced but, 
interestingly, still clearly detectable. Following 5, 10 or 30 minutes of reintroduction 
of stimulatory glucose concentration, no changes in the levels of phosphorylated Ser 
473 were observed. This observation is consistent with previous studies reporting 
that stimulation with 15 mM glucose has no effect on Akt activation (Dickson et al. 
2001). 
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In serum conditions, Ser 235/6 of S6 was highly phosphorylated. This 
phosphorylation was significantly decreased after 24 hours of nutrients deprivation, 
consistent with data previously shown (Figure 5.16). Upon 5 or 10 minutes of 
glucose reintroduction, the phosphorylation levels of Ser 235/6 of S6 were not 
modified. Following 30 minutes of glucose reintroduction, the phosphorylation level 
of S6 increased. This suggests that glucose-induced activation of mTOR pathway 
begins already 30 minutes after treatment. Furthermore, the activation of S6 was 
achieved in experimental conditions that did not seem to induce Akt activation. This 
suggests that the intracellular signalling triggered by glucose reintroduction does not 
require the activation of the canonical class I PI3Ks/Akt axis.  
Importantly, S6 phoshorylation was inhibited in INS1 sh PI3K-C2α cells compared to 
scrambled control. This observation indicates that class II PI3K-C2α is required for 
the activation of mTOR pathway induced by short time points of stimulation with 
glucose. 
In addition, the phosphorylation levels of Thr 308 of Akt and Ser 240/4 of S6 were 
investigated. 
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Figure 5.22: Activation of Akt and S6 upon nutrients deprivation and short time points of glucose 
stimulation (II). Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated 
in serum free medium supplemented with 15 mM glucose for the indicated time points. Lysates 
were analysed by Western Blot and incubated with the indicated primary antibodies specific for 
ERK2, the phosphorylated forms of Akt and S6. Membranes were stripped and reincubated with 
the appropriate antibodies recognising the total Akt or S6. 
 
Results showed that the residues Thr 308 of Akt and Ser 240/4 of S6 were 
phosphorylated at Day 0. Upon 24 hours of nutrients deprivation, Thr 308 displayed 
a slight decrease in the phosphorylation level. After 5, 10 or 30 minutes of glucose 
reintroduction, activation of Akt was not observed. Following 24 hours of nutrients 
deprivation, Ser 240/4 of S6 showed a decreased phosphorylation compared to cells 
in serum. Consistent with the results shown in Figure 5.17, glucose reintroduction 
induced the phosphorylation and subsequent activation of S6 after 30 minutes of 
treatment (Figure 5.22). Interestingly, in INS1 sh PI3K-C2α cells the phosphorylation 
of S6 at this specific residue resulted impaired compared to the scrambled control. 
These data suggest that in the experimental conditions examined, reintroduction of 
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stimulatory concentrations of glucose is able to activate S6 after 30 minutes 
treatment, independently of Akt activation and in a mechanism involving PI3K-C2α. 
In order to further investigate whether treatment with stimulatory concentrations of 
glucose is able to induce Akt activation, longer time points of stimulation were also 
examined. Therefore, Western Blot analysis was performed and the phosphorylation 
of Ser 473 of Akt was investigated after 45 and 60 minutes of glucose reintroduction.  
 
 
Figure 5.23: Activation of Akt upon nutrients deprivation and glucose reintroduction Stable INS1 
cell lines were deprived from nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose for the indicated time points. Lysates were analysed by 
Western Blot and incubated with the indicated primary antibodies specific for ERK2 and 
phosphorylated Ser 473 of Akt. Membrane incubated with pAkt was stripped and reincubated with 
an antibody recognising the total Akt. Representative blot is shown. 
 
 
In these experimental conditions, Ser 473 of Akt was still phosphorylated upon 24 
hours of nutrients deprivation, consistent with data on Akt activation previously 
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shown. Interestingly, the phosphorylation was not increased by treatment with 
stimulatory concentrations of glucose for either 45 or 60 minutes. These data 
further indicate that reintroduction of glucose does not result in Akt activation. 
In the same experimental conditions, I also investigated the activation of the protein 
S6K. INS1 sh scrambled and sh PI3K-C2α cells were deprived from nutrients and 
glucose was reintroduced in the culture medium, in the presence or absence of 
IGF1. 
  
 
Figure 5.24: Activation of S6K upon nutrients deprivation and glucose reintroduction Stable INS1 
cell lines were deprived from nutrients for 24 hours and then incubated in serum free medium 
supplemented with 15 mM glucose for the indicated time points, with or without IGF1. Lysates 
were analysed by Western Blot and incubated with the indicated primary antibodies specific for 
ERK2 and phosphorylated Thr 389 of S6K. Membrane incubated with pS6K was stripped and 
reincubated with an antibody recognising total S6K. Representative blot is shown. 
 
As shown in Figure 5.24, the phosphorylation of S6K was not detectable following 24 
hours of nutrients deprivation, consistent with data previously discussed in Chapter 
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5.2.4. The phosphorylation of Thr 389 S6K was increased by glucose reintroduction, 
as it was detectable after both 45 minutes and 60 minutes treatment. Also, the 
phosphorylation of Thr 389 was potentiated in the presence of IGF1, which suggests 
that two different intracellular pathways are activated by stimulatory concentrations 
of glucose and IGF1. Importantly, downregulation of PI3K-C2α impaired both IGF1-
induced and glucose-induced activation of S6K.  
In the same conditions of nutrients deprivation, shorter time points of glucose 
stimulation were also used to investigate S6 phosphorylation. INS1 sh scrambled 
control and INS1 sh PI3K-C2α cells were deprived from serum and glucose for 24 
hours and then stimulated with 15 mM glucose from a minimum of 5 minutes to a 
maximum of 40 minutes. Results are shown in Figure 5.25.  
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Figure 5.25: Activation of S6 upon nutrients deprivation and short time points of glucose 
stimulation. Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated 
with 15 mM glucose for the indicated time points. Lysates were analysed by Western Blot and 
incubated with primary antibodies specific for the phosphorylated forms of S6. Tubulin was used as 
loading control. Representative blot is shown. 
 
The phosphorylation of both residues of S6 was very low upon 24 hours of 
starvation, consistent with data in Figures 5.16 and 5.17. Treatment with stimulatory 
concentrations of glucose induced the activation of S6 and the phosphorylation of 
both residues Ser 235/236 and 240/244 after 30 and 40 minutes of treatment. 
Interestingly, the activation of S6 resulted remarkably decreased in INS1 sh PI3K-C2α 
cells, compared to the scrambled control (Figure 5.25). This is consistent with data 
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previously discussed in Chapter 5.2.5 and indicates that the intracellular pathway 
activated by glucose requires PI3K-C2α, also during short time stimulation. 
Furthermore, the phosphorylation of Thr 37/46 of 4EBP1 was investigated upon 
short time points of glucose reintroduction. 
 
 
Figure 5.26: Activation of 4EBP1 upon nutrients deprivation and short time points of glucose 
stimulation. Stable INS1 cell lines were deprived from nutrients for 24 hours and then incubated 
with 15 mM glucose for the indicated time points. Lysates were analysed by Western Blot. 
Representative blot of 2 independent experiments is shown. 
 
Upon nutrients deprivation, Thr 37/46 of 4EBP1 showed basal phosphorylation. 
Reintroduction of stimulatory concentrations of glucose induced the progressive 
activation of 4EBP1 in scrambled cells. The increase in 4EBP1 phosphorylation 
started after 10 minutes of glucose reintroduction and was clearly detectable after 
60 minutes. The activation of 4EBP1 was impaired in INS1 sh PI3K-C2α cells, as the 
intensity of the band corresponding to phosphorylated Thr 37/46 is less intense, 
particularly after 60 minutes of stimulation. These data further support the 
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conclusion that stimulation with 15 mM glucose is able to activate mTOR pathway, 
through an intracellular mechanism that involves the activation of PI3K-C2α. 
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5.3 Discussion 
In Chapter 4 I described the protective effect of stimulatory glucose concentrations 
upon nutrients deprivation in INS1 cells. In this Chapter I further investigated the 
molecular mechanisms by which glucose is able to prevent cell death, by analysing 
the activation of the key regulator of cell proliferation, mTOR and its downstream 
effectors by Western blot. The data presented in this chapter indicated that 
reintroduction of 15 mM glucose was able to induce the activation of mTOR 
pathway in pancreatic β cells (Figures 5.3, 5.4 and 5.5), consistent with data in 
literature (Cousin et al. 1999, Dickson et al. 2001, Kwon et al. 2004). Also consistent 
with my data (Figures 5.6 and 5.7), it was shown that glucose-induced activation of 
mTOR pathway is rapamycin sensitive in isolated β cell lines and rat islets (Dickson et 
al. 2001, Kwon et al. 2004). The fact that glucose-induced proliferation was affected 
by rapamycin suggested that the intracellular pathway triggered in INS1 cells 
involves mTORC1, in these experimental conditions. However, mTORC2 complex can 
also be inhibited by long term treatment (24 hours or more) with rapamycin in many 
cell types (Sarbassov et al. 2006) and therefore, it was not possible to completely 
rule out its involvement. Moreover, data in literature indicate that both complexes 
induce cell proliferation mechanisms (Xie and Herbert 2012). However, my data 
indicated that stimulatory concentrations of glucose were able to induce the 
phosphorylation of the direct downstream targets of mTORC1, 4EBP1 and S6K, and 
S6K downstream effector S6 (Figures 5.4, 5.5 and 5.7). Moreover, glucose did not 
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seem to induce phosphorylation of Ser 473 of Akt, which is modulated by mTORC2 
in certain cell types (Sarbassov et al. 2006). These data confirm the hypothesis of a 
specific glucose-induced activation of mTORC1. 
Once assessed that glucose was able to activate mTORC1 in INS1 cells, I then 
decided to investigate the potential role of PI3K-C2α in this glucose-stimulated and 
mTORC1-dependent intracellular signalling pathway. The protective effect of 
stimulatory concentrations of glucose on cell viability was affected by both 
rapamycin (Figure 5.8) and downregulation of PI3K-C2α (Figure 4.8). Importantly, my 
data indicated that rapamycin treatment had no effect on cell viability in INS1 sh 
PI3K-C2α cells. This suggests that both rapamycin and downregulation of PI3K-C2α 
affect the same intracellular pathway. Therefore, I further investigated the 
activation of mTORC1 and its pathway upon downregulation of PI3K-C2α. 
To this end, I analysed glucose-induced activation of mTORC1 pathway in INS1 sh 
scrambled sh PI3K-C2α cells by Western blot and densitometric analysis. Results 
indicated that downregulation of PI3K-C2α affected the phosphorylation of mTOR 
on Ser 2448, 4EBP1 Thr on 37/46, S6K on Thr 389 and S6 on both Ser 235/236 and 
240/244. These data are consistent with a previous report indicating that 
downregulation of PI3K-C2α affects mTORC1 activity in 3T3-L1 adipocytes upon 
insulin stimulation, with no effect on the phosphorylation of Akt (Bridges et al. 2012) 
Importantly, my data indicate that PI3K-C2α mediates the intracellular signalling 
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triggered by glucose and stimulating mTORC1 and its downstream effectors. To the 
best of my knowledge, this has never been reported before. 
Previous studies reported a role for class III PI3K hVps34 in amino acids and glucose-
induced stimulation of mTORC1 pathway (Byfield et al. 2005). The specific 
contribution of hVps34 has not been investigated in my study. However, the 
downregulation of PI3K-C2α was able to reduce, and not completely suppress, the 
activation of mTORC1 pathway in INS1 cells. Therefore, my study does not rule out 
the possibility that class III hVps34 is also involved in glucose-stimulated mTOR 
activation. However, my data indicated that glucose-induced cell survival was not 
affected by the inhibitors wortmannin and LY294002. 
Moreover, my results indicated that nutrients deprivation induced the 
phosphorylation of AMPK, consistent with the activation of this protein following a 
low energy status (Canto and Auwerx 2010). Downregulation of PI3K-C2α caused 
hyperactivation of AMPK, as assessed by phosphorylation of Thr 172 (Figure 5.19). 
Evidence in literature indicated that downregulation of PI3K-C2α affects the 
expression of β glucokinase, the enzyme that phosphorylates glucose modulating 
the rate limiting step of ATP production using glucose as substrate (Leibiger et al. 
2010). As a consequence, the reduced expression of β glucokinase affects ATP 
production, leading to AMPK hyperactivation. Therefore, it is possible that PI3K-C2α 
regulates AMPK activation by modulating β glucokinase expression. Moreover, since 
active AMPK inhibits mTOR phosphorylation, this could explain the decreased 
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glucose-induced activation of mTOR pathway in INS1 sh PI3K-C2α cells. However, 
AMPK phosphorylation was clearly detectable in sh scrambled cells upon glucose 
reintroduction, and this did not affect mTOR phosphorylation or the activation of its 
downstream effectors. 
It has been reported that downregulation of PI3K-C2α affected Akt1 activity and 
subsequently β glucokinase expression, and the resulting decreased ATP production 
upon glucose stimulation could account, at least in part, for the observed decrease 
in insulin secretion in MIN6 cells (Leibiger et al. 2010). In contrast with this, my data 
indicated that downregulation of PI3K-C2α did not affect the phosphorylation levels 
of either Ser 473 or Thr 308 of Akt, in these experimental conditions (Figures 5.18, 
5.21 and 5.22). In fact, no clear modification of the phosphorylation levels of Akt 
was detected in INS1 sh scrambled or sh PI3K-C2α cells upon nutrients starvation 
and glucose reintroduction. This discrepancy might be explained by the different 
cellular system and experimental approach used to assess Akt activity. Furthermore, 
it has been reported that the duration of glucose deprivation can modulate site-
specific activation of Akt in several cell types, protecting cells from death (Gao et al. 
2013). In my experimental conditions, neither residue Thr 308 nor Ser 473 of Akt 
seemed to be affected by glucose stimulation. On the other hand, nutrients 
deprivation induced clear inhibition of mTORC1 and its downstream effectors, 
suggesting that glucose-induced activation of mTORC1 pathway is independent of 
Akt activity. 
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Importantly, short term glucose stimulation of mTOR downstream effectors 
suggested that the activation of this intracellular pathway is specific, glucose 
dependent and requires the activation of PI3K-C2α in INS1 cells. Hence, my data 
indicate that PI3K-C2α is required for glucose-induced mTOR activation and that this 
novel PI3K-C2α/mTORC1 pathway is able to protect pancreatic β cell from death 
induced by nutrients deprivation. This finding is particularly relevant for 
understanding the progression of T2D and the mechanisms underlying the failure of 
pancreatic β cells in this context. 
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Chapter 6 
Mechanisms of PI3K-C2α activation 
 
6.1 Introduction 
Insulin secretion is physiologically triggered in pancreatic β cell by stimulation with 
glucose, which is metabolised and increases ATP/ADP ratio, causing the 
depolarisation of the plasma membrane and the influx of calcium. Ultimately, it is 
the rise in intracellular calcium concentration that causes the fusion of insulin 
granules to the plasma membrane, allowing the release of their insulin content in 
the extracellular space. Treatment with high concentrations of KCl induces insulin 
secretion in vitro in pancreatic β cells, allowing studying insulin exocytosis without 
the metabolic component activated by glucose. Specifically, treatment with KCl 
causes depolarisation of the plasma membrane, which opens the voltage-gated Ca2+ 
channels increasing the intracellular concentration of Ca2+ and inducing insulin 
exocytosis through a mechanism not fully understood (Jewell et al. 2010). 
In this context, previous work from my laboratory has shown that PI3K-C2α is 
necessary for insulin secretion and, in particular, that downregulation of PI3K-C2α in 
INS1 cells affects insulin granules exocytosis upon stimulation with KCl (Dominguez 
et al. 2011). Also, several studies reported that PI3K-C2α is required for exocytosis in 
different contexts. Specifically, it has been found that PI3K-C2α is involved in the 
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exocytosis of neurosecretory granules in neuroendocrine cells and that this process 
requires the intracellular second messenger PtdIns3P (Meunier et al. 2005). In L6 
cells, it has been found that PI3K-C2α is necessary for maximal GLUT4 translocation 
to the plasma membrane, in an exocytotic-like process that also involves the 
synthesis of PtdIns3P (Falasca et al. 2007). These lines of evidence suggest a role for 
PI3K-C2α and, possibly, PtdIns3P in the fusion of intracellular granules to the plasma 
membrane.  
Furthermore, evidence in literature reported that glucose-induced insulin secretion 
requires PI3K-C2α in MIN6 cells, and that insulin-induced synthesis of the lipid 
second messenger PtdIns(3,4)P2 is affected by downregulation of PI3K-C2α, with no 
changes in PtdIns3P and PtdIns(3,4,5)P3 levels (Leibiger et al. 2010). 
Therefore, I sought to investigate the precise role of PI3K-C2α in pancreatic β cells in 
the context of insulin granules exocytosis. In particular, I investigated which lipid 
product(s) were synthesised upon stimulation of insulin granules exocytosis induced 
by KCl and whether PI3K-C2α was involved in this process. 
To this end, I performed High Pressure Liquid Chromatography (HPLC) analysis of 
intracellular PIs upon stimulation of insulin secretion. HPLC is one of the few 
quantitative techniques that can be used to study lipids, which allows detecting 
modifications in the PIs profile within a cell. PIs are amphipathic phospholipids that 
are minor components of cellular membranes. They are made up of a soluble 
inositol head which is linked, through a phosphodiester bond in position 1, to two 
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fatty acid chains that constitute its insoluble tails. As mentioned before, the inositol 
head has five hydroxyl groups, three of which (positions 3, 4 and 5) can be 
phosphorylated in different combinations generating different PIs that play critical 
regulatory roles in several intracellular functions. 
 
 
Figure 6.1: Chemical structure of phosphatidylinositol (PtdIns), the building block of all PIs (Falasca 
and Maffucci 2012). 
 
Previous work optimised the conditions to extract and detect intracellular PIs using 
this technique, and Prof. Falasca and his group optimised the conditions to detect 
specifically PtdIns3P. In brief, cells are labelled with myo-[3H]inositol, which is 
incorporated in the neosynthesised PIs and inositol phosphates. This is achieved 
with incubation of cells in inositol-free medium supplemented with myo-[3H]inositol 
for the time necessary to reach isotopic equilibrium, which depends on the cell type 
and requires optimisation. Then, cells are lysed and lipids are extracted by phase 
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separation using a mix of hydrochloric acid, methanol and chloroform. During this 
step, water soluble inositol phosphates accumulate in the aqueous fraction and can 
therefore be separated by PIs that accumulate in the organic phase, due to their 
hydrophobic acyl chains. Once the organic phase containing phosphoinositides is 
retrieved, solvents are evaporated and PIs can be deacylated using a mix of 
monomethylamine, water, butanol and methanol. This step allows to chemically 
remove the water-soluble glycerophosphoinositol head groups from the acylic 
chains (Figure 6.2), that can affect the binding to the HPLC column.  
 
 
Figure 6.2: Schematic diagram of PtdIns(3,4,5)P3. The cleavage site of monomethylamine reagent is 
shown (Cooke 2009). 
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Aqueous phase containing glycerophosphoinositides is then separated by the 
organic phase containing fatty acyl chains using a mix of butanol, petroleum ether 
and ethyl acetate. Glycerophosphoinositides are then separated from the solvents 
and resuspended in water for HPLC analysis with a strong anion exchange column. 
The number and the position of the phosphate groups on the 
glycerophosphoinositides determine the strength of their bond to the column. 
Therefore, they can be gradually eluted by increasing the ionic force of the buffer 
used, with the non phosphorylated species being eluted first, then the mono, bis 
and the trisphosphorylated glycerophosphoinositides being progressively detached 
from the column at later stages of the run. In order to gradually increase the ionic 
force of the buffer, a mix of two solutions is used (referred to as buffer A and buffer 
B). The ratio between buffer A (1mM EDTA) and buffer B [1.3M (NH4)2HPO4 + 1mM 
EDTA] and how the percentage of buffer B increases with time has been optimised 
to better separate the phosphorylated PIs, and to specifically detect PtdIns3P. This is 
achieved through elution of the sample from the ion exchange column with a non 
linear composition gradient, which is schematically represented in Figure 6.3.  
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Figure 6.3: Schematic diagram of the non linear gradient of buffer A (1mM EDTA) and buffer B 
[1.3M (NH4)2HPO4 + 1mM EDTA]. 
 
The percentage of buffer B in the elution buffer rapidly increases at minutes 40, 75 
and 96. This creates three steps of elution. In the first step, from minute 1 to 39 the 
unphosphorylated phosphatidylinositol is eluted, followed by the 
monophosphorylated species. In the second, from minute 41 to 74, the 
bisphosphorylated PIs are detached from the column, followed in the third step 
(minute 76-95) by the trisphosphorylated species. At minute 96, the percentage of 
buffer B in the elution buffer increases rapidly from 60 to 100%, ensuring the 
removal of any remaining species from the chromatography column. Then, the HPLC 
column is washed with 100% buffer A and re-equilibrated to the initial high aqueous 
solvent composition, which allows subsequent use and loading of a new sample for 
analysis. 
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Eluted sample are collected in fractions, mixed with the appropriate amount of 
scintillation fluid and radioactivity is detected using a beta counter. PIs are 
characterised by high-phosphate content, especially in the later part of run, when 
the bis and trisphosphorylated species are eluted. Therefore, the scintillation fluid of 
choice has to be able to solubilise samples containing high levels of phosphate in 
order to reduce the error and improve counting efficiency (Cooke 2009). 
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6.2 Results 
6.2.1 Optimisation – Labelling and starvation 
In order to investigate what lipid species are synthesised in pancreatic β cells upon 
KCl-induced insulin exocytosis, HPLC was performed.  
As mentioned before, the process of labelling cells with myo-[3H]inositol depends on 
the specific cell line used. The incubation time and conditions had to be optimised 
specifically for INS1 cells. To this purpose, INS1 cells were incubated with an inositol-
free medium (M199) supplied with myo-[3H]inositol. The use of inositol free medium 
ensures that the only inositol present in the culture medium is the myo-[3H]inositol 
supplied. INS1 cells would internalise the tritiated compound, using it for the 
synthesis and the turnover of phospholipids. In this type of studies, the amount of 
FBS used tends to be minimised, since it is source of cold inositol which could 
compete with myo-[3H]inositol. Therefore, INS1 cells were incubated with 5 μCi 
myo-[3H]inositol/ml, in serum free or 1% FBS-supplemented M199 medium for 24 or 
48 hours. Then, INS1 cells were washed, lysed and the radioactivity of the whole 
lysate was measured using a beta counter. In all cases, incubation medium was 
supplemented with 1% fresh glutamine. Results indicated that the presence of FBS 
decreased the amount of internalised compound, while the amount of tritiated 
inositol was slightly increased from 24 to 48 hours incubation. Therefore, I decided 
to set the experimental conditions to 5 μCi myo-[3H]inositol/ml in serum-free M199 
for 24 hours, as a shorter incubation would less affect cell viability. This explorative 
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experiment indicated that INS1 cells were able to survive starvation in inositol free 
medium supplemented with tritiated inositol. Also, cells were able to internalise the 
radioactive compound under these experimental conditions.  
In order to confirm that cells were healthy and still responsive after starvation, 
Western blot experiments were performed in parallel with the HPLC experiments. 
To this end, I assessed whether INS1 cells and stable cell lines were able to respond 
to insulin stimulation, as this stimulus is known to activate class I PI3Ks, leading to 
Akt activation and phosphorylation. Using the same conditions as the HPLC 
experiments, INS1 cells were starved for 24 hours in serum free M199 medium, 
followed by 30 minutes starvation in Krebs Ringer buffer and 30 minutes stimulation 
with 100nM insulin. Phosphorylation of Ser 473 of Akt was then analysed by 
Western blot. A representative experiment is shown in Figure 6.4.  
 
 
Figure 6.4: Representative blot of the indicated INS1 cell lines untreated or stimulated with 100 nM 
insulin for 30 min. Downregulation of PI3K-C2α was determined by using a specific antibody. 
Activation of Akt was assessed by monitoring its phosphorylation at residue Ser473. 
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Western Blot analysis confirmed the efficient knock down of PI3K-C2α in INS1 sh 
PI3K-C2α cells. Upon serum starvation, phosphorylation of Ser 473 of Akt was 
reduced in INS1 parental, sh scrambled and sh PI3K-C2α cells. The phosphorylation 
levels of Akt were increased upon 30 minutes treatment with insulin in all the cell 
lines. This indicated that INS1 parental, sh scrambled and sh PI3K-C2α cells were all 
able to respond to cellular stimulation under the same starvation conditions used 
for HPLC experiments. 
 
6.2.2 Optimisation – HPLC analysis 
HPLC analysis of intracellular PIs had been already optimised and performed in my 
laboratory (Iacovelli et al. 1993, Razzini et al. 2000, Falasca et al. 2007). Therefore, I 
decided to assess whether the same HPLC experimental conditions would allow to 
study the PIs profile in INS1 cells. 
To this end, INS1 cells were labelled with myo-[3H]inositol as previously described. 
Cells were then washed, lysed and cellular extracts were prepared for HPLC analysis 
as described in Chapters 2.6.1 and 6.1. After the run, each sample was collected in 
80 eluted fractions corresponding to 1 ml/min and radioactivity was measured using 
a beta counter. Figure 6.5 shows a representative chromatogram of intracellular 
glycerophosphoinositides from INS1 cells. Y axes shows the amount of radioactivity 
detected, expressed in counts per minute (cpm), x axes shows the retention time of 
each fraction of a single sample. The peaks highlighted by the arrows correspond to 
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the indicated species of PIs and measuring the height of each peak allows to 
estimate its abundance.  
 
 
Figure 6.5: Representative chromatogram of glycerophosphoinositides extracted from INS1 cells 
and analysed by HPLC.  
 
The peak visible at minute 18 corresponds to gPtdIns, the most abundant type of 
PIs, accounting for 90-96% of the total (Falasca and Maffucci 2012). The scale of y 
axes is adjusted to the maximum value of cpm detected. Using this scale, the rest of 
the run appears undistinguishable from the baseline. 
In order to better visualise the different PIs species, which are present in different 
amounts within the cells, the scale of y axes has been gradually decreased for next 
figures. 
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Figure 6.6: Representative chromatogram of glycerophosphoinositides extracted from INS1 cells 
and analysed by HPLC.  
 
Figure 6.6 shows the HPLC run of the same sample as in Figure 6.5, adjusting the 
scale of y axes to a maximum of 2000 cpm. It is possible to detect a peak at 5 
minutes, corresponding to the fraction of sample which did not bind the 
cromatography column (void volume) and therefore, was eluted quicky. Two other 
peaks are detected at minutes 45 and 64, and they correspond to the most 
abundant species of phosphorylated PIs, gPtdIns4P and gPtdIns(4,5)P2 respectively. 
PtdIns4P is the most abundant of the monophosphorylated PIs.  PtdIns4P and the 
bisphosphorylated PtdIns(4,5)P2 represent each 0.05% of total membrane lipids 
(Maffucci 2012). 
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Figure 6.7: Representative chromatogram of glycerophosphoinositides extracted from INS1 cells 
and analysed by HPLC.  
 
Further adjusting the scale of y axes, less abundant species of PIs can be visualised. 
At minute 39 on Figure 6.7, a small peak is visible and it corresponds to gPtdIns3P. 
PtdIns3P is the most abundant of the 3-phosphorylated PIs in unstimulated cells and 
it represents 0.1–0.5% of all PIs. PtdIns(3,4)P2 and PtdIns(3,4,5)P3 are barely 
detectable in unstimulated cells, and their level increase only upon cellular 
stimulation (Falasca and Maffucci 2009). 
This optimisation step indicated that this HPLC protocol allowed to detect PIs 
species present in INS1 cells in unstimulated conditions.  
Previous data from my laboratory have shown that treatment with 60 mM KCl 
induced insulin secretion in INS1 cells (Dominguez et al. 2011). Treatment with KCl, 
rather than a high glucose stimulus, allows to study exclusively the last step of 
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insulin secretion, namely the exocytosis of insulin granules. I then decided to 
investigate which lipid species are synthesised upon KCl stimulation in INS1 cells.  
 
6.2.3 Stimulation of INS1 cells with KCl induces PtdIns3P de novo 
synthesis  
To the best of my knowledge, HPLC analysis of intracellular PIs of INS1 cells upon KCl 
stimulation has never been investigated before. Therefore, an additional 
optimisation step under these experimental conditions was necessary. INS1 cells 
were labelled with myo-[3H]inositol, starved in Krebs Ringer buffer for 30 minutes 
and stimulated with 60 mM KCl, to induce insulin secretion as previously described 
(Dominguez et al. 2011). Time-course experiments (0, 2.5, 5 and 10 minutes) were 
necessary to determine whether KCl stimulation was able to alter the PIs profile in 
INS1 cells.  
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Figure 6.8: Analysis of the levels of PtdIns3P in INS1 cells upon stimulation with KCl. Cells were 
stimulated with 60mM KCl for 2.5 minutes and levels of PtdIns3P were analysed by HPLC. Data are 
expressed as percentage of total PIs. 
 
Data showed that stimulation with KCl for 2.5 minutes only slightly increased the 
levels of PtdIns3P compared to the unstimulated sample (Figure 6.8).  
 
Then, the levels of PtdIns3P, PtdIns4P and PtdIns(4,5)P2 of INS1 cells in starved 
conditions, and upon 5 and 10 minutes of KCl stimulation were analysed. Data 
showed that treatment of INS1 cells with KCl induced de novo synthesis of the lipid 
second messenger PtdIns3P (Figure 6.9). 
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Figure 6.9: Analysis of the levels of PtdIns3P in INS1 cells upon stimulation with KCl. Cells were 
stimulated with 60mM KCl for the indicated time points and levels of PIs were analysed by HPLC. 
Data are expressed as percentage of total PIs and are means ± S.E.M. of 2-6 independent 
experiments. * p value < 0.01 vs unstimulated control. 
 
 
This data was also confirmed by analysis of intracellular localisation of the pool of 
PtdIns3P upon KCl stimulation by confocal microscopy (see Chapter 7).  
 
Analysis of other PIs species showed that the levels of PtdIns4P and PtdIns(4,5)P2 
were not significantly modified by treatment with KCl (Figure 6.10). 
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Figure 6.10: Analysis of the levels of PIs in INS1 cells upon stimulation with KCl. Cells were 
stimulated with 60mM KCl for the indicated time points and levels of PIs were analysed by HPLC. 
Data are expressed as percentage of total PIs and are means ± S.E.M. of 2-6 independent 
experiments.  
 
These data suggest that the observed increase in the levels of PtdIns3P is specifically 
induced by treatment with KCl. 
Data in literature showed that the intracellular second messenger PtdIns3P is the 
product of PI3K-C2α in L6 cells upon stimulation with insulin (Falasca et al. 2007). In 
contrast with these data, it was reported that PI3K-C2α regulates the glucose-
induced synthesis of PtdIns(3,4)P2 in MIN6 cells (Leibiger et al. 2010). Also, data 
showed that downregulation of PI3K-C2α decreased insulin secretion upon 
stimulation with KCl in INS1 cells. In order to investigate whether the KCl-dependent 
pool of PtdIns3P was synthesised upon activation of PI3K-C2α, HPLC analysis of PIs 
profile was performed in INS1 sh scrambled and sh PI3K-C2α upon KCl stimulation. 
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6.2.4 Stimulation of INS1 sh-scrambled and sh-PI3K-C2α cells with KCl 
induces de novo synthesis of PtdIns3P 
INS1 sh scrambled and sh PI3K-C2α cells were labelled with myo-[3H]inositol and 
then incubated in Krebs-Ringer buffer as previously described. Then, cells were 
treated for 5 or 10 minutes with KCl and samples were prepared for HPLC analysis as 
previously described. 
 
 
Figure 6.11: Analysis of the levels of PtdIns3P in INS1 sh scrambled and sh PI3K-C2α cells upon 
stimulation with KCl. Cells were stimulated with 60mM KCl for the indicated time points and levels 
of PtdIns3P were analysed by HPLC. Data are expressed as percentage of total PIs and are means ± 
S.E.M. of 3-4 independent experiments. 5 minutes stimulation with KCl induced a statistically 
significant increase of PtdIns3P compared to the unstimulated control in both cell lines (not 
shown). *p value < 0.05 (sh scrambled cells vs sh PI3K-C2α cells upon 10 minutes stimulation with 
KCl) 
 
Results indicated that treatment with KCl for 5 minutes induced a significant 
increase in the levels of PtdIns3P in both cell lines (Figure 6.11). Interestingly, the 
amount of PtdIns3P detected in sh PI3K-C2α cells upon treatment with KCl was 
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reduced compared to control cells. Also, the amount of PtdIns3P detected upon 10 
minutes of stimulation with KCl was significantly higher in control cells compared to 
INS1 sh PI3K-C2α cells.  
Furthermore, levels of PtdIns4P and PtdIns(4,5)P2 were investigated (Figure 6.12 A 
and B, respectively). 
 
 
Figure 6.12: Analysis of the levels of PIs in INS1 sh-scrambled and sh-PI3K-C2α cells upon 
stimulation with KCl. Cells were stimulated with 60mM KCl for the indicated time points and levels 
of PIs were analysed by HPLC. Data are expressed as percentage of total PIs and are means ± S.E.M. 
of 3-4 independent experiments. 
 
Results indicated that there was no change in the levels of PtdIns4P and 
PtdIns(4,5)P2 upon treatment with KCl.  
Taken together, these results further suggest that KCl specifically increases the levels 
of PtdIns3P, as the profile of the other PIs analysed did not change. Also, data 
indicated that KCl-induced increase of PtdIns3P is affected by downregulation of 
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PI3K-C2α. This suggests that the KCl-dependent pool of PtdIns3P might be 
synthesised through PI3K-C2α activation. These data were also investigated by 
fluorescent microscope analysis of the intracellular pool of PtdIns3P (see Chapter 7). 
 
6.2.5 Glucose induces the synthesis of the lipid product PtdIns3P  
Data shown in Chapter 6.2.4 suggested that synthesis of PtdIns3P induced by cellular 
stimulation able to induce insulin secretion stimulus such as KCl stimulation is 
affected by downregulation of PI3K-C2α in INS1 cells. Also, data shown in Chapter 5 
defined a role for PI3K-C2α in the intracellular signalling cascade activated by 
stimulatory concentrations of glucose. Insulin secretion is induced, in vivo, by a rise 
in glucose concentration in the blood. Therefore, I decided to investigate whether 
glucose was able to modulate the levels of PdtIns3P in a mechanism involving PI3K-
C2α. 
These experiments required a further optimisation of the HPLC protocol, since the 
starvation conditions previously used for HPLC experiments did not deprive INS1 
cells from glucose. Also, as glucose induces insulin secretion through a different 
intracellular mechanism than KCl, a wider time course was used to analyse the 
profile of intracellular PIs. Preliminary experiments were performed by incubating 
INS1 cells with serum-free M199 medium supplied with 5 μCi myo-[3H]inositol/ml, as 
previously described. Then, cells were further incubated with Hank's Balanced Salt 
Solution (HBSS), with low glucose and in the absence of amino acids for 1 hour and 
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then stimulated with serum-free RPMI supplemented with 15mM glucose for 2.5, 5, 
10 or 20 minutes or left in HBSS as a control. As an additional control, one sample 
was left in serum-free, inositol-free M199 medium. This additional condition allowed 
to assess whether incubation in amino acid-free, low glucose HBSS medium itself 
was able to affect the levels of PtdIns3P of unstimulated INS1. The results of these 
experiments are shown in Figure 6.13. 
 
 
Figure 6.13: Analysis of the levels of PtdIns3P in INS1 cells upon stimulation with 15mM glucose. 
Cells were stimulated for the indicated time points and levels of PIs were analysed by HPLC. Data 
are expressed as percentage of total PIs. n = 1 - 2 
  
Levels of PtdIns3P were analysed and they are expressed as a percentage of total 
intracellular PIs. Controls in M199 and in HBSS showed comparable basal levels of 
PtdIns3P.  This indicated that 1 hour incubation in low glucose and amino acid-free 
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medium did not induce variations of PtdIns3P levels compared to samples in M199. 
Moreover, stimulation with RPMI supplemented with 15 mM glucose induced a 
time-dependent increase in the levels of PtdIns3P, which peaked at 5 minutes 
stimulation and slowly declined at longer time points. These experiments indicated 
that PtdIns3P levels are increased upon treatment with RPMI supplemented with 
stimulatory concentrations of glucose. 
Since HBSS contains low concentrations of glucose and no amino acids, additional 
experimental conditions were also tested to further investigate the mechanisms of 
glucose-dependent increase of PtdIns3P levels. Therefore, in order to determine 
whether glucose or amino acids were responsible for the observed increase in 
PtdIns3P levels, I decided to incubate cells with RPMI supplemented with 0.5 mM 
glucose for 1 hour rather than HBSS. 
Therefore, INS1 cells were labelled with tritiated inositol in serum-free M199 
medium as previously described and then they were incubated with RPMI 
supplemented with 0.5 mM glucose for 1 hour. In contrast with previous 
experiments, in these experimental conditions INS1 cells were incubated in low 
glucose concentrations. As an additional control, one sample was left in inositol-free 
M199 medium for 1 hour, to assess whether the levels of PtdIns3P were altered by 
the starvation conditions. Results are shown in figure 6.14.  
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Figure 6.14: Analysis of the levels of PtdIns3P in INS1 cells upon stimulation with 15mM glucose. 
Cells were stimulated for the indicated time points and the levels of PIs were analysed by HPLC. 
Data are expressed as percentage of total PIs. 
 
Data indicated that levels of PtdIns3P were not modified by treatment with RPMI 
supplemented with 0.5 mM glucose for 1 hour. Indeed, levels of PtdIns3P upon 24 
incubation in serum free medium containing 0.5 mM glucose were comparable to 
those observed upon incubation in M199 or HBSS. This indicates that glucose 
deprivation has no effect on the levels of PtdIns3P, in these experimental conditions. 
Interestingly, reintroduction of stimulatory concentrations of glucose induced a 
remarkable increase in the levels of PtdIns3P. This suggests that reintroduction of 
glucose in INS1 cells is able to induce synthesis of the lipid second messenger 
PtdIns3P. 
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Taken together, these preliminary results suggest that glucose is able to induce 
synthesis of the 3-phosphorylated phosphoinositide PtdIns3P in INS1 cells. Further 
experiments are needed to confirm these data and to investigate whether or not 
PI3K-C2α has a role in glucose-induced synthesis of PtdIns3P.  
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6.3 Discussion 
PI3Ks have a well established role in regulating many intracellular processes and 
deregulation of their pathway is associated with the onset of several diseases, 
including diabetes and cancer. There is currently an increasing interest in 
understanding the specific role of distinct PI3Ks isoforms and to determine whether 
their function within the cell is redundant or complementary. Among the three 
classes of PI3Ks, class II is the least investigated. Nevertheless, accumulating 
evidence suggest a role for these enzymes in several cellular functions. For instance, 
it has been shown that PI3K-C2α has a role in glucose-induced insulin secretion in 
MIN6 cells (Leibiger et al. 2010). Also, previous studies reported that 
downregulation of PI3K-C2α impairs the fusion of insulin granules to the plasma 
membrane upon KCl stimulation in INS1 cells, with no effect on total insulin content, 
on the number of insulin granules proximal to the plasma membrane or on the 
expression of proteins involved in exocytosis (Dominguez et al. 2011). This, together 
with the fact that high mRNA levels of PI3K-C2α were detected in human pancreatic 
β cells (Muller et al. 2006), suggests that PI3K-C2α has a role in the complex 
mechanism of insulin secretion.  
Interestingly, different studies highlighted a more general role for PI3K-C2α in 
exocytosis in different cellular contexts, suggesting a common role of the enzyme in 
the fusion of different types of granules or vesicles to the plasma membrane (Mazza 
and Maffucci 2011, Falasca and Maffucci 2012). For instance, it has been shown that 
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PI3K-C2α is implicated in the fusion of neurosecretory granules in adrenal 
chromaffin cells (Meunier et al. 2005) and it is required for maximal translocation of 
GLUT4 to the plasma membrane in L6 muscle cells (Falasca et al. 2007). Therefore, 
these data suggest that PI3K-C2α may represent a key regulator of exocytosis, with a 
role in the very late steps of this process.  
In order to analyse the final steps of insulin granules exocytosis, I stimulated INS1 
cells with KCl. This treatment induces membrane depolarisation which opens the 
voltage-gated Ca2+ channel, increasing the intracellular concentration of Ca2+, which 
triggers the fusion of insulin granules to the plasma membrane (Jewell et al. 2010). 
This approach allows studying exclusively the exocytotic steps of insulin secretion, 
without the metabolic component activated by glucose stimulation. As mentioned 
before, it was shown that PI3K-C2α is involved in KCl-induced insulin secretion, but 
the precise role of the enzyme and the specific mechanisms by which PI3K-C2α can 
regulate this step are still unclear. Therefore, I performed HPLC analysis of PIs of 
INS1 cells in order to determine whether these lipids are synthesised upon KCl-
induced insulin exocytosis. 
Data shown in figure 6.9 indicate that KCl treatment induced a significant increase of 
PtdIns3P levels. Also, the levels of the other PIs analysed were not modified under 
these experimental conditions, suggesting that KCl treatment specifically induced an 
increase in PtdIns3P levels. Consistent with these results, preliminary experiments 
performed using glucose to trigger insulin exocytosis also indicated an increase in 
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the levels of PtdIns3P. However, previous studies on insulin secreting HIT T15 cells 
reported a glucose-induced increase of PtdIns(3,4,5)P3, PtdIns(3,4)P2 and 
PtdIns(3,5)P2, with no effect on PtdIns3P levels. (Yu et al. 2007). This difference can 
be explained by the different experimental conditions and cellular model used. 
In order to study whether the observed increase in PtdIns3P levels was dependent 
on the action of PI3K-C2α, I compared the PIs profile in INS1 sh scrambled and sh 
PI3K-C2α cells.  
Results indicated that there was no difference in the PIs profile between the two cell 
lines in unstimulated conditions (Figure 6.11). This suggests that the lack of PI3K-C2α 
does not affect the levels of the PIs detected when the cells are in resting 
conditions. Moreover, KCl treatment for 5 minutes increased PtdIns3P levels in both 
cell lines. Interestingly, data showed that the levels of PtdIns3P upon 10 minutes 
stimulation with KCl were significantly lower in INS1 sh PI3K-C2α cells compared to 
the scrambled control. Also, there was a trend for a reduced PtdIns3P increase in 
cells lacking PI3K-C2α after 5 minutes stimulation. These data indicate that KCl-
dependent synthesis of PtdIns3P is affected by downregulation of PI3K-C2α. 
Therefore, these data suggest that PI3K-C2α is activated in INS1 cells under these 
experimental conditions. The fact that PtdIns3P synthesis was only partially inhibited 
in PI3K-C2α knock down cells is consistent with previous data showing that 
downregulation of PI3K-C2α in INS1 cells resulted in an impaired but not totally 
blunted insulin secretion (Dominguez et al. 2011). Furthermore, these data are 
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consistent with the observation that, in a different cell type and context, PI3K-C2α is 
involved in PtdIns3P synthesis. Specifically, it has been reported that PI3K-C2α is 
responsible for PtdIns3P synthesis at the plasma membrane in L6 cells upon insulin 
stimulation, contributing to the exocytotic-like process of GLUT4 translocation 
(Falasca et al. 2007). Also, depletion of PI3K-C2α in HUVEC cells caused a decreased 
intracellular content of PtdIns3P, but not of PtdIns(3,4)P2, PtdIns(3,5)P2 or 
PtdIns(3,4,5)P3 and reduced motility, fusion and fission of vesicles containing 
PtdIns3P (Yoshioka et al. 2012). 
In contrast with this, previous data reported that transient downregulation of PI3K-
C2α in pancreatic β cells MIN6 affects insulin-induced synthesis of PtdIns(3,4)P2, 
whereas no change in PtdIns3P or PtdIns(3,4,5)P3 was detected in control or 
knockdown cells (Leibiger et al. 2010). A possible explanation to this could be the 
different cellular model and stimulation conditions, the presence of serum and the 
use of inhibitors. Also, the fact that KCl does not seem to induce synthesis of 
PtdIns(3,4)P2 or PtdIns(3,4,5)P3 could be attributed to the time points of stimulation 
used or to the experimental conditions that might not have allowed to detect less 
abundant species of PIs. In any case, it was reported that KCl-dependent insulin 
secretion in INS1 cells does not induce phosphorylation and activation of either Akt 
or the insulin receptor (Dominguez et al. 2011). This observation further suggests 
that class I PI3Ks are not involved in KCl-dependent insulin exocytosis in these 
experimental conditions, as the classical pathway class I PI3Ks/PtdIns(3,4,5)P3/Akt is 
not activated. Also, KCl stimulation does not seem to activate a feedback loop 
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(Dominguez et al. 2011) as previously reported in glucose-stimulated MIN6 (Leibiger 
et al. 2010). Taken together, these data indicate that both KCl and glucose-induced 
insulin exocytosis induce an intracellular increase of PtdIns3P levels. The fact that 
the increase in PtdIns3P levels is lower in PI3K-C2α knock down cells suggest that 
this enzyme is involved, but it is not necessarily the sole responsible, of PtdIns3P 
synthesis upon KCl or glucose stimulation. Moreover, both KCl and glucose 
ultimately lead to an intracellular increase of Ca2+ levels, which triggers insulin 
exocytosis. It was proposed that the increase in Ca2+ levels is able to activate PI3K-
C2α, as shown by in vitro kinase assays performed on endogenous protein 
immunoprecipitated from de-endotheliased rabbit aortic vascular smooth muscle 
(Wang et al. 2006). This could represent a possible explanation of the mechanism of 
action of PI3K-C2α. 
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Chapter 7 
Mechanisms of PI3K-C2α action  
7.1 Introduction 
Insulin secretion is a complex mechanism that ultimately requires the fusion of 
insulin granules to the plasma membrane and the release of their insulin content in 
the extracellular space. The fusion of insulin granules to the plasma membrane of 
pancreatic β cells is an exocytotic process mediated by SNAREs. KCl and other 
nonnutrient stimuli induce the ‘first phase insulin release’, which occurs 5-10 
minutes after β cell stimulation. Glucose and fuel type secretagogues also induce a 
‘second phase insulin release’, which might last several hours if the insulin-secreting 
stimulus persists (Jewell et al. 2010). These two mechanisms involve distinct SNAREs 
isoforms. KCl-induced insulin secretion requires two SNARE proteins associated to 
the plasma membrane, SNAP 25 and syntaxin 1 or syntaxin 4, which associate with 
VAMP2 on the secretory granule, forming a stable complex (Jewell et al. 2010, 
Torrejon-Escribano et al. 2011). 
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Figure 7.1: SNAREs core complex. Interactions between VAMP2 on the vesicle and SNAP 23/25 and 
syntaxin at the plasma membrane are necessary for exocytosis. Adapted from Jewell et al., 2010. 
 
Glucose-induced insulin secretion is regulated by the same SNAREs isoforms that 
modulate glucose uptake in insulin target cells. This process requires syntaxin 4, 
SNAP 23, and VAMP2. The isoform syntaxin 1 is involved in the first, but not the 
second phase of insulin release (Jewell et al. 2010). The assembly of this core 
complex is also influenced by accessory proteins that interact with the SNARE core 
complex (Renström and Rorsman 2008). 
Previous work demonstrated that PI3K-C2α downregulation inhibited KCl-induced 
insulin secretion in INS1 cells, without affecting the expression levels of key proteins 
involved in the exocytotic machinery, such as SNAP 25, VAMP2, syntaxin 1 and 
syntaxin 4 (Dominguez et al. 2011). Nevertheless, a potential role for PI3K-C2α in 
regulating the assembly or the activity of the complex cannot be excluded. 
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Interestingly, it was reported that downregulation of PI3K-C2α in INS1 cells was 
associated with a reduced proteolysis of SNAP 25 upon KCl stimulation (Dominguez 
et al. 2011). Hence, this observation and the fact that SNAP 25 proteolysis is 
associated with insulin secretion (Marshall et al. 2005) suggested that PI3K-C2α 
might be involved in the association or the functioning of the SNARE complex during 
the fusion step of insulin granules.  
SNAP 25 proteolysis has been reported to depend on calpain 10 activity. Calpains 
are a family of proteases that are able to cleave cytoskeletal proteins and therefore, 
they might be involved in vesicle trafficking. Calpain 10 in particular has been 
reported to bind the SNAREs core complex and the inhibition of its activity reduced  
SNAP 25 cleavage (Marshall et al. 2005). Also, it has been reported that glucose 
stimulation increased calpain activity and protein expression of calpain 10 and  
genome scan studies identified the protein calpain 10 as a susceptibility gene for 
T2D (Turner et al. 2007). Therefore, it is possible that PI3K-C2α has a role in 
modulating the assembly of the SNAREs complex necessary for insulin exocytosis, or 
its activity through calpains family members. 
Data presented in the previous chapter indicated that stimulation of insulin 
secretion with KCl (and possibly also with glucose) induced the synthesis of the lipid 
second messenger PtdIns3P. PtdIns3P can derive from direct phosphorylation of 
PtdIns by class III PI3K hVps34 or members of class II PI3Ks (Maffucci 2012). It was 
proposed that PtdIns3P might have different functions, based on its intracellular 
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localisation and stimulation (Falasca and Maffucci 2009, Maffucci 2012). Results 
presented so far showed that synthesis of PtdIns3P was affected by downregulation 
of class II PI3K-C2α in INS1 cells. In addition, it has been observed that PI3K-C2α was 
localised in nuclear and perinuclear regions in L6 cells in resting conditions, and that 
a rapid and transient translocation of the enzyme to the plasma membrane occurred 
upon insulin stimulation (Falasca et al. 2007). Moreover, it has been shown that 
PI3K-C2α associates with secretory granules in chromaffin cells (Meunier et al. 
2005). It is still unknown whether PI3K-C2α translocates to the plasma membrane or 
associates to insulin vesicles in pancreatic β cells following cellular stimulation. 
Nevertheless, based on these observations, it was proposed that PI3K-C2α and/or its 
lipid product PtdIns3P might have a general role in exocytotic mechanisms, 
facilitating the fusion of insulin granules and other intracellular vesicles to the 
plasma membrane in different cell types (Mazza and Maffucci 2011). In an effort to 
determine how PI3K-C2α regulates insulin secretion, in this chapter I sought to 
investigate the localisation of the PI3K-C2α-dependent pool of PtdIns3P generated 
upon stimulation with KCl in INS1 cells and the potential role of PI3K-C2α. 
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7.2 Results 
7.2.1 Analysis of calpain family members protein expression 
As mentioned before, the protein expression of the protease calpain 10 is positively 
regulated in response to glucose stimulation (Turner et al. 2007). It has also been 
proposed that calpain 10 is involved in the proteolysis of SNAP 25, an event 
associated with insulin granule fusion (Marshall et al. 2005). Furthermore, previous 
data showed an impaired proteolysis of SNAP 25 in INS1 upon downregulation of 
PI3K-C2α, and a concomitant decrease in insulin secretion (Dominguez et al. 2011). 
Therefore, I decided to test whether downregulation of PI3K-C2α would affect 
calpain 10 protein expression using Western Blot analysis. To this end, the 
expression of calpain 10 and of the two major ubiquitously expressed calpain family 
members, calpain 1 and 2, was investigated in INS1 parental, sh scrambled and sh 
PI3K-C2α cells. 
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Figure 7.2: Analysis of calpain family members protein expression. Lysates from stable INS1 cell 
lines were analysed by Western Blot and incubated with the indicated antibodies. Representative 
blots are shown. 
 
Results indicated that the protein expression of calpain 10, calpain 1 and calpain 2 
was not affected by the downregulation of PI3K-C2α in unstimulated conditions. 
This suggests that PI3K-C2α is not involved in modulating the expression levels of 
the examined calpains isoforms. However, a potential role for PI3K-C2α in 
modulating calpain family members activity cannot be excluded. 
 
7.2.2 Investigation of potential effects of PI3K-C2α downregulation on 
SNAREs interaction 
The exocytosis of insulin granules requires the formation of a complex of proteins 
(SNAREs core complex and accessory proteins) which allows the fusion of the vesicle 
with the plasma membrane.  
Specifically, insulin release requires the association of VAMP2, located on the insulin 
granule, with syntaxin and SNAP proteins on the plasma membrane, securing the 
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physical interaction of the two cellular compartments. Specifically, the first phase of 
insulin secretion requires syntaxin 1 isoform, while the second phase of insulin 
release involves either syntaxin 1 or syntaxin 4 (Jewell et al. 2010). It has been 
shown that downregulation of PI3K-C2α did not affect the expression of key proteins 
involved in the insulin secreting machinery, including syntaxin 1 and VAMP2 
(Dominguez et al. 2011). This finding, however, does not rule out a role for PI3K-C2α 
in the formation of the complex and/or its activity. 
In order to investigate whether downregulation of PI3K-C2α affects the association 
of syntaxin 1 and VAMP2, I performed coimmunoprecipitation assays. Sh scrambled 
and sh PI3K-C2α cells were starved for 30 minutes in Krebs Ringer buffer and then 
stimulated for 30 minutes with KCl to induce insulin secretion or left untreated as 
previously described (Dominguez et al. 2011). Then, an antibody anti VAMP2 was 
used to immunoprecipitate and isolate the complex from the whole lysate and the 
amount of VAMP2 and syntaxin 1  was investigated by Western blot (Figure 7.3). 
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Figure 7.3: Association between syntaxin 1 and VAMP 2 in the presence or absence of KCl. Cell 
lysates were immunoprecipitated with an antibody anti VAMP2. Previous data from my laboratory 
showed that no VAMP2 or syntaxin 1 were immunoprecipitated by control IgG in these 
experimental conditions. 
 
Results showed that a basal interaction between VAMP2 and Syntaxin 1 is 
detectable in both sh scrambled and sh PI3K-C2α cells. This is consistent with 
previous reports indicating that a number of insulin granules is already pre-docked 
to the plasma membrane in unstimulated conditions (Rorsman and Renstrom 
2003).Treatment with KCl for 30 minutes did not seem to increase the association of 
the SNAREs complex in these experimental conditions. This suggested that these 
experimental conditions did not allow to appreciate any changes in syntaxin 
1/VAMP2 association. Nevertheless, they showed that there was no difference in 
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syntaxin 1/VAMP2 association between sh scrambled and sh PI3K-C2α cells in 
unstimulated conditions or upon KCl treatment for 30 minutes. 
Therefore, I decided to perform time-course experiments to test whether an 
increase in the association of the two proteins occurred at earlier time points. 
Preliminary experiments were performed in INS1 cells, varying the time of KCl 
stimulation from a minimum of 1 to a maximum of 30 minutes. A representative 
experiment is shown in Figure 7.4. 
 
 
Figure 7.4: Association between syntaxin 1 and VAMP 2 in the presence or absence of KCl. Cell 
lysates were immunoprecipitated with an antibody anti VAMP2. Previous data from my laboratory 
showed that no VAMP2 or syntaxin 1 were immunoprecipitated by control IgG in these 
experimental conditions. 
 
Results indicated that no clear increase in the amount of syntaxin 1 
coimmunoprecipitated with VAMP2 was detected upon KCl stimulation even at 
shorter time points. 
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7.2.3 Optimisation of GFP-2XFYVEHrs plasmid transfection 
As mentioned before, PI3K-C2α has a role in KCl-induced insulin secretion. Data 
presented in Chapter 6 indicated that KCl stimulation induced de novo synthesis of 
the lipid second messenger PtdIns3P in a mechanism involving PI3K-C2α. In order to 
clarify the role of this PI3K-C2α/PtdIns3P pathway in insulin secretion, I investigated 
the intracellular localisation of this PI3K-C2α dependent PtdIns3P pool using a 
specific fluorescent probe. GFP-2XFYVEHrs can be inserted into the cells by 
transfection of a plasmid containing its sequence using transfecting agents or 
electroporation. Once expressed by the cells, it selectively binds PtdIns3P and it can 
be detected by fluorescent or confocal microscopy because of its GFP tag, allowing 
the study of the intracellular localisation of PtdIns3P. The method of insertion of 
GFP-2XFYVEHrs plasmid had to be optimised for INS1 cells. First, I decided to use 
electroporation to transfect INS1 cells. 
INS1 cells were detached from the flask and counted as described in Materials and 
Methods, electroporated with Amaxa Nucleofector® according to the 
manufacturer’s instructions and seeded. Plated cells were monitored for 72 hours by 
fluorescent microscope observation to assess the efficiency of transfection and GFP-
2XFYVEHrs plasmid expression. INS1 cells began to express GFP-2XFYVEHrs plasmid 
30 hours post electroporation. The maximal intensity of GFP expressed was 
observed 48 hours post transfection. Although the protocol allowed a good 
efficiency of transfection (60%), the overall intensity of fluorescence was low. 
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Therefore, I decided to try alternative methods to insert GFP-2XFYVEHrs in INS1 cells, 
such as transfection using Lipofectamine®. 
In order to optimise the transfection protocol, different factors were considered. 
Transfection efficiency may vary based on the confluence of cells, the ratio of 
plasmid DNA/transfecting agent, the amount of DNA and transfecting agent used. 
INS1 cells were seeded on coverslips in 12 wells plates at a confluence of 0.6, 1.2 or 
1.8 x106 cells/plate. Transfection was then performed, using GFP-2XFYVEHrs and 
Lipofectamine® as a transfecting reagent. Different ratios of plasmid 
DNA/transfecting agent were used (1:2, 1:3, 1:4) and transfection efficiency was 
monitored by fluorescence microscopy. Results showed that 48 hours were 
necessary to obtain a maximal plasmid expression, as assessed by GFP fluorescence 
intensity, consistent with experiments performed using electroporation. Also, 
results indicated that the best combination was obtained by plating 1.2x106 
cells/plate and using 0.5μg of plasmid and 2μl of Lipofectamine®/well 
(DNA/Lipofectamine® ratio 1:4) in a 12-well plate. Although the transfection 
efficiency was lower compared to the electroporated cells (30%), the intensity of 
the fluorescence was higher. 
In parallel experiments, transfection using Lipofectamine® 2000 was performed and 
the transfection efficiency was comparable to those obtained with Lipofetamine®. 
However, the viability of INS1 cells was more affected by Lipofectamine® 2000 
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compared to INS1 cells treated with Lipofectamine®. Therefore, Lipofectamine® was 
used as transfection reagent for the following experiments. 
 
7.2.4 GFP-2XFYVEHrs translocates to the plasma membrane upon KCl 
treatment 
INS1 parental cells were plated on coverslips and transfected after 24 hours with 
GFP-2XFYVEHrs plasmid. After 48 hours cells were starved in Krebs Ringer buffer for 
30 minutes and stimulated with KCl for 30 minutes, following a protocol previously 
established in my laboratory to induce insulin secretion (Dominguez et al. 2011). 
Then, coverslips were fixed in paraformaldehyde and analysed by confocal 
microscopy.  
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 Figure 7.5: Analysis of intracellular localisation of PtdIns3P. INS1 cells were transfected with GFP-
2XFYVE
Hrs
 , starved in Krebs Ringer buffer for 30 minutes and then stimulated with 60 mM KCl for 
30 minutes or left untreated. Cells were then analysed by confocal microscopy. 
 
The results of this preliminary experiment indicated that GFP-2XFYVEHrs plasmid was 
expressed in INS1 cells 48 hours post transfection. The expression of GFP-2XFYVEHrs 
appeared as the typical punctuate staining (Figure 7.5), consistent with the 
localisation of PtdIns3P in intracellular endosomes (Maffucci 2012). The localisation 
of PtdIns3P was not modified by stimulation with KCl for 30 minutes. Therefore, I 
decided to perform a time-course analysis.  
INS1 cells were plated on coverslips and transfected with GFP-2XFYVEHrs as 
previously described. Then, cells were starved in Krebs Ringer buffer for 30 minutes 
and stimulated with KCl, for 2.5, 5, 7.5 and 10 minutes, respectively. Coverslips were 
fixed in paraformaldehyde and analysed by epifluorescent microscopy. Results 
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indicated that KCl treatment induced the translocation of the GFP tagged 2XFYVE 
probe to the plasma membrane upon 2.5 and 5 minutes treatment with KCl. The 
number of cells displaying a plasma membrane localisation of GFP-2XFYVEHrs was 
maximal after 2.5 minutes stimulation and it was decreased upon 5 minutes 
treatment. The intracellular localisation of GFP-2XFYVEHrs upon 7.5 and 10 minutes 
stimulation was comparable to control cells. This suggested that the synthesis of 
PtdIns3P induced by KCl is time-dependent, since the neosynthesised pool of 
PtdIns3P is undetectable 7.5 minutes after KCl stimulation. 
In order to better visualise the plasma membrane localisation of GFP-2XFYVEHrs, I 
decided to investigate the intracellular localisation of PtdIns3P using confocal 
microscopy analysis. INS1 cells on coverslips were transfected with GFP-2XFYVEHrs 
and, 48 hours post transfection, they were starved in Krebs Ringer buffer and 
stimulated with KCl for 2.5 or 5 minutes, or they were left in starvation buffer. 
Results obtained by confocal microscopy analysis are shown in Figure 7.6 and 
confirmed the result observed in the preliminary experiments. 
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Figure 7.6: Analysis of intracellular localisation of PtdIns3P. INS1 cells were transfected with GFP-
2XFYVE
Hrs
 , starved in Krebs Ringer buffer for 30 minutes and then stimulated with 60 mM KCl for 
2.5 and 5 minutes or left untreated. Cells were then analysed by confocal microscopy. GFP-
2XFYVE
Hrs
 translocation is indicated by arrows. 
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Results indicated that GFP-2XFYVEHrs translocated to the plasma membrane upon 
2.5 minutes of KCl stimulation. This suggested that a pool of PtdIns3P is specifically 
synthesised in this cellular compartment following stimulation with KCl. Consistent 
with the previous experiment, a reduced number of cells displaying plasma 
membrane staining with GFP-2XFYVEHrs was observed upon 5 minutes of 
stimulation. 
In order to futher investigate the intracellular localisation of the KCl-dependent pool 
of PtdIns3P, co-staining with syntaxin 1 was performed. Syntaxin 1 is an intrinsic 
transmembrane protein localised at the plasma membrane, and its staining allowed 
to better visualise this intracellular compartment in INS1 cells. Therefore, it was 
possible to assess whether the newly synthesised PtdIns3P pool was on the plasma 
membrane or in its proximity. INS1 cells were transfected with GFP-2XFYVEHrs 
plasmid, starved in Krebs Ringer buffer and stimulated for 2.5 minutes with KCl. 
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Figure 7.7: Analysis of intracellular localisation of PtdIns3P. INS1 cells were transfected with GFP-
2XFYVE
Hrs
 , starved in Krebs Ringer buffer for 30 minutes and then stimulated with 60 mM KCl for 
2.5 minutes or left untreated. Cells were permeabilised, incubated with an antibody specific for 
syntaxin 1 and then with Alexa Fluor 555 Goat Anti-Mouse IgG. Cells were then fixed in 
paraformaldehyde and analysed by confocal microscopy using a 63X objective. Staining with 
syntaxin 1 (A), GFP-2XFYVE
Hrs
 (B), and merged (C) images are shown. 
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These preliminary results indicated that staining with syntaxin 1 was specific and 
clearly outlined the plasma membrane of INS1 cells. GFP-2XFYVEHrs fluorescent 
probe was located close to the plasma membrane upon 2.5 minutes of KCl 
stimulation. Merged images suggested the absence of colocalisation of the two 
fluorescent signals. Therefore, it appeared that KCl-dependent pool of PtdIns3P is 
synthesised in close proximity to the inner plasma membrane of INS1 cells. 
In order to investigate whether the newly synthesised, KCl-dependent pool of 
PtdIns3P is produced through the action of PI3K-C2α, similar experiments were 
performed using INS1 sh scrambled and sh PI3K-C2α cells. Stable cell lines were 
transfected, starved and stimulated as previously described. Then, the number of 
cells displaying plasma membrane staining of GFP-2XFYVEHrs was counted using 
epifluorescent microscopy.  
 
 
241 
 
 
Figure 7.8: Quantitative analysis of GFP-2XFYVE
Hrs
 translocation. INS1 cells plated on coverslips 
were transfected with GFP-2XFYVE
Hrs
 and analysed by epifluorescent microscopy. Data are 
expressed as percentage of cells displaying plasma membrane localisation of GFP-2XFYVE
Hrs
 and are 
means ± s.e.m. from 3 independent experiments. *p value < 0.05 sh scrambled vs sh PI3K-C2α cells. 
 
Results indicated that upon KCl stimulation, GFP-2XFYVEHrs translocated to the 
plasma membrane in sh scrambled cells. The higher percentage of cells displaying 
plasma membrane staining with GFP-2XFYVEHrs was detectable upon 2.5 minutes of 
KCl stimulation, and it progressively decreased at later time points, becoming 
comparable to unstimulated cells upon 10 minutes of KCl treatment. Quantitative 
analysis indicated that there was no difference between sh scrambled and sh PI3K-
C2α cells in the number of GFP-2XFYVEHrs staining at the plasma membrane in 
unstimulated conditions. Also, downregulation of PI3K-C2α did not affect the 
endosomal staining of GFP-2XFYVEHrs, suggesting that PI3K-C2α does not alter the 
endosomal pool of PtdIns3P. Results indicated that downregulation of PI3K-C2α 
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impaired translocation of GFP-2XFYVEHrs to the plasma membrane upon KCl 
stimulation. Specifically, the percentage of cells displaying plasma membrane 
staining with GFP-2XFYVEHrs upon KCl stimulation was not statistically significant at 
any time points. 
These results indicated that PI3K-C2α regulates the synthesis of a KCl-dependent 
pool of PtdIns3P at the plasma membrane. 
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7.3 Discussion 
Evidence in literature reported that PI3K-C2α is involved in the fusion of 
neurosecretory granules in adrenal chromaffin cells (Meunier et al. 2005), in insulin 
exocytosis in INS1 cells (Dominguez et al. 2011) and in the translocation of glucose 
transporter GLUT 4 to the plasma membrane in muscle cells (Falasca et al. 2007). 
Although these studies focus on different cell lines, contexts and cellular 
mechanisms, taken together they indicate that PI3K-C2α might have a general role 
in exocytotic-like processes. However, the precise role for PI3K-C2α and the specific 
mechanisms by which this enzyme might regulate exocytosis are still unclear. In 
order to investigate this aspect, I focused my research on the proteins involved in 
insulin granules exocytosis. The SNARE core complex necessary for insulin secretion 
requires the association of VAMP2 on the insulin granules and syntaxin 1 and SNAP 
25 on the plasma membrane. During insulin exocytosis SNAP 25 undergoes a Ca2+ 
dependent proteolytic cleavage, probably through the action of the protease calpain 
10 (Marshall et al. 2005, Turner et al. 2007). It was also reported that the protein 
expression and the activity of calpain 10 are increased by glucose stimulation 
(Turner et al. 2007) and that the proteolytic cleavage of SNAP 25 was affected by 
PI3K-C2α downregulation during KCl-induced insulin secretion (Dominguez et al. 
2011). Nevertheless, data presented in this chapter indicated that downregulation 
of PI3K-C2α did not affect the protein expression of either calpain 10 or the isoforms 
calpain 1 and 2 (Figure 7.2). However, the present study does not rule out the 
244 
 
possibility that PI3K-C2α might regulate the activity of calpain 10 or other calpain 
family members, therefore affecting insulin secretion. 
Another hypothesis might be that PI3K-C2α has a role in regulating the assembly or 
the activity of the SNAREs core complex during the fusion of insulin granules to the 
plasma membrane. In order to investigate this aspect, coimmunoprecipitation 
studies were performed. Data showed that, PI3K-C2α downregulation did not seem 
to modify the association between VAMP2 and syntaxin 1 in unstimulated 
conditions or after 30 minutes of stimulation with KCl. More specifically, no increase 
in the association of VAMP2 and syntaxin 1 was detected upon stimulation with KCl 
and therefore, it was not possible to determine the potential contribution of PI3K-
C2α in this context. Nevertheless, no difference in the basal association was 
detected between sh scrambled and sh PI3K-C2α cells. This is consistent with the 
findings that insulin granules are docked to the plasma membrane of pancreatic β 
cells in resting conditions (Jewell et al. 2010) and that downregulation of PI3K-C2α 
does not affect the number of granules proximal to the plasma membrane 
(Dominguez et al. 2011). 
Results shown in Chapter 6 indicated that a pool of PtdIns3P is neosynthesised in 
INS1 cells upon stimulation of insulin secretion induced by KCl. In order to further 
investigate the role of PI3K-C2α in the context of insulin granules exocytosis, I 
investigated the intracellular localisation of the KCl-dependent pool of PtdIns3P. 
PtdIns3P constitutes 0.1–0.5% of all intracellular PIs and it is the most abundant 
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among the 3-phosphorylated PIs species in mammalian cells in resting conditions. 
The majority of PtdIns3P is localised in intracellular endosomes and it is regulated by 
class III PI3K hVps34 (Maffucci 2012). The role of this constitutive pool of PtdIns3P is 
mainly to modulate receptor-independent trafficking events, such as endocytic 
membrane traffic and autophagy (Lindmo and Stenmark 2006). It was reported that 
an inducible pool of PtdIns3P was detected upon cellular stimulation at the plasma 
membrane in different cell types, together with an increase of PtdIns3P levels 
(Maffucci et al. 2005, Falasca et al. 2007). Evidence suggested that the function of 
this specific pool of PtdIns3P is distinct from the endosomal pool and its synthesis 
depends on the action of class II PI3Ks, rather than class III hVps34 (Maffucci 2012). 
In particular, it was shown that insulin stimulation induced PI3K-C2α-dependent 
PtdIns3P synthesis at the plasma membrane in L6 cells, facilitating GLUT4 
translocation (Falasca et al. 2007). It is possible then that PI3K-C2α and PtdIns3P 
might facilitate the fusion of insulin granules in pancreatic β cells using a similar 
mechanism. Data obtained with HPLC analysis revealed that the KCl-dependent pool 
of PtdIns3P involves PI3K-C2α activation. In order to further investigate this aspect, I 
investigated the localisation of PtdIns3P in INS1 cells following KCl stimulation using 
the specific PtdIns3P probe GFP-2XFYVEHrs. 
Results indicated that the inducible pool of PtdIns3P was synthesised in close 
proximity to the plasma membrane of INS1 cells (Figure 7.7). In addition, 
downregulation of PI3K-C2α impaired GFP-2XFYVEHrs translocation to the plasma 
membrane, further suggesting that PI3K-C2α is involved in the synthesis of the 
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inducible pool of PtdIns3P in this cellular compartment. Consistent with this, 
preliminary data indicated that PtdIns3P is synthesised in INS1 cells following 
treatment with glucose, the physiological stimulus for insulin secretion.  
These data, together with the observation that PI3K-C2α downregulation affects 
insulin exocytosis following stimulation with KCl or with secretagogue mixture, with 
no effect on total insulin content or on the expression of proteins involved in 
exocytotic machinery (Dominguez et al. 2011), suggest that PI3K-C2α and PtdIns3P 
have a role specifically in the fusion step of insulin secretion in INS1 cells. 
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Chapter 8 
Final conclusions and future work 
8.1 Conclusions 
PI3Ks have a well established role in many intracellular functions, and impairment of 
their signalling pathway has been associated with defects in metabolic regulation. 
Most of our knowledge about PI3Ks signalling comes from the study of class I PI3Ks, 
and it is now generally accepted that these enzymes have a central role in both 
insulin target tissues and insulin producing tissues. These observations highlighted 
that deregulation of PI3Ks or their intracellular pathway is crucial for the 
pathogenesis and progression of metabolic diseases, such as T2D. Amongst all PI3Ks, 
class II remains, to date, the least investigated. However, in the last few years 
interest in the function of class II PI3K, and particularly PI3K-C2α, has increased.  
This study focussed on the investigation of the intracellular functions and signalling 
pathways regulated by PI3K-C2α and its mechanisms of activation. Evidence 
indicated PI3K-C2α has an important role in insulin signalling, regulating glucose 
uptake in muscle cells through the synthesis of its lipid product PtdIns3P. In 
addition, it was demonstrated that PI3K-C2α mRNA is highly expressed in human 
pancreatic β cells, while it is reduced in islets from T2D subjects compared to non-
diabetic controls. Also, PI3K-C2α contributes to glucose and KCl-induced insulin 
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granules exocytosis. The dual role of PI3K-C2α in insulin release and action suggests 
that this enzyme may represent a novel therapeutic target for T2D. 
Results from this study indicated that the protein levels of class I p110α and class II 
PI3K-C2α were selectively downregulated by addition of free fatty acids in the 
culture medium of INS1 cells. As PI3K-C2α is important for pancreatic β cell function, 
this might add important information to understand the role of lipotoxicity in the 
context of pancreatic β cell failure and diabetes progression. The reduced levels of 
PI3K-C2α do not seem to be responsible for reduced β cell viability in lipotoxic 
conditions, since INS1 cells lacking PI3K-C2α were as prone as control cells to death 
induced by lipotoxicity. 
On the other hand, these results indicated for the first time that PI3K-C2α is involved 
in intracellular signalling activated by stimulatory concentrations of glucose 
following nutrients deprivation. Specifically, glucose was able to prevent cell death 
induced by nutrients deprivation in control cells. Downregulation of PI3K-C2α 
significantly inhibited the glucose-dependent survival effect. Nutrients deprivation 
was able to trigger both apoptotic and autophagic processes in INS1 cells. Notably, 
reintroduction of stimulatory concentrations of glucose was not able to revert 
autophagy, while it was able to inhibit apoptosis, in a mechanism involving PI3K-
C2α. This suggests that PI3K-C2α is involved in the anti-apoptotic role of stimulatory 
glucose concentrations in INS1 cells. 
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Further analysis on the intracellular pathway revealed that glucose activated 
mTORC1 and its downstream effectors, and this is required for the anti-apoptosis 
effect. This conclusion was confirmed by the use of mTOR inhibitor rapamycin, 
which impaired cell viability in the presence of glucose. The reduced cell viability 
caused by treatment with rapamycin was similar to the one observed in cells lacking 
PI3K-C2α, suggesting that PI3K-C2α and mTORC1 are part of the same signalling 
pathway. Indeed, Western Blot analysis indicated that glucose-induced activation of 
mTORC1 pathway was impaired by downregulation of PI3K-C2α. Specifically, 
downregulation of PI3K-C2α inhibited phosphorylation of mTORC1 and the 
downstream effectors S6K, 4EBP1 and S6. Notably, glucose-induced effect on cell 
viability was not inhibited by classical PI3K inhibitors, suggesting that glucose was 
not able to activate mTOR pathway through the class I PI3K/Akt/mTOR pathway. 
Investigation of Akt activation at both long and short time points of stimulation with 
glucose confirmed this hypothesis, as mTOR and downstream targets resulted 
activated in absence of detectable Akt phosphorylation. Taken together, these data 
indicated for the first time that stimulatory concentrations of glucose are able to 
activate mTOR and its downstream effectors, through an intracellular pathway that 
involves the activation of PI3K-C2α. 
The second part of this project focussed on the investigation of the mechanisms of 
activation of PI3K-C2α and the identification of the lipid product specifically 
synthesised by this enzyme in pancreatic β cells. Previous work had demonstrated 
that downregulation of PI3K-C2α impaired insulin granules exocytosis in INS1 cells 
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(Dominguez et al., 2011). Preliminary data suggested that PtdIns3P is synthesised in 
pancreatic β cells upon stimulation with glucose, the physiological stimulus for 
insulin secretion. Also, results indicated that KCl stimulation induced the synthesis of 
the lipid second messenger PtdIns3P in β cells. Importantly, the levels of PtdIns3P 
were significantly reduced by downregulation of PI3K-C2α upon KCl stimulation. This 
suggests that PI3K-C2α is activated in INS1 cells upon depolarisation of the plasma 
membrane, and that it specifically catalyses the synthesis of PtdIns3P, which can 
then facilitate insulin granules exocytosis. Indeed, fluorescence microscopy analysis 
revealed that the KCl-induced pool of PtdIns3P was localised in close proximity to 
the plasma membrane. Importantly, this specific pool of PtdIns3P was reduced by 
downregulation of PI3K-C2α. Furthermore, PtdIns3P synthesis was not completely 
inhibited in PI3K-C2α knock down cells, consistent with the previous observation 
that ~80% downregulation of PI3K-C2α levels in INS1 cells resulted in an impaired 
but not totally blunted insulin secretion (Dominguez et al. 2011). These data are also 
consistent with previous reports showing that PtdIns3P and PI3K-C2α were involved 
in the exocytotic-like process of GLUT4 translocation in muscle cells (Falasca et al. 
2007). Interestingly, insulin secretion and GLUT4 translocation require the assembly 
of an exocytotic machinery that involves similar proteins. Analysis of the SNAREs 
syntaxin 1 and VAMP2 in the presence or absence of KCl stimulation showed that 
PI3K-C2α did not seem to be involved in this process. Similar mechanisms were also 
observed in different cell types, and a role for PI3K-C2α was reported in the 
exocytosis of neurosecretory granules (Meunier et al. 2005). Given these similarities, 
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it is likely that PI3K-C2α has a general role in exocytosis in distinct cellular contexts. 
Therefore, further experiments are needed to elucidate the precise role of PI3K-C2α 
in this context. 
 
8.2 Future work 
Several questions arisen from the experiments showed in this thesis remain 
pending. Observation of the phenotype of a conditional knock-out mouse model 
with deletion of the kinase specifically in pancreatic β cells would be the best option  
to study the function of PI3K-C2α in this specific cell type.  
 
Other short-term future work will focus on: 
 
Function of PI3K-C2α 
Since PI3K-C2α does not seem to affect the exocytotic machinery, its precise role in 
the context of insulin secretion is still unclear. Further work will clarify how PI3K-C2α 
and PtdIns3P are involved in fusion of granules to the plasma membrane.  
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Lipid product of PI3K-C2α in pancreatic β cells 
Further experiments are required to identify the lipid product of PI3K-C2α upon 
glucose stimulation in pancreatic β cells. 
 
mTORC1 activation 
Data showed that downregulation of PI3K-C2α impaired mTORC1 and its 
downstream targets upon glucose stimulation. Additional experiments are required 
to understand the involvement of signalling pathway(s) involved upstream of 
mTORC1. Also, further work is necessary to elucidate whether the glucose 
reintroduction and PI3K-C2α activation are needed for cell proliferation, rescue from 
apoptosis or a combination of these processes. Cell cycle analysis and investigation 
of specific markers for proliferation and apoptosis are necessary.  
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